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Abstract 
Administering immunoregulatory cells to patients as medicinal agents is a potentially 
revolutionary approach to the treatment of immunologically mediated diseases. By isolating 
and modifying cells in vitro before applying them to patients, specific cellular functions can be 
induced, opening astonishing new possibilities for antigen-specific treatments in autoimmunity, 
chronic inflammatory disorders and especially in transplantation medicine. During the last years 
our research group has developed a novel cell-based medicinal product containing human 
regulatory macrophages, called Mreg_UKR, for treatment of transplanted patients. 
 
Developing these cells is a long and complicated process. It begins with a detailed 
understanding of macrophage biology and pathophysiology, including different states of 
polarisation and their function in allograft damage and repair. Based on this understanding, we 
have been able to identify an immunoregulatory macrophage phenotype that in vitro proved to 
be T-cell-suppressive. These so called Mregs reflect a unique state of macrophage 
differentiation, distinguished from macrophages in other activation states by their mode of 
derivation and robust phenotype. Owing to IFN-γ-induced indolamine 2,3-dioxygenase (IDO) 
activity and contact-dependant deletion of activated T-cells, Mregs are capable of suppressing 
mitogen-stimulated T-cell proliferation in vitro and drive the development of an activation 
induced regulatory T-cell (iTreg). No evidence of clinically significant adverse reactions was 
revealed when subjecting Mregs to conventional safety pharmacology and toxicology testing in 
mice. Two kidney transplanted patients have been treated with an Mreg containing suspension 
and show satisfactorily stable renal function with only low-dose Tacrolimus monotherapy more 
than five years after transplantation. These promising results and the need for a detailed 
clinical safety assessment warrant further clinical studies, which will be conducted within The 
ONE Study. My thesis depicts this process of developing an Mreg containing medicinal product 
fƌoŵ ͞ďeŶĐh to ďedside͟.  
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Übersicht  
Die klinische Anwendung immunregulatorischer Zellen als medizinisches Produkt ist ein 
potentiell revolutionäres Therapiekonzept zur Behandlung immunologisch bedingter 
Erkrankungen. Durch in vitro Isolierung und Modifizierung der Zellen vor Applikation können 
spezifische Zellfunktionen induziert werden, die völlig neue Behandlungsmöglichkeiten 
bezüglich Autoimmun- und chronisch inflammatorischen Erkrankungen darstellen und 
insbesondere in der Transplantationsmedizin angewandt werden können. Unsere 
Forschungsgruppe hat in den letzten Jahren ein neuartiges Zell-basiertes medizinisches Produkt 
zur Therapie transplantierter Patienten entwickelt, das menschliche regulatorische 
Makrophagen enthält und als Mreg_UKR bezeichnet wird.  
 
Die Entwicklung dieser Zellen ist ein langer und komplizierter Prozess. Er beginnt mit fundierten 
Kenntnissen von Physiologie und Pathophysiologie der Makrophagen, vor allem von 
verschiedenen Polarisierungszuständen der Zellen und ihrer Funktion in Abstoßungsreaktionen 
und Reparaturmechanismen im Transplantat. Auf dieser Basis konnten wir einen 
immunregulatorischen Makrophagentyp identifizieren, der sich in vitro als T-Zell-suppressiv 
bewiesen hat. Diese sogenannten Mregs sind charakterisiert durch einen einzigartigen 
Differenzierungsgrad und unterscheiden sich in ihrer Herkunft und dem robusten Phänotyp 
deutlich von anderen Markophagen. Durch die IFN-γ-induzierte Indolamin-2,3-Dioxygenase-
Aktivität und die Eliminierung aktivierter T-Zellen nach direktem Zellkontakt sind Mregs in der 
Lage, die Proliferation Mitogen-stimulierter T-Zellen zu supprimieren und darüber hinaus die 
Bildung eines regulatorischen T-Zelltyps anzuregen (iTreg). Pharmakologische und 
toxikologische Sicherheitsstudien in Mäusen gaben keine Hinweise auf klinisch signifikante 
Nebenwirkungen nach Mreg-Applikation. Zwei Nieren-transplantierte Patienten sind mit einer 
Mreg-haltigen Zellsuspension behandelt worden. Mehr als fünf Jahre nach der Transplantation 
weisen beide Patienten eine stabile Nierenfunktion auf, trotz einer nur niedrig dosierten 
Tacrolimus-Monotherapie. Aufgrund dieser vielversprechenden Ergebnisse sollen nun im 
Rahmen der The ONE Study  detaillierte klinische Sicherheitsstudien durchgeführt werden. 
Meine Dissertation beschreibt den Entwicklungsprozess der Mregs als medizinisches Produkt 
ǀoŵ „LaďoƌtisĐh ďis hiŶ zuŵ KƌaŶkeŶďett͞.  
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Zusammenfassung 
Allgemeine Einleitung 
In der experimentellen Forschung ist es bereits eine weit verbreitete Methode, 
immunregulatorische Zellen eines immunologisch toleranten Spenders einem nicht toleranten 
Empfänger zu übertragen, um dadurch  eine immunologische Toleranz auf Seiten des 
Empfängers zu induzieren [1]. Dennoch hat die klinische Anwendung dieser Technik erst seit 
kurzem Aufmerksamkeit erlangt [2]. Zurzeit sind mehrere immunregulatorische Zelltypen im 
präklinischen Bereich so weit entwickelt, dass einige nun schon in frühen klinischen Studien als 
immunsuppressive Therapie geprüft werden. Zu diesen Zellen gehören unter anderem 
regulatorische T-Zellen [3], tolerogene dendritische Zellen [4] und die vielversprechenden 
regulatorischen Makrophagen, mit denen ich mich im Rahmen meiner Dissertation beschäftigt 
habe [5]. Ein breites Spektrum an Erkrankungen des Immunsystems könnte möglicherweise mit 
einer zellbasierten immunregulatorischen Therapie erfolgreich behandelt werden, wie 
beispielsweise T-Zell-vermittelte Autoimmunerkrankungen [6], chronische 
Entzündungsreaktionen [7], Graft-versus-Host-Reaktionen [8] und Abstoßungsreaktionen eines 
Transplantats [9]. Mit einer Zell-basierten immunregulatorischen Therapie könnte man die bis 
jetzt notwendigen immunsuppressiven Medikamente reduzieren oder gar umgehen und somit 
dem Patienten die bekannten gravierenden Nebenwirkungen der konventionellen 
immunsuppressiven Therapie ersparen. Da die immunologische Toleranz, die durch 
regulatorische Zellen induziert werden kann, von dominanter und selbsterhaltender Natur ist, 
besteht die fast unglaubliche Möglichkeit, Krankheiten zu heilen, die sonst eine lebenslange 
immunsuppressive Therapie erfordern würden.  
 
Diese Dissertation gibt einen Überblick über die wichtigsten Beiträge zuŵ Eƌfolg des „Mƌeg 
Pƌojekts͞ ǁähƌeŶd meiner dreijährigen Mitarbeit in der Abteilung für experimentelle Chirurgie. 
Schwerpunkte dabei sind die genetische Charakterisierung von Zellen, die Entwicklung der 
technischen Herstellung des Zellprodukts sowie die Evaluierung der pharmakologischen 
Eigenschaften der Zellen in Tierversuchen. Während dieser Zeit konnte ich zwei 
wissenschaftliche Arbeiten als Erstautor veröffentlichen und brachte mich als Koautor in 
diverse weitere Veröffentlichungen ein (s.u.). Daten, die ich bereits erhoben habe und bis jetzt 
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noch nicht publiziert wurden, werden in weiteren Veröffentlichungen unserer 
Forschungsgruppe zu finden sein. Diese Dissertation stellt also eine zusammenfassende 
Abhandlung meiner Publikationen dar. 
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Spezielle Einleitung 
Makrophagen sind extrem vielseitige Zellen, die in der Lage sind, sowohl immunstimulatorische 
als auch immunsuppressive Effekte auszuüben. Diese Wandlungsfähigkeit kann nicht einfach 
durch eine strikte Einteilung in bestimmte Untergruppen erklärt werden, sondern spiegelt 
vielmehr die Fähigkeit von Makrophagen wider, zwischen verschiedenen Funktionszuständen 
zu wechseln. Ein solcher einzigartiger Differenzierungsgrad wird durch die regulatorischen 
Makrophagen (Mregs) beschrieben, die sich durch ihre Herkunft, den robusten Phänotyp und 
durch ein ausgeprägtes Potential zur Immunsuppression auszeichnen [5]. Durch eine INF-γ-
induzierte Indolamin-2,3-Dioxygenase-Aktivität (IDO) sind Mregs in vitro in der Lage, den 
Proliferationsprozess Mitogen-stimulierter T-Zellen zu inhibieren und diese sogar nach 
direktem Kontakt aktiv zu eliminieren [10]. Dieses Potential macht Makrophagen zu einem 
durchaus interessanten und vielversprechenden Ziel in der Zell-basierten Therapie zur 
Toleranzinduktion in transplantierten Patienten. 
 
Bereits in präklinischen Experimenten konnte anhand von Herz-transplantierten Mäusen 
nachgewiesen werden, dass eine Behandlung mit Spender-Mregs das Überleben eines 
Allografts in nicht immunsupprimierten Empfängern verlängerte [11]. Es stellte sich heraus, 
dass sich die allogenetischen Makrophagen nach intravenöser Infusion zunächst in den 
pulmonalen Gefäßen aufhielten, bevor sie dann nach kurzer Zeit in weitere Organe migrierten, 
wie Leber, Milz und Knochenmark, nicht aber in periphere Lymphknoten. In diesen Organen 
persistierten die Mregs für etwa vier Wochen. Nach Applikation von 111Indium-Oxin-gelabelten, 
donorspezifischen Mregs wurden im menschlichen Organismus vergleichbare Ergebnisse erzielt 
[10]. Folglich scheinen Mregs nach Infusion in den Empfängerorganismus recht kurzlebig zu 
sein, sind aber dennoch befähigt, einen therapeutischen Nutzen zu erzielen, der weit über ihre 
Lebensdauer hinausgeht.  
 
Auch im klinischen Stadium hat die Zell-basierte immunsuppressive Therapie mit Mregs bereits 
erste Erfolge erzielt. Einfache Mreg-haltige Zellpräparate wurden insgesamt 19 Nieren-
transplantierten Patienten im Rahmen von Fallstudien und klinischen Studien infundiert [10, 
12–15]. Zwei weitere Patienten erhielten vor Lebendspende einer Niere stark gereinigte, 
donorspezifische Mregs. Zum jetzigen Zeitpunkt, mehr als fünf Jahre nach der Transplantation, 
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erfreuen sich beide Patienten einer guten Nierenfunktion mit einer nur sehr niedrig dosierten 
Tacrolimus-Einnahme als einzige immunsuppressive Erhaltungstherapie [10]. Aufgrund dieser 
einzigartigen Ergebnisse sollen nun im Rahmen der The ONE Study weitere klinische Studien mit 
größeren Patientenzahlen durchgeführt werden.  
 
Der genaue Wirkmechanismus von donorspezifischen Mregs nach Infusion in den Empfänger ist 
bislang ungeklärt. Jedoch gibt es einige Ansätze, die sowohl die Wirkung an T-Zellen als auch 
den anhaltenden Effekt nach Ableben der Mregs erklären können. Einerseits könnten Mregs 
direkt mit T-Zellen des Empfängers interagieren und so Effektorzellen anergisieren und sogar 
eliminieren, oder direkt die Bildung von regulatorische T-Zellen induzieren [9]. Andererseits ist 
bekannt, dass Alloantigene generell ein tolerogenes Potential entwickeln können [16]. Somit ist 
es sehr wahrscheinlich, dass Antigene von Mregs durch Antigen-präsentierende Zellen des 
Empfängers exprimiert werden, die so ihrerseits wiederum die T-Zell-Antwort modifizieren. 
Diese beiden generellen Mechanismen könnten selbstverständlich auch parallel zueinander 
ablaufen. 
 
Bevor Mregs als Zell-basierte immunsuppressive Therapie zugelassen werden können, ist es 
noch ein weiter Weg. Dennoch hat sich unsere Forschungsgruppe diesem Ziel genähert, indem 
der exakte Phänotyp der Zellen und mögliche Wirkmechanismen genau analysiert wurden. Der 
Herstellungsprozess als medizinisches Produkt wurde präzise und reproduzierbar erläutert, 
mögliche Nebenwirkungen und Risiken für den Patienten identifiziert. In den folgenden 
Zusammenfassungen meiner wissenschaftlichen Arbeiten sollen genau diese Elemente 
abgehandelt werden.  
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Ergebnisse - Hauptprojekte 
Meine zwei Veröffentlichungen mit Erstautorschaft repräsentieren den Hauptbestandteil 
meiner Doktorarbeit. Beide Projekte werden nachfolgend beschrieben. Anschließend sind die 
vier weiteren Arbeiten dargestellt, an denen ich mich mit meinen Ergebnissen beteiligt habe.    
 
Paper 1: Regulatory macrophages as therapeutic targets and therapeutic agents in solid organ 
transplantation 
Dieser Review gibt eine allgemeine Übersicht über die Physiologie der Makrophagen und ihre 
Rolle in Abstoßungsreaktionen bzw. Reparaturmechanismen nach Organtransplantation. 
Zudem ist es die Intention dieses Papers, die wichtigsten Forschungsergebnisse der letzten Zeit 
im Bereich der immunsuppressiven Makrophagen – also deŶ „status Ƌuo͞ –zu erfassen. Die 
Experimente in diesem Review, die ich mit konzipiert und im Labor durchgeführt habe, sind 
eine essentielle Grundlage für das Verständnis der Mregs und deren Weiterentwicklung zum 
Zell-basierten medizinischen Produkt: Via FACS- und qPCR-Validierungen konnte ich zunächst 
die verschiedenen Reifestadien von Monozyten des peripheren Blutes abgrenzen. Auf gleiche 
Weise konnte ich später den Genotyp der Mregs identifizieren. Basierend auf diesen 
handfesten Kriterien konnte ich den Herstellungsprozess von Mregs bezüglich Kulturdauer, 
Serum und Stimulation präzisieren. 
Zuletzt werden in diesem Review verschiedene Möglichkeiten zur Manipulation von 
Makrophagen erklärt, um das Überleben eines Transplantats ohne hochdosierte 
immunsuppressive Medikamente zu ermöglichen. 
 
Makrophagen sind extrem anpassungsfähige Effektorzellen, die mit völlig unterschiedlichen, oft 
sogar antagonistischen Aktivitäten im Immunsystem eine Rolle spielen: sie können eine 
Immunreaktion sowohl fördern als auch abmildern, Gewebe zerstören als auch regenerieren 
[17]. Neben der Fähigkeit zur Bildung von Abszessen und Granulomen reagieren Makrophagen 
äußerst sensibel auf pathologische Veränderungen in ihrer Umgebung. Dies ist auf ihre große 
Anzahl an Rezeptoren zurückzuführen, die sowohl einzelne Pathogene als auch Bestandteile 
abgestorbener Zellen erkennen können [18, 19]. Die so aktivierten Makrophagen sezernieren 
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daraufhin toxische Substanzen wie Perforin, Granzym und TNF-α. Außerdem dienen 
Makrophagen als professionelle Antigen-präsentierende Zellen und können hohe 
Konzentrationen an kostimulatorischen Molekülen exprimieren, wie beispielsweise 
verschiedene Zytokine [20]. Sie sind dadurch in der Lage, Immunantworten von naiven T-Zellen 
zu initiieren und so den Charakter von Reaktionen des erworbenen Immunsystems zu 
regulieren [21]. Umgekehrt sezernieren aktivierte T-Zellen wiederum Zytokine wie IL-12 und 
primen so weitere Makrophagen, wodurch die Immunantwort zusätzlich verstärkt wird. Nach 
dem gleichen Prinzip werden auch die Hemmung eines Immunprozesses, 
Geweberekonstruktion und Gefäßneubildungen durch anti-inflammatorische Eigenschaften von 
Makrophagen bewirkt. Hier spielt die Unterdrückung von T-Zellen durch IL-10 die tragende 
Rolle [22].   
 
Abhängig von der Art des aktivierenden Stimulus und des Einflusses von anderen Effektorzellen 
ändern Makrophagen ihre Expression von Zytokinen, kostimulatorischen Molekülen und ihre 
zytotoxischen Mechanismen, um eine möglichst passende Immunantwort zu induzieren. Je 
nach Funktionsprinzip werden Makrophagen deswegen von einigen Autoren in M1- bzw. M2-
polarisierte Zellen unterteilt, die entweder die Immunantwort von Th1-Zellen bzw. Th2-Zellen 
vorantreiben [23]. Diese Einteilung ist jedoch aus mehreren Gründen kritisch zu betrachten, 
nicht zuletzt weil sie keinen Raum lässt für die Differenzierung des 
regulatorischen/suppressiven Makrophagentyps [24–26]. Suppressive Eigenschaften in 
kultivierten Makrophagen werden durch verschiedenste Stimuli induziert, wie beispielsweise 
M-CSF, IL-10, 1,25-Dihydroxyvitamin D3 und Glukokortikoide [27–31]. Besonders die 
Kombination aus 1,25(OH)2D3 und Glukokortikoiden erzeugt ein sehr stabiles 
immunsuppressives Stadium [32]. Paradoxerweise können auch proinflammatorische Faktoren 
wie INF-γ, TLR-2, TLR-4, TLR-9 und PGE2 über verschiedene Mechanismen suppressive 
Funktionen in Makrophagen induzieren und so die Proliferation von Effektor-T-Zellen 
verhindern, die Bildung von regulatorischen T-Zellen induzieren und immunologische Toleranz 
etablieren [7, 33–43].   
 
Mit dem Ziel, ein Zell-basiertes medizinisches Produkt zur Induktion immunologischer Toleranz 
nach Transplantationen zu erhalten, hat sich unsere Forschungsgruppe auf die sogenannten 
regulatorischen Makrophagen (Mregs) konzentriert. Diese Zellen stellen durch ihren robusten 
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Phänotyp und ihre potente Suppression von T-Zellen in vitro entweder durch 
Indolamindioxygenase-Aktivität oder durch direkten Zell-zu-Zell-Kontakt einen einzigartigen 
Differenzierungsgrad dar. Mregs entstammen CD14+ peripheren Monozyten aus dem Blut und 
reifen in einer 7-tägigen Zellkultur. Während dieser werden die Zellen M-CSF, 10% humanem 
Serum und am Ende einem 24-stündigem Zusatz INF-γ ausgesetzt [44]. Die so erhaltenen Mregs 
zeichnen sich durch eine besondere Zellmorphologie aus und sind homogen CD14-/low HLA-DR+ 
CD80-/low CD86+ CD16- CD64+ TLR2- TLR4- und CD163-/low [10]. Außerdem sind sie befähigt, 
regulatorische T-Zellen zu induzieren (iTregs, siehe Paper 5).  
 
Als eine vielseitige Zellart, die bei Transplantationen sowohl das angeborene als auch das 
erworbene Immunsystem aktivieren oder abschwächen kann, sind Makrophagen ein 
interessantes therapeutisches Ziel. Es können drei Mechanismen in Erwägung gezogen werden, 
um nutzbringende immunregulatorische Prozesse und Gewebsheilung in Gang zu setzen und 
gleichzeitig schädliche Immunprozesse zu unterbinden. Zunächst besteht die Möglichkeit – wie 
bereits an Tierversuchen gezeigt – Makrophagen zu eliminieren, die sonst das Transplantat 
schädigen. Klinisch einsetzbare Antikörper sind jedoch noch in der Entwicklungsphase und 
stehen derzeit nicht zur Verfügung [45].  Alternativ kann versucht werden, die Rekrutierung von 
Makrophagen zu verhindern [46–49]. Eine zweite Möglichkeit stellt die Transformation von 
Makrophagen in Richtung eines suppressiven Phänotyps in vivo dar. Einige Medikamente, die 
heute in der Transplantationsmedizin eingesetzt werden (mTOR-Inhibitoren, Mycophenolat 
Mofetil, IVIg), sind in der Lage, den Reifungsgrad und die Zytokinsekretion von Makrophagen zu 
verändern [50–60]. Eine dritte, sehr elegante Methode, stellt die Isolation von Monozyten dar, 
die in Kulturen zu suppressiven Makrophagen (Mregs) differenziert werden. Diese Zellen 
können dann als medizinisches Produkt in transplantierten Patienten angewandt werden. 
Unsere Forschungsgruppe kann als Vorreiter in der Anwendung dieser zellbasierten Therapie 
für Organ-transplantierte Patienten angesehen werden. Die generelle Durchführbarkeit und 
Verträglichkeit dieser Therapie wurde bereits an insgesamt 20 Nieren-transplantierten 
Patienten in zwei klinischen Studien der Phase I mit einfachen Zellpräparationen, die 
regulatorische Makrophagen enthielten, bestätigt (TAIC-I-/ TAIC-II-Studien) [12–15]. Zwei 
weitere Nieren-transplantierte Patienten wurden im Rahmen einer Fallstudie mit gereinigten 
Mreg-Präparaten des Spenders behandelt [10]. Genauere Details hierzu werden in der 
Zusammenfassung des Papers 3 beschrieben. 
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Paper 2: In question: the scientific value of preclinical safety pharmacology and toxicology 
studies with cell-based therapies 
Im nachfolgenden Paper wurden die Versuche durch mich geplant und größtenteils 
durchgeführt. Lediglich die Transplantationen, das Infundieren der Zellpräparate sowie das 
Gewinnen von Gewebe post mortem wurden freundlicherweise von spezialisierten medizinisch 
technischen Assistenten übernommen.  
 
Die Richtlinie der europäischen Arzneimittelagentur für Zell-basierte medizinische Produkte 
schreibt vor, dass neue Zellprodukte den allgemeinen pharmakologischen und toxikologischen 
Sicherheitsstudien unterzogen werden müssen, welche normalerweise an Tiermodellen erstellt 
werden. In dieser Arbeit werden deshalb die Pharmakokinetik und die 
Sicherheitspharmakologie eines Mreg-haltigen Zellprodukts an immundefizienten Mäusen 
überprüft.  
 
Um Überlebensdauer von Mregs und deren Verteilung im Gewebe zu detektieren, wurden NSG 
Mäuse mit humanen Mregs behandelt. Die qualitative Anwesenheit in verschiedenen Organen 
wurde via Durchflusszytometrie überprüft. Mregs waren in der Lunge, im Blut und in der Leber 
bis sieben Tage nach der Infusion nachweisbar und behielten ihren Phänotyp während dieser 
Beobachtungsphase bei.  
 
Athymische Nacktmäuse wurden in drei Testgruppen inkl. Kontrollgruppe mit unterschiedlich 
hohen Mreg Konzentrationen behandelt. Genaue Beobachtungen innerhalb drei Stunden nach 
Infusion ergaben keine Hinweise auf klinisch fassbare Reaktionen, v.a. bezüglich Herzfrequenz 
und –rhythmus. Weitere Untersuchungen in den nächsten sieben Tagen waren ebenfalls 
unauffällig: Todesfälle, Störungen im Herz-Kreislaufsystem, respiratorische, konstitutionelle und 
neurologische Probleme waren nicht zu vermerken. Auch post mortem zeigten sich keine 
Pathologien und kein Unterschied zwischen der Kontrollgruppe und den mit Mregs 
behandelten Mäusen.  
 
Da Mregs scheinbar primär in die Leber wandern, wurden Empfängermäuse auf pathologische 
Leberwerte untersucht. Serumalbumin und alkalische Phosphatase (auch Parameter bei 
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systemischen Entzündungsreaktionen und erhöhtem Knochenstoffwechsel) waren in keiner 
Behandlungsgruppe signifikant erhöht. Jedoch zeigte sich eine erhöhte AST in der Gruppe mit 
der höchsten Mreg Exposition, wobei die Bedeutung dieses Phänomens bislang unklar ist. 
Wichtig ist dabei, dass in den mit Mregs behandelten menschlichen Patienten keine 
eingeschränkte Leberfunktion bemerkt wurde. Serumkreatininwerte als Parameter der 
Nierenfunktion und Blutzuckerspiegel, Indikator für Ischämie, Sepsis und endokrine Störungen, 
waren ebenso unauffällig.  
 
Weiterhin ist es essenziell, das Risiko der Sensibilisierung zu erfassen. Dazu wurden in Herz-
transplantierten BALB/c Mäusen nach präoperativer Donor-Mreg-Therapie die 
donorspezifischen anti-MHC-Klasse-I Antikörper gemessen. Es war kein vorzeitiger Verlust der 
Transplantate zu vermerken, sodass davon ausgegangen werden kann, dass die präoperative 
Behandlung mit Mregs zu keiner Sensibilisierung geführt hat. Diese Schlussfolgerung wird 
dadurch gefestigt, dass sieben Tage nach Transplantation geringere Mengen an Alloantikörper 
in den mit Mregs behandelten Mäusen nachgewiesen wurden als in der Kontrollgruppe. Dieses 
Ergebnis kann jedoch nicht einfach auf den menschlichen Organismus übertragen werden, da 
Mäuse-Mregs nicht identisch mit denen von Menschen sind, also auch eine unterschiedliche 
Immunogenität aufweisen könnten. 
 
Um die Toxizität und Karzinogenität von infundierten Mregs zu beurteilen, wurden in drei 
Gruppen C.B-17 SCID-Mäuse mit unterschiedlichen Dosierungen Mreg-haltiger 
Zellpräparationen behandelt. Innerhalb von 295 Tagen sowie post mortem konnten zu keinem 
Zeitpunkt Hinweise auf Tumore, biochemische oder hämatologische Störungen und 
histopathologische Veränderungen erfasst werden.  
 
Es kann also davon ausgegangen werden, dass sich an Tiermodellen die Behandlung mit Mregs 
als sicher erwiesen hat und daher die Anwendbarkeit einer Mreg-basierten Therapie für 
Menschen zukünftig im Focus stehen sollte. Es bleibt fraglich, ob die Ergebnisse präklinischer 
Sicherheitsstudien mit einem immunologisch aktivem Zell-Produkt wie Mregs ohne 
Einschränkungen auf den Menschen übertragen werden können. Ein zentrales Problem stellt in 
diesem Fall die Inkompatibilität der unterschiedlichen Spezies dar, durch die entweder die 
biologische Relevanz ausbleibt oder keine direkte Information über das menschliche 
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Zellprodukt geliefert wird. Auch was das Risiko der Sensibilisierung betrifft, können aufgrund 
präklinischer Studien keine Rückschlüsse auf den menschlichen Organismus gemacht werden, 
da tierische und menschliche Mregs zwar ähnlich, nicht aber identisch sind und so ein 
unterschiedlich ausgeprägtes immunogenes Potential haben können. 
 
Diese Schwachpunkte lassen auf den ersten Blick die Ergebnisse der Sicherheitsstudien weniger 
relevant erscheinen. Diese Problematik steht zunächst in Konflikt mit den Vorgaben des EMA 
Komitees (European Medicines Agency) für menschliche medizinische Produkte. Dennoch 
sollten aufgrund der medizinischen Relevanz und aufgrund der positiven Pilotstudien weitere 
klinische Studien gemäß der EMA Richtlinien durchgeführt werden, um eine vage Vorstellung 
über Sicherheit und Pharmakokinetik der Zellen zu erhalten.  
 
Aus den o.g. Gründen sollte ein größerer Schwerpunkt auf klinische Studien mit Mregs gesetzt 
werden. Betrachtet man die präklinischen Ergebnisse zusammen mit der klinischen Erfahrung, 
die bereits mit Mregs gemacht wurde, so kann berechtigterweise gefordert werden, in Zukunft 
mehr explorative klinische Studien zuzulassen, ohne dass umfangreiche Tierexperimente 
durchgeführt werden müssen. 
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Ergebnisse - Nebenprojekte 
Im Laufe meiner Mitarbeit in unserer Forschungsgruppe war ich in eine Reihe von Projekten 
involviert, die sich mit dem Thema Mregs beschäftigt haben. Die entsprechenden 
Veröffentlichungen werden im Folgenden beschrieben. Sie belegen mein Mitwirken am Projekt 
Mreg und die Tragweite meiner Experimente im weiteren Sinne zu belegen. Diese 
Veröffentlichungen stellen jedoch nicht den Hauptbestandteil meiner Doktorarbeit dar. 
Eingebracht habe ich mich in diese Projekte hauptsächlich mit den Ergebnissen und Techniken 
meiner Versuche der beiden oben genannten Papers sowie Herstellung der diversen 
Zellkulturen.  
 
Paper 3: Immunological consequences and trafficking of human regulatory macrophages 
administered to renal transplant recipients 
In dieser Arbeit werden zwei Fälle Nieren-transplantierter Patienten beschrieben, die 
erfolgreich mit Mregs zur immunsuppressiven Therapie behandelt wurden. MM ist eine 23-
jährige Patientin, die ein Spenderorgan von ihrer Mutter erhielt (HLA-B und HLA-DR) und sechs 
Tage vor der Transplantation einer zentralvenösen Infusion mit 8.0 x 106 Spender-Mregs 
unterzogen wurde unter Absicherung von Azathioprin sowie später Steroiden und Tacrolimus. 
Azathioprin und Steroide wurden einige Wochen nach Transplantation ohne gravierende 
Effekte abgesetzt, Tacrolimus bei konstant guter Nierenfunktion auf niedrigste 
Serumkonzentrationen reduziert. Vergleichbar wurde mit dem 47-jährigen Patienten CA 
verfahren, der die Niere eines nicht verwandten Spenders erhielt (kompletter HLA-Mismatch).  
 
In Biopsien von Patientin MM konnten zu keinem Zeitpunkt Zeichen einer akuten 
Abstoßungsreaktion gefunden werden. In peripheren Blutproben war keine T-Zellexpansion zu 
erkennen, was als Anzeichen für eine fehlende Aktivität der T-Zellen gegenüber dem 
Transplantat gedeutet werden kann. Normale TOAG-1-Expression – bei akuten 
Abstoßungsreaktionen massiv vermindert – und das Fehlen von HLA-Antikörpern ist ebenfalls 
als )eiĐheŶ eiŶeƌ iŵŵuŶologisĐheŶ ToleƌaŶz zu ǁeƌteŶ. Die )uŶahŵe des Foǆpϯ/α-
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Mannosidase-Verhältnis nach etwa vier Wochen kann darauf hindeuten, dass die Anzahl an 
regulatorische T-Zellen im Verhältnis zu aktivierten inflammatorischen T-Zellen relativ zunahm.  
 
Neben den immunologischen Parametern wurde bei Patientin MM das Verhalten von Mregs im 
menschlichen Körper verfolgt. Hierzu wurde ein Teil der infundierten Mregs mit 111Indiumoxin 
markiert und mittels Ganzkörperspektroskopie dargestellt. Die Mregs hielten sich zunächst im 
Lungenkreislauf auf, bevor sie sich nach etwa drei Stunden im Blutkreislauf verteilten und dann 
in Leber, Milz und Knochenmark anreicherten. Die Abwesenheit von Mregs im Harntrakt 
beweist, dass die meisten Mregs nach Infusion zunächst am Leben bleiben. Auch wenn uns 
diese Beobachtungen eine vorläufige Beschreibung über das pharmakodynamische Verhalten 
von infundierten Mregs geben, ist dennoch das weitere Schicksal dieser Zellen unklar.  
 
Die immunologischen Parameter von Patient CA verhielten sich vergleichbar zu denen von 
Patientin MM. Die Genexpression beider Patienten wurde mehrfach genau analysiert und 
anhand des Indices of Tolerance (IOT) Forschungsnetzwerks evaluiert. Sowohl Patientin MM als 
(etwas später) auch Patient CA ähnelten in Bezug auf ihr genetisches Profil gesunden 
Testpersonen bzw. toleranten Patienten.  
 
Auch wenn die Applikation von Zellpräparaten sicherlich nicht ohne Risiko ist, haben die Fälle 
beider Patienten die Realisierbarkeit dieser immunsuppressiven Therapie bewiesen. Weder 
MM noch CA zeigte unerwünschte Nebenwirkungen auf das Zellprodukt, und in beiden Fällen 
konnte schon nach wenigen Wochen die sonst übliche, hochdosierte immunsuppressive 
Therapie massiv reduziert werden, ohne dass es zu einer Abstoßungsreaktion des Transplantats 
kam. Sogar zum jetzigen Zeitpunkt, über fünf Jahre nach der Transplantation, sind die 
Nierenwerte beider Patienten stabil und zufriedenstellend. Aufgrund dieser überzeugenden 
Ergebnisse können an das Zellprodukt Mreg hohe Erwartungen gestellt werden. Im Rahmen der 
The ONE Study sollen deswegen weitere klinische Studien durchgeführt werden, wie 
beispielsweise die Studie ONEMreg12, in der 16 Patienten mit Spender-Mregs und begleitender 
MMF Therapie sieben Tage vor Transplantation behandelt werden sollen.  
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Paper 4: Clinical management of patients receiving cell-based immunoregulatory therapy 
Auch wenn die Anwendung immunregulatorischer Zellen als medizinisches Produkt ein 
revolutionärer Ansatz zur Toleranzinduktion ist, muss dennoch Klarheit bestehen über die 
Anwendung, die pharmakologischen Eigenschaften und über potentielle klinische Risiken für 
den Patienten. Diese sollen im Folgenden anhand von Beispielen Nieren-transplantierter 
Patienten kritisch bewertet werden.  
Wie Transfusionen mit Spendervollblut gezeigt haben [61], besteht nach präoperativem 
Kontakt mit Spender-Antigenen die Gefahr der Sensibilisierung. Spender-reaktive T- und B-
Zellen könnten aktiviert werden und somit eine akute Abstoßungsreaktion in Gang setzen [62, 
63]. Vollblut besteht jedoch aus Thrombozyten, Erythrozyten und Leukozyten mit einem großen 
Anteil potentiell aktivierender Antigen-präsentierender Zellen. Das Mreg-Zellprodukt hingegen 
enthält nur eine einzige homogene Zellpopulation und wird im Gegensatz zu donorspezifischen 
Bluttransfusionen nur einmalig appliziert, was das kumulative Risiko der Sensibilisierung 
abwendet. Außerdem haben präklinische und klinische Daten gezeigt, dass die Gefahr der 
Sensibilisierung gegen Spenderantigene nach Mreg-Applikation äußerst gering ist [10, 13–15].  
 
Eine weitere Problematik stellen Hypersensitivitätsreaktionen nach Mreg-Infusion dar. Bis jetzt 
zeigte keiner der mit Mregs behandelten Patienten Zeichen einer IgE-vermittelten 
Hypersensitivität (Typ I-Reaktion). Da das Risiko dennoch bestehen bleibt, ist die Therapie mit 
Mregs bei Patienten mit Heparinallergie oder IgA-Mangel untersagt [64]. Zudem ist die 
Möglichkeit einer Antikörper- oder Komplement-vermittelten Typ II-Reaktion nicht 
ausgeschlossen, da fieberhafte und hämolytische Reaktionen auch nach Transfusion anderer 
Blutbestandteile beobachtet wurden [65, 66].  Auch wenn bei einer Antikörper-vermittelten 
Destruktion von infundierten Mregs nicht mit solch schwerwiegenden Folgen zu rechnen ist, 
müssen bei der Herstellung von Mreg-Infusionen sämtliche Antikörper gegen Blutbestandteile 
des Spenders herausgefiltert werden. Zur Vermeidung einer nicht-hämolytischen Typ II-
Reaktion soll in weiteren klinischen Mreg-Studien prophylaktisch Paracetamol zur Antipyrese 
zum Einsatz kommen [67]. Im Falle einer fieberhaften Reaktion soll zunächst die Infusionsrate 
vermindert, bei Persistenz der Symptome muss die Infusion abgesetzt werden.  
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Auch ist das geringe Risiko einer Immunkomplex-vermittelten Reaktion (Typ III) nicht gänzlich 
auszuschließen,  obwohl  eine derartige Komplikation nach Bluttransfusionen und bei den mit 
Mregs behandelten Patienten nicht aufgefallen ist.  
 
Eine seltene, aber gefürchtete Komplikation nach Bluttransfusionen ist die Graft-versus-Host-
Krankheit (GvHD) [68]. Sie wird durch alloreaktive T-Zellen hervorgerufen, die vom Empfänger 
nicht abgewehrt werden können. Für die Herstellung von Mregs werden magnetische 
Polymerpartikel verwendet, um selektiv CD14+ Monozyten als Startmaterial zu erhalten und so 
die meisten anderen Leukozyten wie T-Zellen von der Zellpräparation auszumustern. Die 
Kontamination mit T-Zellen in einem Mreg-Produkt liegt typischerweise unter 1% und so ist die 
Wahrscheinlichkeit einer GvHD nach Infusion sehr gering.   
 
Ein weiteres Problem nach Transfusionen im Allgemeinen ist das sogenannte Transfusions-
bedingte Lungenödem (TRALI), hervorgerufen durch aktivierte neutrophile Granulozyten und 
Thrombozyten, die das Endothel in den pulmonalen Gefäßen schädigen [65]. Bis jetzt gibt es 
keinen Hinweis, dass Mregs neutrophile Granulozyten der Lunge aktivieren können. Dennoch 
sollen Mreg-Präparate nicht Patienten infundiert werden, die erhöhte Werte neutrophiler 
Granulozyten aufweisen.  
 
Neben den immunologischen Risiken müssen auch physiologische Komplikationen reflektiert 
werden. Wird ein Zellprodukt zentralvenös appliziert, können durch Zellaggregate, 
Ablagerungen oder Embolisation pulmonale Gefäße verschlossen werden. Mregs in einer 
Suspension haben einen Durchmesser von etwa 15-ϯϬμŵ, KapillaƌeŶ ďzǁ. AƌteƌioleŶ deƌ 
ŵeŶsĐhliĐheŶ LuŶge Đa. ϳ.ϱμŵ ďzǁ. ϭϱ-ϭϱϬμŵ [69]. Demnach ist es denkbar, dass einzelne 
Mregs kleine Endarteriolen verschließen können. Experimente in Großtieren haben gezeigt, 
dass die Infusion von ca. 108 Zellen/kg/KG oder ähnlich großer Partikel eine tödliche Dosis 
darstellt, während ca. 107 Zellen/kg/KG nur einen signifikanten Anstieg des mittleren 
pulmonalarteriellen Drucks (PAP) bewirken [70–73]. Diese Dosen liegen jedoch weit über der 
empfohlenen Dosis einer Mreg-Infusion für Patienten (2.5 – 7.5 x 106 Mregs/kg/KG). Somit kann 
nach langsamer Infusion der mittlere PAP ansteigen, jedoch ist ein Patient mit normaler 
Herzfunktion in der Lage, diese Veränderung zu kompensieren. Dennoch werden im Rahmen 
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der ONEmreg12 Studie Patienten mit hochmolekularem Heparin voll antikoaguliert um das 
Risiko einer intrapulmonalen Koagulation zu verhindern. 
 
Auch das Überangebot an Flüssigkeit durch die Infusion mit Gefahr eines Lungenödems muss 
kritisch evaluiert werden. Eine Mreg-Infusion beinhaltet 100ml, zusätzlich können bis zu 400ml 
Spülflüssigkeit benötigt werden. In kürzlich dialysierten Patienten sollte aber eine langsame 
Infusion dieser Menge keine klinisch signifikanten Ödeme hervorrufen.  
 
Einige biochemische Veränderungen sollen noch erörtert werden: Nach Mreg-Infusion ist eine 
unmittelbare Zelllyse nicht auszuschließen, was theoretisch zur Hämolyse führen kann. Da 
jedoch die therapeutischen Dosen von Mregs sehr gering sind, ist eine derartige Komplikation 
nicht zu erwarten. Außerdem könnten Mregs aufgrund ihrer Expression von TNF-α die 
Produktion von Tissue-Faktor induzieren und so einen leichten pro-koagulatorischen Effekt  im 
menschlichen Organismus bewirken. In den bis jetzt behandelten Patienten waren jedoch keine 
Anzeichen eines thrombotischen Geschehens zu erkennen. Ein höheres Risiko besteht in der 
Aktivierung der Bradykinin-Sekretion als Folge der aktivierten Gerinnungskaskade. Vor allem in 
Kombination mit ACE-Hemmern kann dies zu ausgeprägten hypotensiven Reaktionen führen.  
 
Durch eine Mreg-Infusion könnten neoplastische Zellen übertragen oder das Wachstum 
autochtoner Tumore begünstigt werden [17]. Malignität wird jedoch meist durch primitive 
Formen der myelomonozytären Zellreihe und nicht durch post-mitotische Monozyten bzw. 
Makophagen hervorgerufen. Außerdem ergab die Behandlung immundefizienter Mäuse mit 
Mregs keine Hinweise auf maligne Entartungen (siehe Paper 2).  
 
Die Übertragung von möglichen Keimen zählt ebenfalls zu den potentiellen Risiken der Mreg-
Therapie.  Deshalb wird im Spender und auch während des Herstellungsprozesses nach 
strengen Vorgaben regelmäßig nach bestimmten Erregern gefahndet. So kann das 
Infektionsrisiko minimiert werden.  
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Paper 5: Generation of BTNL8+ iTregs by Human Regulatory Macrophages is IDO- and B7-
dependent 
Neben der Fähigkeit zur T-Zell-Suppression bzw. Eliminierung sind Mregs in der Lage, 
regulatorische T-Zellen zu induzieren (iTregs). Eine signifikante Hochregulation von CD25 
konnte in CD4+-Zellen nach Ko-Kultur mit Mregs detektiert werden. Um die 
Suppressionsleistung zu prüfen, wurden T-Zellen nach Mreg Ko-Kultur re-isoliert und mit 
Responder-T-Zellen kultiviert. Dabei wurde die Proliferation von stimulierten Responder-T-
Zellen verhindert. Außerdem konnte gezeigt werden, dass CD4+ T-Zellen nach Mreg-Ko-Kultur 
die vollständige Reifung dendritischer Zellen unterbinden. Diese Erkenntnisse können Hinweis 
dafür sein, dass die therapeutischen Effekte von Mregs auch noch nach deren Ableben anhalten 
und so eine lebenslange Toleranz in transplantierten Patienten ausgebildet wird. 
 
Die Genanalyse von T-Zellen nach Ko-Kultur mit Mregs zeigte Gene wie EBI3 und FOXP3 
hochreguliert, die klassische Treg-assoziierte Marker darstellen. Vergleichbare Ergebnisse 
waren in der Durchflusszytometrie zu erkennen. Die Stabilität der iTregs wurde anhand der 
FOXP3-Expression gemessen: nach 10 Tagen ohne Restimulation nahm die FOXP3-Expression 
bis auf ca. 64% des Ausgangswerts ab. Interessanterweise exprimieren Mregs während der Ko-
Kultur mit T-Zellen relativ viel SOCS2 mRNA, die einen stabilisierenden Einfluss auf FoxP3+ Tregs 
hat [74].  
 
Bei der genetischen Identifikation  von iTregs fiel als immunologisch relevanter Marker vor 
allem das Butyrophilin-like Protein 8 (BTNL8) auf, das funktionell mit den B7-kostimulatorischen 
Molekülen verwandt ist [75]. Genaue Analysen haben gezeigt, dass in Vergleich zu CD4+ T-
Zellen in iTregs die B7-like Splicevariante von BTNL8 exprimiert wird. Hingegen herkömmlicher 
Meinung ist BTNL8 auch in CD4+-Zellen des menschlichen Blutes nachweisbar, vor allem in nicht 
aktivierten CD4+-Zellen und zentralen T-Gedächtniszellen. Zudem ist bekannt, dass orthologe 
BTNL-Gene in Mäusen T-Zell-suppressive Eigenschaften aufweisen [76–78]. Mit dieser 
Information lässt sich spekulieren, dass BTNL8 die T-Zellaktivierung limitiert und somit Zellen 
wie iTregs einen immunsuppressiven Charakter verleiht.  
 
Die genauen Mechanismen, mit denen Mregs eine T-Zell-Antwort beeinflussen, sind noch nicht 
geklärt. Klar ist, dass sich Mregs von allen bisher beschriebenen Polarisationszuständen in 
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Makrophagen unterscheiden, nicht zuletzt durch ihre ausgeprägte Expression von DHRS9, einer 
wenig bekannten Retinol-Dehydrogenase [79]. Retinolsäure spielt in der Induktion und 
Stabilisierung von Tregs eine tragende Rolle [80]. Es lässt sich also vermuten, dass die DHRS9 
Expression von Mregs bei der Interaktion mit T-Zellen bedeutend ist.  
 
Die Induktion von iTregs ist nicht Alloantigen-abhängig, denn sie wurde auch in autologen Ko-
Kulturen beobachtet. Experimente haben bewiesen, dass zudem ein direkter physiologischer 
Kontakt zwischen Mregs und T-Zellen unabdinglich ist. Die Induktion von iTregs geschieht über 
den B7-kostimulatorischen Signalweg durch einen IDO-abhängigen Mechanismus, welcher 
durch Medikamente wie Tacrolimus oder Rapamycin nicht beeinflusst wird.  Die IDO-Aktivität 
scheint aber nicht der einzige relevante Mechanismus zu sein: INF-γ-Makrophagen werden 
ähnlich wie Mregs kultiviert, jedoch nicht in Humanserum (HABS) sondern in fetalem 
Kälberserum (FCS). Sie sind aber nicht in der Lage, die Bildung von iTregs anzuregen. Folglich 
sind zusätzliche Wirkmechanismen zur Induktion von iTregs vonnöten, die nur Mregs zu eigen 
sind und entweder durch Faktoren in HABS induziert oder aber durch FCS inhibiert werden.  
  
Treffen diese in vitro erhobenen Erkenntnisse über Mregs und iTregs auch auf ihre 
Eigenschaften in vivo zu, könnte dies eine Erklärung für den anhaltenden immunsuppressiven 
Effekt einer Mreg-Therapie sein. Es ist zu hoffen, dass die oben erwähnten Parameter im 
Rahmen der The ONE Study Mreg Studie auch in therapierten Patienten untersucht werden.  
 
Paper 6: Laser ablation-inductively coupled plasma mass spectrometry: An emerging 
technology for detecting rare cells in tissue sections  
Ausschlaggebend zur Bestimmung biologischer Effekte und Sicherheit eines Zell-basierten 
medizinischen Produkts ist die Pharmakokinetik, also die Verteilung und das Schicksal der Zellen 
im menschlichen Organismus. Im Falle von Mregs ist dies jedoch problematisch, da keine 
adäquaten Methoden zur Verfügung stehen, die Zellen nach Infusion im Patienten längerfristig 
zu verfolgen. Die laser ablation inductively coupled Massenspektrometrie (LA-ICP-MS) stellt ein 
Verfahren dar, das kleinste Proben, z.B. seltene Erdmetalle, mit einem fokussierten Laserpuls 
vaporisiert. Das vaporisierte Material wird dann mit Hilfe der Massenspektrometrie analysiert. 
Die in dieser Arbeit beschriebene Technik ermöglicht es, menschliche Mregs zu detektieren.  
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Mregs werden dual mit Gold und mit 154Samarium-markierten Anti-HLA-DR oder 174Ytterbium-
markierten anti-CD54 Antikörpern gelabelt. Auf diese Weise können die Zellen mit Hilfe des LA-
ICP-MS in Geweben äußerst präzise nachgewiesen werden. Mausmodelle zeigten auf diese 
Weise, dass sowohl eine als auch sieben Stunden nach Mreg-Infusion die Zellen in der Lunge, 
der Leber und der Milz nachgewiesen werden konnten.   
 
Dieses Verfahren ist noch weit davon entfernt, als Standard in der immunologischen Forschung 
zu dienen. Nicht zuletzt die Auflösung der Bilder, die Markierungsverfahren sowie die zeitliche 
Verarbeitung sind verbesserungsbedürftig. Dennoch präsentieren die Daten ein 
außerordentliches Potential der LA-ICP-MS-Technologie, biologische Einzelproben zu 
detektieren, was als äußerst vielversprechend in Bezug auf klinische Mreg-Studien angesehen 
werden kann. 
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Ausblick 
Mregs haben unserer Meinung nach ein ausgesprochenes Potential zur effektiven Zell-basierten 
immunsuppressiven Therapie. Wäre es möglich, mit einer Mreg-Therapie die jetzigen 
Abstoßungsraten nach Organtransplantation zu erhalten und gleichzeitig aber die schädlichen 
Wirkungen der herkömmlichen Immunsuppressiva zu vermeiden, so könnte die Morbidität und 
Mortalität transplantierter Patienten wesentlich reduziert werden. Genau dies ist das Ziel, das 
wir mit der Entwicklung der Mreg-basierten Therapie verfolgen. Die Pilotstudien mit den 
Patienten MM und CA haben die generelle Durchführbarkeit einer solchen Therapie in 
transplantierten Patienten bewiesen, auch wenn es noch weiterer größer angelegter Studien 
bedarf, um eine definitive Aussage zur Effektivität dieser Zellen zu treffen.  
 
Die Wirkweise und Effektivität einer Mreg-Therapie, besonders in Bezug auf die T-Zell-
Interaktion, konnte bereits an Tiermodellen gezeigt werden. Diese Ergebnisse sind jedoch nicht 
einfach auf den menschlichen Organismus zu übertragen: menschliche Mregs als Zellprodukt 
können im Menschen selber andere immunologische Reaktionen hervorrufen als in Tieren. 
Dennoch muss Klarheit geschaffen werden über die genaue Pharmakokinetik und die 
Wirkmechanismen im Menschen. Die einzige Möglichkeit, dieses Ziel zu erreichen, sind weitere 
klinische Untersuchungen. Doch wie können diese gerechtfertigt werden? Betrachtet man die 
wenigen bis  jetzt durchgeführten klinischen Studien mit Mreg-haltigen Präparaten zusammen 
mit den Ergebnissen der präklinischen Sicherheitsstudien, so waren keinerlei schwerwiegende 
Komplikationen nach Mreg-Infusion erkennbar.  Auch wenn dies nur eine vage Sicherheit ist, 
sollte in Zukunft der Fokus auf klinische Studien gesetzt werden.  
 
Methoden wie das LA-ICP-MS sind bereits in Entwicklung, um genaue Details über das 
Verhalten von Mregs im menschlichen Körper nachzuvollziehen. Verschiedene Parameter in T-
Zellen wurden identifiziert, um auch den Wirkmechanismus zwischen Mregs und Tregs im 
Menschen zu verstehen. Genau dieses Ziel verfolgt die ONEmreg12-Studie: unter genauer 
Überwachung sollen insgesamt 16 Nieren-transplantierte Patienten mit donorspezifischen 
Mregs unter MMF-Therapie sieben Tage vor Transplantation behandelt werden und genauere 
Auskunft über das Verhalten von Mregs und ihren anhaltenden immunsuppressiven Effekt 
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geben. Aufgrund der bis jetzt äußerst vielversprechenden Ergebnisse der Mreg-basierten 
Therapie kann dieser Studie – sowie auch weiteren klinischen Studien – durchaus positiv 
entgegengeblickt werden.  
 
Insgesamt kann also die Zell-basierte immunsuppressive Therapie mit Mregs als sehr 
aussichtsreich angesehen werden. Das erhebliche Potential dieser Zellen sollte genutzt werden 
und – wie in der ONEmreg12-Studie – weitere klinische Studien mit einer größeren 
Patientenzahl durchgeführt werden.  
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An Essay on the Biology of Macrophages 
The role of macrophages in innate and adaptive immunity 
Macrophages play an important role in innate immunity. They are located in areas which are 
easily reached by pathogens, such as the airway or gastrointestinal tract, and thus are often the 
first cells to initiate an immune response. Once macrophages encounter an antigen, they 
phagocytose it and the inflammatory cascade is launched, recruiting other immunological cells, 
which for their part are responsible for the further resolution of an infection. As part of this 
defence mechanism, macrophages are responsible for the formation of granulomata and 
abscesses, anticipating the diffusion of the pathogen from the infection site and thus reducing 
the risk of sepsis [81].  
 
Recognition of a pathogen is the key process in generating an immune response. In order to 
recognize a pathogen, macrophages bear a diverse repertoire of pathogen-recognition 
receptors, so called pattern-recognition receptors, most notably, the Toll-like receptors (TLR) 
(figure 1). Different subtypes of TLR are responsible for the detection of different pathogen-
associated molecules. TLR-2 recognizes many viral, bacterial and fungal antigens, including 
zymosan, bacterial peptidoglycan and lipoteichoic acid. TLR4 is an essential receptor for 
lipopolysaccharide (LPS) recognition and is also involved in the recognition of endogenous 
ligands such as heat shock proteins, fibrinogen, hyaluronic acid and heparan sulfate. TLR5 has 
been shown to recognize flagellin. TLR7, TLR8 and TLR9 recognize nucleic acid-like structures of 
viruses, especially uridine- or guanidine-rich single-stranded viral RNA. In contrast, TLR3 is 
capable of detecting double-stranded RNA, mostly produced during the replication phase of 
viruses [82]. Besides the TLRs, several other classes of pattern-recognition receptors have been 
identified. The macrophage mannose receptor (MMR, CD206) is a member of the C-type lectin 
receptor family, which recognizes carbohydrate patterns on the bacterial and viral surface. 
Dectin-1 is a ß-glucan receptor responsible for the detection of fungi or fungal debris. 
Scavenger receptors, such as CD36, recognize modified low-density-lipoprotein and are 
responsible for the binding and phagocytosis of negatively charged macromolecules and 
senescent cells. Playing an important part in phagocytosis of pathogens, macrophages also bear 
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opsonic receptors such as Fc-receptors and complement-receptors which empower them to 
indirectly recognise and up-take opsonized pathogens.  
 
Figure 1: Macrophage receptor systems for detecting pathogen and tissue stress 
 
A fundamental task of macrophages is phagocytosis of pathogens, dead cells and other foreign 
particular matter. Upon encountering a pathogen, it is ingested and directed into a phagosome, 
where various proteolytic enzymes and peroxides digest the particle. A small amount of the 
pathogen material is decomposed by proteases to small polypeptides and then transferred to 
the cell-surface in association with an MHC Class II molecule. Macrophages are also able to 
directly kill parasites, antibody-coated cells and neoplastic cells via release of various 
substances such as TNF-α, serine proteases and perforin.  
 
Macrophages are part of the antigen-presenting cell (APC) system. Presenting the antigen 
particle via the MHC-II-complex, macrophages are able to stimulate responses to recall antigens 
by activating resting T-cells. However, it is the conventional immunological view that they are 
not able to initiate naïve T-cell responses, which is the sole preserve of dendritic cells (DC). The 
stimulating effect on T cells is dependent upon several co-stimulatory molecules, such as CD80 
and CD86. Apart from providing TCR ligands and costimulation, macrophages are capable of 
polarizing T cell responses by secreting different cytokines and other inflammatory mediators, 
especially CCL2 and CCL5. Through IL-1 and IL-6 production, macrophages recruit other 
inflammatory cells to the site of inflammation, primarily neutrophils and T cells. Another 
cytokine produced by macrophages called TNF-α increases the vascular permeability to plasma 
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proteins and extravasating leucocytes. In turn, cytokines generated by activated lymphocytes, 
such as IFN-γ, feedback on macrophages and boost their antigen presenting capacity, 
accelerating the immune response [83].  
 
Macrophages are not only responsible for the initiation of an immune response, but also 
participate in its resolution by activating anti-inflammatory features, clearing apoptotic or 
necrotic cells from the site of inflammation and promoting tissue repair. Regenerating activities 
include the promotion of new blood vessel formation and secretion of various tissue-trophic 
factors [84]. 
 
The origin of monocytes and macrophages 
Hematopoietic stem cells (HSC) are the progenitors of the lympho-hematopoietic cell system 
including monocytes, characterized by an extremely high self renewal and proliferation 
potential. Focusing on the development of monocytes and macrophages, the common myeloid 
progenitor (CMP) gives rise to the granulocyte/monocytes progenitor (GMP) and the 
megakaryocyte/erythrocyte progenitor. After further development, the GMP differentiates into 
the monocytes colony forming unit (M-CFU), giving rise to monoblasts, promonocytes and 
finally monocytes. All the mentioned stages of development are induced by various colony 
stimulating factors (CSF), such as granulocyte-monocyte colony stimulating factor (GM-CSF) as 
well as a number of cytokines, most importantly IL-3 [5].  
 
After maturation, monocytes exit the bone marrow and circulate in the peripheral blood for 
several days, until either being recruited to inflammatory sites or entering tissues to become 
tissue-resident macrophages, such as Kupffer cells or alveolar macrophages. Differentiation into 
macrophages entails loss or gain of various phenotypic markers and functions, depending on 
the particular tissue or inflammatory conditions (figure 2).   
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Figure 2: Monocytes are precursors to macrophages. Circulating monocytes ultimately derive from 
haematopoietic stem cells (HSC) and give rise to tissue macrophages. 
 
Diversity of monocytes 
Monocytes released from the bone marrow are morphologically heterogeneous with respect to 
size, granularity, nuclear morphology and antigenic markers. Based on the cell surface marker 
expression, monocytes are divided in two different subsets, the main markers being CD14 and 
CDϭϲ ;FĐǇRIIIͿ. ͞IŶflaŵŵatoƌǇ ŵoŶoĐǇtes͟ aƌe deliŶeated ďǇ a CD14high CD16- phenotype, 
whereas CD14+/- CD16+ Đells defiŶe the gƌoup of ͞ƌesideŶt ŵoŶoĐǇtes͟. Both suďsets eǆpƌess 
distinct chemokine, immunoglobulin, adhesion and scavenger receptors. For example, resident 
monocytes express the chemokine receptor 5 (CCR5), wheres inflammatory monocytes rather 
express CCR2 [85]. Based on the chemokine receptor CX3CR1 expression, the CD14+/- CD16+ 
monocytes are believed to be the precursors to resident macrophages that are prone to 
differentiate into lymph node-resident DC. CD14high CD16- monocytes express lower levels of 
CX3CR1, but instead express a number of receptors that respond to inflammatory chemokines. 
Thus these cells are thought to be precursors to inflammatory macrophages [86, 87] (figure 3).  
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Figure 3: Distinct populations of human peripheral blood monocytes (Population I: inflammatory monocytes, 
population II/III: resident monocytes and dendritic cells). 
 
Besides these two monocyte subsets, a third subset can be defined by a CD14+/- CD16+ CD64+ 
marker phenotype. This subset combines typical DC and monocyte characteristics, having a 
pronounced phagocytic activity and cytokine-producing capacity. This type of monocytes is 
suspected to have an immunoregulatory phenotype, which is based on an intermediate 
phenotype between monocytes and DCs [23, 88]. 
 
Diversity of macrophages 
Macrophage populations in tissues may be renewed through the entry of new monocytes from 
the peripheral blood or by local proliferation. The physiological change of monocytes into 
macrophages features a series of individual phenotypic changes in order to fulfill the new 
functional activity of the particular tissue. Tissue-specific macrophages include osteoclasts, 
alveolar macrophages, Kupffer cells, mesangial cells, microglia as well as thymic, splenic and gut 
mucosal macrophages. It still remains uncertain, if monocytes are also versed to differentiate 
into DCs in vivo, as has been proven in vitro.  
 
It is obvious that tissue specific macrophages fulfill different specialized tasks depending on 
their organ of residence. The most important macrophage groups and their functions are 
introduced in the paragraphs below: Thymus macrophages represent a significant component 
in the thymus physiology and play an essential role in negative selection of 
CD11b CD11c HLA-DR
I
II
III
CD14
CD
16
I
III II
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developing T-cells. They are responsible for the clearance of apoptotic thymocytes, which are 
constantly deleted during the process of thymic selection.  
 
The gut mucosal macrophage population constitutes the largest population of the human body. 
They reside within the lamina propria, fending for efficient phagocytosis and also antibacterial 
protection. Interestingly, gut mucosal macrophages do not respond to gut bacteria, which 
would cause perpetual intestinal inflammation; instead, these macrophages produce only non-
inflammatory cytokines and are important in preventing gut inflammation. 
 
Concerning the spleen, different subsets of macrophages have been identified, each of which 
occupies a discrete microanatomic location. Marginal zone macrophages express membrane 
receptors for bacterial polysaccharides which lead to efficient phagocytosis, characterizing 
them as an important part of the mobile surveillance system of the blood. In contrast to 
marginal zone macrophages, residing in the outer boarder of the marginal zone, metallophilic 
macrophages are found on the inner boarder adjacent to the white pulp. Metallophilic 
macrophages play a fundamental role in the response to viral infections [89]. The presence of 
Fc-receptors on so-called red pulp macrophages may facilitate recognition of senescent, 
antibody-sensitized cells [90]. Specialised phagocytic macrophages known as tingible body 
macrophages are located in the white pulp in the microenvironment of germinal centers. These 
presumably endocytose immune-complex-coated bodies and regulate the germinal center 
reaction by presenting this antigen [91]. 
 
Alveolar macrophages are found in the interstitium of the lung, where they clear inhaled 
microorganisms. Thus, alveolar macrophages are characterized by a very high expression of 
pattern-recognition receptors [92]. They are also responsible for tissue remodeling, as 
pulmonary fibrosis is thought to commence with a combination of pulmonary injury and 
alveolar macrophage recruitment. 
 
Osteoclasts are a highly specialized population of macrophages, which are characterized by 
their multinucleated morphology and residence in bone. Unlike many other macrophages 
phagozytosing pathogens, osteoclasts resorb bone material. Hand-in-hand with this
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remodeling process, they play a vital role in systemic electrolyte regulation, especially the 
Calcium concentration. 
 
Kupffer cells are liver-resident macrophages that are exclusively located in the hepatic 
sinusoids. They play a role in homeostasis of the liver and participate in acute and chronic 
responses of the liver to noxious agents.  
 
There are several different types of CNS macrophages, which are phenotypically different from 
most other macrophage populations. The largest population of CNS macrophages is known as 
microglia. When activated, these cells may have a detrimental effect in brain pathology through 
the promotion of inflammatory processes and neurotoxic substances, for instance in 
Alzheiŵeƌ’s disease aŶd PaƌkiŶsoŶ’s disease [93]. Bone marrow-derived perivascular cells are a 
small heterogeneous group of macrophages found in the CNS, located in the perivascular space 
of cerebral microvessels and thus situated at the intersection between brain parenchyma and 
blood [94]. Likewise, meningeal and choroid plexus macrophages are located at the blood-
cerebrospinal interface, but these populations have not been well-studied yet.  
 
Macrophage activation 
As previously mentioned, circulating blood monocytes can be recruited to sites of inflammation 
to become activated macrophages, which are characterized by a high degree of functional 
heterogeneity. In response to different environmental signals, macrophages undergo various 
forms of polarised activation, depending on what kind of response foils the pathogen best. This 
polarisation forms the basis of two different macrophage groups, M1- and M2-polarised 
macrophages [95] (figure 4).  
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Figure 4: Macrophage polarisation. M1 macrophages promote Th1-type T cell responses, whereas M2 
macrophages promote Th2-type T cell responses.  
 
M1 macrophage activation (or classic activation) is defined by a high capacity to present 
antigens in response to IFN-γ oƌ ŵiĐƌoďial pƌoduĐts suĐh as LP“. The seĐƌetioŶ of high levels of 
IL-12 and IL-23 as well as the production of large amounts of proinflammatory cytokines (e.g. IL-
1ß, TNF-α aŶd IL-6) and chemokines (eg. CXCL9, CXCL10, CXCL11) particularly drive Th1-type T 
cell responses. M1 macrophages also produce nitric oxide and reactive oxygen intermediates, 
enabling them to be potential effector cells to kill intracellular micro-organisms and tumor cells.  
 
M2-polarised macrophages are considered to be more heterogeneous than M1 macrophages. 
They can be divided into three different subtypes, namely M2a, M2b and M2c macrophages, 
and are often described as alternatively-activated macrophages [96]. M2a-polarised 
macrophages are generally induced by exposure to IL-4 or IL-13. On stimulation they produce 
CCL17 and develop a high endocytotic capacity as well as special receptors to scavenge tissue 
debris. They are also efficient in tissue remodeling and angiogenesis. M2b-polarised 
macrophages are activated by immune complexes or IL-1ß. Similar to M2a macrophages, they 
are responsible for phagocytosis and in addition play a role in microbicidal activities. M2b 
macrophages produce CCL1 and express sphingosine kinase 1. Both subtypes take over a major 
part in Th2-type T cell responses and strongly express MHC-II receptors. In contrast to the first 
two subtypes, M2c-polarised macrophages do not enhance immune responses, but instead 
seem to down-regulate other macrophage responses by secreting anti-inflammatory mediators 
such as IL-10, TGF-ß, PGE2, CCL18, CCL16 or CXCL13. They are themselves activated by IL-10, 
TGF-ß and glucocorticoids. Besides their capacity to down-regulate immune responses, M2c-
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polarised macrophages are able to promote wound repair and angiogenesis. This subtype of 
macrophages is often found in chronically inflamed tissues [97] (figure 5).  
 
 
 
Figure 5: Macrophages as versatile effector cells. Depending on the stimulus, resting macrophages are either 
polarised to M1 macrophages or different subtypes of M2 macrophages and thus fulfill different functions upon 
stimulation. 
 
All the above-mentioned differences in macrophage polarisation have been measured in vitro. 
It is unclear whether this paradigm applies so neatly to macrophage activation in vivo, where 
the cells are likely to be exposed to a mixture of polarising stimuli. However, it is known that 
the different kinds of macrophage polarisation are not just a definite state, but macrophages 
rather switch from one state to another depending on what stimuli they are activated by. Thus, 
macrophage polarisation can be considered a steady-state flow and not just a strict 
classification.  
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An essay on transplant immunology 
Immunological tolerance 
There are two principal mechanisms by which T cells are prevented from reacting against self-
antigens: Firstly there is central tolerance, which is achieved by positive and negative selection 
of developing T cells in the thymus. This mechanism ensures that T cells are capable of 
recognizing self-MHC molecules. Secondly, in the periphery under non-inflammatory 
conditions, mature T cells with aberrant self-reactivity are continuously eliminated by 
deletional mechanisms or are actively suppressed by regulatory T cell populations. 
 
Taking a closer look at the thymic selection of T cells, two basic steps can be identified. The first 
step comprises the positive selection of those T cells, which recognize self MHC-peptide 
complexes expressed by cortical epithelial cells. Approximately 95% of thymocytes (premature 
T cells) fail this selection aŶd uŶdeƌgo ͞death-by-ŶegleĐt͟ [98]. The thymocytes that survive this 
positive selection migrate into the thymic medulla, where they encounter a broad range of self-
peptides presented by dendritic cells and macrophages. The broad expression of self-antigens 
of these cells is governed by a transcription factor called Auto-Immune Regulator Protein 
(AIRE). It has been shown in this context that mutations in AIRE cause a breakdown of central 
tolerance, generating a decrease of the expression of self antigens in the thymus [99] (figure 6).  
 
 
Figure 6: T cell development and restriction to self-MHC 
 
Despite this precise system of T cell repertoire selection in the thymus, not all of the self-
reactive T cells are eliminated before reaching the periphery. Consequently, there must be 
mechanisms to protect the body from autoimmune responses, which may be passive or active. 
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One passive mechanism is called immunological ignorance and describes the exclusion of T cells 
from certain tissues: This phenomenon operates in the testes and the central nerve system. 
 
There are three active ways to achieve and conserve self tolerance in the periphery, namely 
clonal T cell deletion, T cell anergy and T cell-mediated regulation. It is important to understand 
that T cell activation comprises the recognition of an MHC-antigen-complex by the T cell-
receptor and the subsequent costimulatory signal of the APC. In case of T cell anergy, there is a 
lack of costimulatory signals and the T cell fails to produce IL-2 and to differentiate into a T 
effector cell; consequently, no activation of further T cells takes place and they become 
refractory to further activating stimuli. Anergic T cells persist as inactive effector cells and 
hypothetically suppress T cell responses by occupying antigens presented by APCs [100].  
 
The second mechanism, clonal T cell deletion, occurs through a process of activation-induced 
cell death (AICD) and is a crucial mechanism to maintain self tolerance. AICD of T cells results 
from the interaction of a Fas-bearing lymphocyte and Fas-ligands in tissues or other 
lymphocytes [101]. AICD can also be evoked by other death receptors, such as tumor necrosis 
factor receptor (TNFR) and death receptors 4 or 5 [102]. This kind of cell death is often 
described as clonal deletion, as self hazardous clones of T cells are eliminated on contact with a 
certain antigen.  
 
The third mechanism, T cell mediated regulation, requires the existence of naturally occurring T 
regulatory cells (T regs). These cells seem to be essential for the downregulation of T cell 
responses.  T reg deficiencies play a crucial role in a wide variety of autoimmune diseases and 
hypersensitivity responses [103]. An important factor decisive for T reg function is the Forkhead 
winged helix transcription factor (FOXP3). This transcription factor is responsible for the 
development and suppressive capacity of T regs. Notably, mutations or deficiencies in FOXP3 
lead to the development of severe autoimmune syndromes [104]. On a molecular level, T regs 
are characerised by the CD4+ CD25+ FoxP3+ phenotype and arise during normal thymic T cell 
development [105]. T regs exert their suppressive function through a variety of mechanisms, 
including cytokine secretion and cognate interactions with APCs and other T cells. A crucial 
mechanism of T reg function is inhibition of B7-mediated T cell costimulation: CD28 interaction 
with one of its ligands (CD80 or CD86, also known as B7 molecules) is one of the best 
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characterized costimulatory pathways of T cells. Cytotoxic T-lymphocyte-associated protein 
(CTLA-4) is a competitive T cell inhibitor of CD28 binding to CD80 or CD86. Thus CTLA-4 
expression by T regs down-regulates T cell activation by antagonizing CD28 signalling [106]. 
 
Transplantation rejection 
In general, there are two principal mechanisms of graft rejection: cell-mediated (CMR) or 
antibody mediated rejection (AMR). Antibody-mediated rejection is based on antibodies 
against MHC molecules of the donor (which, in clinical transplantation are usually called Human 
Leucocyte Antigens or HLA). In case a kidney graft is transplanted into a patient with significant 
levels of antibodies directed against antigens of the kidney, the graft is likely to be rapidly killed 
in a process known as hyper-acute rejection [107]. Especially the foreign blood vessels in the 
graft are attacked by these antibodies. Consequently, the complement system is activated and 
phagocytic cells are recruited, resulting in vascular injury. The retraction of endothelial cells 
allows an interaction of platelets and underlying matrix [108]. Subsequent processes include 
coagulation, thrombosis, inflammation and ischemia (figure 7).   
 
Figure 7: A summary of kidney transplant rejection. Multiple redundant effector mechanisms lead to allograft 
destruction. However, all are initiated by recognition of alloantigen by T cells.   
 
HUMAN REGULATORY MACROPHAGES: FROM BENCH TO BEDSIDE             An essay on transplant immunology 
 _______________________________________________________________________________________________________________ ________________________________________ 
 
 
40 
 
Cell-mediated rejection is based on antigen-presenting cells (APC) from the donor activating 
alloantigen-reactive recipient T cells. Host T cells detect the foreign MHC from donor APCs in 
two ways (figure 8): Firstly, a proportion of recipient T cells own T cell-receptors that can 
directly bind to foreign MHC molecules, leading to T cell activation in the so-called direct 
pathway; secondly, MHC antigens can be processed like conventional antigens by recipient DCs, 
leading to recipient T cell activation via the indirect pathway. This process results in a typical 
immune reaction as described before. 
 
Figure 8: Direct (a) and indirect (b) pathways of antigen presentation 
 
 
Immunosuppressive therapy in transplantation 
Up to now, immunosuppressant drugs play the most important role in immunosuppression. In 
the next paragraphs, the historical development of four essential immunosuppressants – 
glucocorticoids, anti-proliferatives, calcineurin-inhibitors and mTOR-inhibitors – is depicted. A 
basic illustration of the function of these immunosuppressants is shown in figure 9.   
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Figure 9: Points of action of classical immunosuppressants 
 
 
In the early 1960s steroids like cortisone were the first drugs to be found successful in 
minimising acute rejection reaction in solid organ transplantation between genetically variant 
individuals [109]. At the same time, Azathioprine featured immunosuppressant effects in 
kidney transplanted patients by reducing de novo purine synthesis and dampening T- and B 
lymphocyte proliferation [110]. More than ten years later, Cyclosporine A, a fungal metabolite, 
proved to be an effective immunosuppressive drug increasing the one-year survival of 
transplanted patients enormously [111, 112]. Cyclosporine A is a calcineurin-inhibitor that 
inhibits T cell proliferation and is used as a basic immunosuppressant drug in transplanted 
patients until today. 
 
In the next following years, several drugs have been developed for immunosuppressive 
therapy, none of which improving the outcome of transplanted patients significantly. It was not 
before 1982 that another promising drug was developed: the type 2 isoform inosine 5'-
monophosphate dehydrogenase (IMPDH) inhibitor mycophenolate mofetil (MMF). Comparing  
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this drug to Azathioprine, being one of the standard immunosuppressants at that time, it could 
be shown that MMF is more lymphocyte-specific and more potent in preventing graft rejection 
[113, 114]. In addition to that, MMF proved to be even more effective in combination with 
other immunosuppressive drugs and thus has replaced Azathioprine in the daily clinical use 
[115]. 
 
Another promising drug, Tacrolimus, was developed in 1986. Tacrolimus is a calcineurin-
inhibitor (CNI) like Cyclosporine A, but has been described to be up to 100-fold more potent in 
in vitro suppression assays [116]. Besides, Tacrolimus is capable of suppressing the activation, 
differentiation and proliferation of naïve and memory effector CD4+ and CD8+T cells by 
inhibiting the enzyme calcineurin [117, 118]. At the same time, successful T cell suppression 
does not affect myeloid cells on the same levels of concentration [119]. Comparing Tacrolimus 
with its CNI-antecessor Cyclosporine A, it turned out to be more potent in acute rejection 
episodes and graft loss [120, 121]. 
 
In 1989, a microbial product called Rapamycin (Sirolimus) was tested in transplantation models, 
featuring structural similarities to Tacrolimus. Though binding the same protein, Rapamycin 
does not inhibit calcineurin, but rather the mammalian target of Rapamycin (mTOR) [159]. This 
ŵeĐhaŶisŵ ƌesults iŶ the aƌƌest of the T Đells’ Đell-cycle [122].  
 
Besides glucocorticoids and small-molecule immunosuppressive drugs, a third group of 
immunosuppressants exist, namely biologicals. This group includes fusion proteins such as 
CTLA-4-Ig, depleting antibodies and non-depleting antibodies [115]. Antibody therapy as 
induction of immunosuppression reaches back to the early ϭϵϴϬ’s. Common antibody drugs are 
Anti-Thymocyte globulin (ATG) and Campath-1H (Alemtuzumab), both depleting T- and B cells, 
and also Basiliximab, which is a non-depleting anti-IL2R antibody. A great number of protein 
immunosuppressive drugs is now being developed (e.g. non-depleting CD40L antibodies 
ASKP1240 or 4D11) or in use (e.g. Belatacept) for blockade of the costimulatory CD40/CD40L or 
theCD28/CD80/CD86 pathways [123]. 
 
Keeping in mind the groups of immunosuppressants discussed in the previous paragraphs, it 
can be said that the common therapy protocol in transplantation consists of an induction phase 
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with an antibody such as Basiliximab and higher doses of CNI plus an anti-proliferative drug like 
MMF and tapered steroids. After this phase, the so called maintenance phase is mainly based 
on CNI, often combined with MMF or Rapamycin to reduce CNI doses and thus its toxicity [124, 
125]. 
 
Immunosuppressive therapy and its toxicity  
Even though short-term graft survival has been remarkably improved thanks to CNI, long-term 
outcomes of transplanted patients are still amendable [126]. Undesirable side effects like 
nephrotoxicity, neurotoxicity, disruption of glucose metabolism and even the risk of evoking 
malignancies have been associated with CNI treatment [127, 128]. Several studies aimed to 
reduce these adverse effects by combining or replacing CNIs with both MMF and Rapamycin. 
However, late conversion of a combined CNI - MMF treatment to MMF - Rapamycin therapy 
resulted in impaired kidney function, whereas early conversion was shown to initially improve 
it. Nevertheless, Rapamycin itself can cause severe side effects like proteinuria, bone marrow 
suppression and impaired wound healing [129]. The application of a Rapamycin - MMF 
combination without CNIs resulted in worse graft survival and acute rejection episodes 
compared to an addition of CNIs [124]. In contrast, treating stable renal transplant patients 
with low-dose Tacrolimus in combination with MMF, best results have been achieved in terms 
of graft survival, and impaired renal function could even be improved. Still, even though 
applying low dose immunosuppressants, general toxicity of Tacrolimus, Cyclosporin A or 
Rapamycin has obviously not been diminished and immunosuppressive therapy remains a 
tightrope walk between allograft tolerance and nephrotoxicity [130, 131]. 
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Drug-free induction of tolerance 
It has to be recognized that a major progress has been achieved in the management of acute 
rejection throughout the last decades. However, life expectancy and especially quality of life of 
transplanted patients is still low compared to the general population. Besides, long term graft 
survival has not been improved satisfactorily. The toxicity of immunosuppressive drugs, first of 
all CNIs, mainly account for these impairments [132, 133]. Thus, there is a strong need to find 
alternatives to the classic immunosuppressive therapy. 
 
It was noted that some transplanted patients seem to accept their graft without any 
immunosuppressive therapy and with proper organ functions. In most cases, patients did not 
use immunosuppressant drugs due to non-compliance [134]. This state of drug-free acceptance 
is called operational tolerance, meaning stable graft function and immunocompetence at the 
same time [135]. In addition, operational tolerance describes the absence of a donor-specific 
response measured by donor-specific antibodies (DSA) [136]. Having substantiated examples of 
allograft tolerance at hand, it has become an essential aim to actively induce this condition in 
transplanted patients.  
 
A well-known technique to achieve tolerance in transplanted individuals from rodent models to 
humans is to induce haematopoietic chimerism [137]. Up to now, this has been the only way to 
induce allograft tolerance in human renal transplant patients [138]. Nevertheless, 
haematopoietic stem cell transplantation prior to renal transplantation entails extremely 
radical preparative treatments and is associated with undesirable side effects like graft-versus-
host-disease (GvHD). Thus, this kind of therapy must not be acquiesced in transplantation 
medicine without intensively searching for better alternatives.  
 
Cell-based approaches to the induction of transplantation tolerance 
Adoptive transfer of transplantation from tolerant to non-tolerant individuals with the transfer 
of populations of regulatory cells is a well-established method in experimental immunology, but 
only recently its clinical translation has received serious attention [2]. 
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The cells of greatest interest in inducing cell-based tolerance in transplanted patients are T cells 
and APCs. Dendritic cells and macrophages, both APCs, influence the character of T cell 
responses and are potentially capable of inducing and maintaining peripheral tolerance. As 
described above, these cells receive both harmful and inoffensive signals from adjacent tissues 
and lymphocytes. After the integration of the signals, they are conveyed to T cells by a variation 
of co-stimulatory receptor and cytokine expression, while the T cells encounter their cognate 
antigen. In case of an apt stimulation, DCs and macrophages can acquire a tolerogenic 
phenotype, and on appropriately stimulating T cells they are capable of suppressing T cell 
activation or inducing the differentiation of peripheral T regulatory cells.  
 
Besides DC, macrophages belong to the group of APCs. Since they operate similar to DCs, a 
large interest has been assigned to them in terms of inducing peripheral tolerance. 
Macrophages called transplant acceptance-inducing cells have been described, owning the 
capacity to dampen allograft rejection [139]. The original idea to apply macrophages for the 
induction of tolerance accrued from experiments, in which recipient DA rats were 
preoperatively treated with embryonic stem cells (ESC) derived from WKY strain animals, 
serving as donors. These experiments demonstrated that ESC treatment indefinitely prolonged 
DA-strain heart graft survival. This phenomenon was based on the development of the progeny 
of WKY-cells in the recipient rats. After infusion, the ESC gave rise to myelomonocytic cells, 
resulting in a limited but stable state of chimerism. This way, there was a continuous exposure 
of the recipient animals to alloantigenic stimuli of the donor without causing sensitization, 
which is necessary for the induction and maintenance of active peripheral tolerance after 
transplantation. Nevertheless, this method cannot be applied to human individuals, since the 
infusion of ESC is legitimately not contrivable. Thus, an alternative has been seen in the 
progeny of the infused ESC, namely a certain type of macrophage, which were called Transplant 
Acceptance-inducing Cells (TAIC). Treatment with TAICs has proven to be an effective method 
to ensure survival after various transplantations like heart, lung and kidney in mice, rats and 
minature pigs. However, this model is only valid, if the TAIC derive from ESC of the donor 
animal, which also donates the graft. Applying this technique to third party allografts, 
transplantations result in acute rejection. 
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On the basis of these promising preclinical results, two early-phase clinical trials were 
performed, namely the TAIC-I and TAIC-II studies. In the TAIC-I study, 10 patients received in 
addition to conventional immunosuppression intravenous TAIC-infusion therapy five days after 
renal transplantation. The renal grafts were donated from deceased patients; TAICs were 
generated from donor splenocytes. This first TAIC study demonstrated that TAICs can be 
infused into patients without acute adverse reactions, verifying that TAIC treatment can be 
considered a safe clinical therapy. However, since the study cohort was very small, no 
conclusions about TAIC treatment efficiency after transplantations could be made [14].  
 
In the second trial, the TAIC-II studǇ, TAICs ǁeƌe geŶeƌated fƌoŵ the doŶoƌ’s peƌipheƌal ďlood 
monocytes obtained by leukapheresis. The resultant TAICs were then administered to 
recipients five days prior to transplantation. As in the first trial, the TAIC-II study proved that it 
is feasible to administer TAICs as a pre-transplant therapy, but the study was not large enough 
to draw safety or efficacy conclusions. Nevertheless, the study gave hints that pre-
transplantation exposure to donor specific antigen via TAICs renders the recipients hypo-
responsive: Treated patients did not tolerate their kidney graft without immunosuppressants, 
but they only required very low doses of immunosuppression to maintain their transplants; 
moreover, immunological measurements of anti-donor reactivity (in MLR and biomarker 
studies) indicated attenuated responses [13]. 
 
Two living-donor renal transplant recipients have been treated with a suspension containing 
donor derived Mregs. Within 24 weeks post transplantation both patients were minimised to 
low-dose tacrolimus monotherapy and now, after more than five years, still maintain stable 
graft function. By one year post transplantation, both patients displayed patterns of peripheral 
blood gene expression converging upon the Indices of Tolerance (IOT-RISET) tolerance 
signature. These studies indicate that monocytes/macrophages are a potential target in 
inducing peripheral tolerance. However, before being able to apply macrophages as an 
approved therapy for transplant patients, more detailed and precise information about this 
type of cell and its characteristics has to be gained. 
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cell-based therapies 
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 CURRENTOPINION Regulatory macrophages as therapeutic targets and
therapeutic agents in solid organ transplantation
Christiane Broichhausen, Paloma Riquelme, Edward K. Geissler, and
James A. Hutchinson
Purpose of review
This review aims to provide a basic introduction to human macrophage biology and an appreciation of the
diverse roles played by macrophage subsets in allograft damage and repair. Current and future strategies
for therapeutically manipulating macrophage behaviour are discussed.
Recent findings
Macrophages are extremely versatile effector cells that exert both immunostimulatory and
immunosuppressive effects. This adaptability cannot be explained by differentiation into committed
sublineages, but instead reflects the ability of macrophages to rapidly transition between states of functional
polarisation. Consequently, categorisation of macrophage subpopulations is not straightforward and this, in
turn, creates difficulties in studying their pathophysiology. Nevertheless, particular macrophage
subpopulations have been implicated in exacerbating or attenuating ischaemia-reperfusion injury, rejection
reactions and allograft fibrosis. Three general strategies for therapeutically targeting macrophages can be
envisaged, namely, depletional approaches, in-situ repolarisation towards a regulatory or tissue-reparative
phenotype, and ex-vivo generation of regulatory macrophages (M reg) as a cell-based therapy.
Summary
As critical determinants of the local and systemic immune response to solid organ allografts, macrophage
subpopulations represent attractive therapeutic targets. Rapid progress is being made in the implementation
of novel macrophage-targeted therapies, particularly in the use of ex-vivo-generated M regs as a cell-based
medicinal product.
Keywords
cell-based medicinal product, M reg, regulatory macrophage, the ONE study
INTRODUCTION
Before discussing their possible pharmacological
manipulation, it is first necessary to familiarise
the reader with the origin, development, pheno-
typic diversity and functions of the many diverse
forms of macrophage that are known to exist [1].
This leads immediately into controversial territory,
as there is no general agreement amongst experts
as to what exactly constitutes a macrophage subset,
how functionally-specialised macrophage popula-
tions might best be classified, or even whether
macrophages and dendritic cells are distinct lineages
or merely varieties [2,3]. Although categorising
macrophages as eitherM1-polarised orM2-polarised
may be unsatisfactory in a number of respects, it
provides a workable description of macrophages
present in solid organ allografts [4
&&
]. Macrophages
contribute to the development of transplant patho-
logy at many levels. Although the importance of
local proinflammatory macrophages in aggrevating
acute allograft injury is now well recognised,
there remains much to be learnt about the role of
intragraft macrophages in chronic injury and repair
processes, as well as the often-overlooked participa-
tion of splenic and lymphoid tissue macrophages in
promoting and regulating adaptive immune res-
ponses against alloantigens. As a therapeutic strategy
in transplantation, biasing macrophage-mediated
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responses towards regulation and the reestablish-
ment of tissue homeostasis has much to commend
it. Experimental methods of deleting activated
macrophages, or preventing their recruitment into
allografts, have shown potential therapeutic benefit,
but no agents for specifically depletingmacrophages
are presently approved for use in patients. A number
of drugs in current clinical use affect the activation
state of macrophages, albeit not very selectively.
A radically alternative approach to conventional
pharmacological manipulation of macrophages is
their use as a cell-basedmedicinalproduct after being
driven to a regulatory state by ex-vivo culture [5
&&
].
The relative merits of these three macrophage-
targeted therapeutic strategies – depletion, pheno-
typic modulation and ex-vivo manipulation – are
discussed in this review.
A PRIMER IN MACROPHAGE BIOLOGY
Macrophages are highly adaptable effector cells
that engage in diverse, often antagonistic activities:
macrophages can both heighten and diminish
immunological responses, and participate in both
tissue-destructive and tissue-reparative processes
[6]. Macrophages can be rapidly recruited from
blood to sites of inflammation, but are also constit-
utive elements of normal tissue stroma, and special-
ised forms are essential cellular components of
bone, kidney, liver and neuronal tissue [1,7]. This
astonishing functional adaptability is reflected by
the remarkable capacity of macrophages to induci-
bly express a very broad range of genes [8–10].
Macrophages play a critical role in innate immunity,
constituting a first line of defence against many
pathogens. Upon detecting a pathogen, macro-
phages are reponsible for both eliminating that
pathogen and initiating the inflammatory cascade
which leads to recruitment of other immunological
effector cells. In addition, macrophages are respon-
sible for the formation of abscesses and granulo-
mata, structures which limit the extent of acute
and chronic inflammatory reactions and prevent
the wider dissemination of pathogens and other
noxious agents.
Owing to their expression of an array of
receptors recognising ligands normally associated
with pathogens, but which also sense constituents
of dying cells, macrophages are exquistively sensi-
tive to the pathological condition of their environ-
ment [11,12]. Binding of ligands to these receptors
stimulates phagocytosis, whereupon macrophages
destroy ingested material in phagosomes by several
mechanisms, including acidification, fusion with
protease-containing lysosomes, or production of
reactive oxygen and nitrogen intermediates. Upon
activation, macrophages also secrete toxic sub-
stances, such as perforin, granzyme and TNF-a.
Macrophages serve as professional antigen-present-
ing cells and can inducibly express high levels of
costimulatory molecules [13]. It was formerly held
that macrophages, unlike dendritic cells, were inca-
pable of priming naive T cell responses, but this old
dogma has now been overturned [14,15]. Through
the elaboration of cytokines and other soluble
factors, macrophages are able to polarise T cell
responses and thereby govern the nature of adaptive
immune responses [16]. Reciprocally, activated
effector T cells secrete cytokines that activatemacro-
phages, enhancing their antigen-presenting capa-
bility and production of inflammatory mediators,
thus amplifying adaptive immune responses. An
example of this positive feedback is IL-12 pro-
duction by activated macrophages, which drives
Th1 cells to produce IFN-g and this, in turn, further
activates macrophages.
The resolution of inflammation also depends
on anti-inflammatory properties of macrophages.
Production of IL-10 by macrophages restrains T cell
and macrophage responses, and promotes tissue-
reparative processes through clearance of apoptotic
or necrotic cells, stimulating new vessel formation,
secretion of tissue-trophic factors and opposing
fibrosis [17]. The conditions that dictate whether
macrophages in vivo switch to a quiescent state and
help to restore tissue homeostasis, or remain in an
activated condition and promote chronic inflam-
mation, are presently not well understood [18,19].
MONOCYTES ARE PRECURSORS TO
MACROPHAGES
Macrophages ultimately derive from blood mono-
cytes, which exit the bone marrow and circulate
for several days before being recruited to inflamed
tissues to become activated macrophages or enter-
ing noninflamed sites to become tissue-resident
macrophages [1]. Human monocytes vary greatly
KEY POINTS
 Macrophages conduct both detrimental and beneficial
processes during innate and adaptive responses
against solid organ transplants.
 Macrophages represent an attractive therapeutic target
in solid organ transplantation.
 Treatment with regulatory macrophages (M reg) as a
cell-based medicinal product is a promising clinical
strategy for promoting immunological regulation
against transplantation antigens.
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in morphology and marker phenotype, most nota-
bly in their expression of CD14 and CD16, but also
with respect to their chemokine receptor expression
profiles [20–22]. On the basis of these phenotypic
differences, two principal subsets of human peri-
pheral blood monocytes can be identified: inflam-
matory monocytes are CD14þ CD16-, whereas
resident monocytes are CD16þ (Fig. 1). CCR2-
expressing inflammatory monocytes traffic prefer-
entially to sites of inflammation wherein they
become activated macrophages. Resident mono-
cytes, which likely develop from inflammatory
monocytes under noninflammatory conditions,
are believed to be precursors of tissue-resident
macrophage populations and lymph node-resident
dendritic cells [23].
MACROPHAGE ACTIVATION STATES
Inflammatory monocytes are recruited to sites of
tissue injury where they become activated macro-
phages. Depending upon the nature of the activating
stimulus and the influence of other immunological
effector cells, activated macrophages alter their
expression of cytokines, costimulatory molecules
and cytotoxic apparatus to promote themost appro-
priate response to the pathological insult. Thus,
some authors draw a distinction between M1-polar-
ised macrophages, which preferentially drive Th1
responses, and M2-polarised macrophages, which
promote Th2 responses (Fig. 2) [1]. M1-polarisation,
or classical activation, is induced by IFN-g combined
with microbial stimuli, such as lipopolysaccharide.
M2-polarised macrophages have been subclassified
into three groups: M2a, M2b andM2cmacrophages.
M2amacrophages, otherwise known as alternatively
activated macrophages, are induced by IL-4 or IL-13
treatment [24]. M2b macrophages arise when
resting macrophages are stimulated with immune
complexes [25].M2cmacrophages, otherwise collec-
tively known as deactivated macrophages, are
a heterogeneous grouping of anti-inflammatory
macrophages generated by exposure to such diverse
stimuli as IL-10, glucocorticoids, activin A and IL-21
[26,27].
The convention of classifying activated
macrophages according to their phenotypic simi-
larity with classically or alternatively activated
macrophages has held sway for many years. Yet this
taxonomy fails in several important respects. Firstly,
Th1 responses
Cellular immunity
Intracellular pathogens
Tissue destruction
Tumor resistance
 
 
Th2 responses
Humoral immunity
Parasite encapsulation
Clearence of dead cells
Tissue remodelling and angiogenesis
Tumor promotion
Immunoregulation
 
 
M1
M2
Classical activation
M2a
Alternative activation 
                       
M2c “Deactivation“  
M2b
DC
Monocyte-derived DC
LPS  + IFN-γ
IL4, IL-13
IC + LPS/IL-1  
IL-10,
GC,
TGF-β 
   MDSC
FIGURE 1. Classification of macrophage polarisation states. M1-polarised macrophages are induced by lipopolysaccharide
and IFN-g stimulation. M1 macrophages exhibit potent antimicrobiocidal activities, including Reactive Nitrogen Species and
Reactive Oxygen Species production, and secrete proinflammatory cytokines (IL-1b, IL-6 and TNFa) and chemokines. M1
macrophages express high levels of MHC Class II, CD80 and CD86, and promote Th1 responses. M2a-polarised
macrophages (also known as alternatively activated macrophages) are induced by IL-4 or IL-13 exposure. M2a macrophages
have a high endocytic capacity, express high levels of antigen-capture receptors, such as Dectin-1 and MMR, and play crucial
roles in resistance to parasitic infections and tissue repair. M2b-polarised macrophages arise after stimulation with immune
complexes and are characterised by secretion of IL-10 and not IL-12. M2c-polarised macrophages comprise a heterogeneous
group of ‘deactivated’ or suppressive macrophage phenotypes induced by a variety of stimuli, including IL-10, TGF-b, inhibitory
receptor ligation (e. g. CD200R) or glucocorticoids. (For a detailed review of macrophage polarisation states see [1]).
M regs as therapeutic targets and agents Broichhausen et al.
1087-2418  2012 Wolters Kluwer Health | Lippincott Williams & Wilkins www.co-transplantation.com 3
CE: Namrta; MOT/829; Total nos of Pages: 11;
MOT 829
because macrophage phenotypes are so readily
disturbed by extrinsic stimuli, in an inflammed-
tissue environment, it is unreasonable to think
that a phenotypically homogeneous macrophage
population could arise that neatly corresponds
to any in-vitro-induced state of activation [28].
Secondly, under normal physiological conditions,
reactions by macrophages to inflammatory stimuli
are checked by the constitutive action of anti-
inflammatory tissue factors, so all ex vivo-generated
macrophage types are necessarily artificial [29].
Thirdly, there is no clear place in the M1/M2
classification scheme for suppressor macrophages
[30]. Nevertheless, much of our understanding
of the roles of macrophages in transplant pathology
is framed in terms of the preponderance of M1-
polarised or M2-polarised macrophages within
allografts because this scheme of classification is
workable.
HUMAN SUPPRESSOR MACROPHAGES
The existence of anti-inflammatory, T cell-suppres-
sive cells of the myeloid lineage has long
been recognised. Broadly speaking, such myeloid
suppressor cells are either characterised by an
arrested state of immaturity, when they are known
as myeloid-derived suppressor cells, or a more
mature phenotype, reflecting the ability of myeloid
Antigen Presenting Cell (APCs) to switch into
a suppressive mode under certain conditions [31].
Several excellent reviews concerning myeloid-
derived suppressor cell biology have been published
recently, so they need not be revisited here [32–34].
On the other hand, some of the diverse stimuli,
which drive mature macrophages (or dendritic
cells) to a suppressor phenotype, deserve mention.
Suppressive activities in cultured macrophages
are induced by a wide range of unrelated stimuli,
including M-CSF, IL-10, immune complexes,
vitamin D, glucocorticoids, IFN-g, repetitive resti-
mulation through TLR-2, TLR-4 or TLR-9, and
prostaglandin E2 (PGE2). Accordingly, there is no
unique phenotype or mechanism of action associ-
ated with suppressor macrophage populations.
Induction of suppressor macrophages
Treatment of cultured macrophages with M-CSF,
in contrast to GM-CSF treatment, shifts them
away from being efficient antigen-presenting cells
and promotes an IL-10-producing suppressor
phenotype [35
&&
]. Treatment of mice with M-CSF
induces the expansion of immunosuppressive
macrophage populations that hinder contact sensi-
tivity reactions and impair protective immune
responses against experimental brucellosis [36].
IL-10 is a broadly suppressive cytokine which acts
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FIGURE 2. Subtyping of human peripheral blood monocytes. Human monocytes are conventionally divided into subsets
according to their expression of CD14 and CD16. In fact, the recognised subsets of CD14þ CD16 inflammatory monocytes
(gate I and black traces), CD14þ CD16þ (gate II and grey traces) and CD14low CD16þ resident monocytes (gate III and
unfilled traces) probably represent stages in the maturation of inflammatory monocytes into resident monocytes. Inflammatory
monocytes express higher levels of CD11b, CD1d, CCR2 and CD64 than resident monocytes. Conversely, CD16þ monocytes
express higher levels of CD11c, HLA-DR and CX3CR1 than inflammatory monocytes.
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on macrophages to prevent their expression of
IFN-g and other proinflammatory cytokines, and
to downmodulate expression of costimulatory
molecules [37]. Importantly, autocrine stimulation
by IL-10 reinforces its own expression in human
macrophages in a STAT3-dependent manner,
possibly through upregulation of TPL2 and conse-
quent ERK activation, ensuring the phenotypic
stability of IL-10-producing suppressor macro-
phages [27,38]. Classically, IL-10 produced by sup-
pressor macrophages prevents the development of
Th1-type T cell responses, but also inhibits Th2 cells
and enhances the differentiation of IL-10-producing
Treg cells [39]. 1,25-dihydroxyvitamin D3 inhibits
the expression of costimulatorymolecules andMHC
Class II bymacrophages, and limits their production
of IL-12 and IL-23 [40]. In addition, 1,25(OH)2D3
induces macrophages to express IL-10 and MIP3a,
thereby rendering them suppressive. Glucocorti-
coids have profound effects on many aspects
of macrophage function, including inhibition of
the NFkB pathway [41]. The combination of
1,25(OH)2D3 and glucocorticoid treatment drives
macrophages and dendritic cells to such a stably
immunosuppressive state that some groups have
proposed their use as a cell-based medicinal product
[42].
Paradoxically, a number of classically pro-
inflammatory factors can induce macrophage sup-
pressor functions. Foremost amongst these is IFN-g,
which is secreted by activated T cells and normally
enhances the antigen-presenting capability, IL-12
production and antimicrobiocidal activity ofmacro-
phages. Surprisingly, in some circumstances, IFN-g
fails to induce upregulation of CD80 andMHCClass
II in macrophages, but does induce expression of
indoleamine 2,3-dioxygenase (IDO), programmed
death ligand-1 (PD-L1) and FasL [43]. IDO is a
tryptophan-catabolising enzyme which inhibits
effector T cell proliferation through tryptophan
deprivation and promotes T reg development
by generating kynurenine [44,45]. In mice, IDO is
indispensible for maintaining maternal tolerance
of allogeneic conceptuses [46] and plays a critical
role in the establishment of allograft tolerance
by adoptive transfer of T regs [47]. When activated
T cells expressing receptors for PD-L1 and FasL
(PD-1 and Fas, respectively) encounter PD-L1-
and FasL-expressing APCs, they are induced to
undergo apoptosis. A vital role for both PD-L1 and
FasL expression by macrophages in the induction
and maintenance of transplant tolerance has
been demonstrated, underscoring the importance
of deletional mechanisms in the establishment of
tolerance [48,49]. It is now well established that
continuous physiological exposure of macrophages
and dendritic cells to TLR-2, TLR-4 or TLR-9
ligands drives them to a suppressive state [50–52].
In mice, repetitive sublethal challenge with lipo-
polysaccharide (LPS) up-regulates expression of
heme oxygenase-1 (HO-1) in macrophages. HO-1
catalyses the degradation of heme, ultimately lead-
ing to the generation of carbon monoxide (CO),
bilirubin and free iron. Amongst other effects, CO
released by HO-1 renders macrophages suppressive
through the inhibition of LPS-stimulated proinflam-
matory cytokine production [53]. PGE2 is a potent
inflammatory mediator, causing local vasodilation
and recruitment of monocytes and neutrophils
to sites of acute inflammation, but it also exerts
immunosuppressive effects through macrophages
[54
&&
]. Acting at the EP2 receptor, PGE2 down-
regulates the antimicrobial activites of macro-
phages, limits their phagocytic activity, induces
their expression of IL-10 and antagonises TLR-
dependent TNF-a expression.
Human regulatory macrophages
For some years now, efforts in our laboratory to
develop a cell-based medicinal product for use in
promoting transplant tolerance in renal transplant
patients have focused on a type of suppressormacro-
phage, which we call regulatory macrophages
(M reg). The human regulatory macrophage reflects
a unique state of macrophage differentiation,
distinguished frommacrophages in other activation
states by its particular mode of derivation, robust
phenotype and potent T cell suppressor function.
These cells arise from CD14þ peripheral blood
monocytes during a 7-day culture period during
which the cells are exposed to M-CSF, 10% human
serum and a final 24-h pulse of IFN-g [55]. M regs
derived in this manner adopt a characteristic
morphology and are homogeneously CD14/low
HLA-DRþ CD80/low CD86þ CD16 CD64þ TLR2
TLR4 and CD163/low [5
&&
]. Human M regs are
potently suppressive of T-cell proliferation in vitro,
both through IFN-g-induced IDO activity and
contact-dependent deletion of activated T cells
[5
&&
]. After administration to a patient by central
venous infusion, allogeneic M regs remain viable
and rapidly partition into the liver, bone marrow
and spleen, butdonot accumulate inother lymphoid
tissues.
MACROPHAGES AND TRANSPLANT
PATHOLOGY
Acting within grafts, but also at distant sites,
macrophages profoundly influence the develop-
ment of various transplant pathologies. Early after
M regs as therapeutic targets and agents Broichhausen et al.
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transplantation, macrophages respond to ischaemia-
reperfusion injury bymounting a rapid, stereotypical
inflammatory response that leads to secondary
tissue damage. Similarly, infiltration of allografts
by macrophages during acute rejection episodes
exacerbates tissue damage. In the longer term,
macrophages are key mediators of chronic allograft
inflammation and fibrosis. More than being simple
effectors of the innate response, macrophages also
serve as amplifiers of the adaptive immune response
by supporting T cell reactions within allografts.
On the contrary, not all macrophage-mediated
processes are detrimental to allografts; in particular,
re-establishment of tissue homeostasis by anti-
inflammatory macrophages appears to be a deter-
minant of long-term transplant survival.
The origin of macrophages within allografts
In the context of solid organ transplantation,
macrophages found within allografts may stem
from three immediate sources. Firstly, as a normal
stromal component, tissue-resident macrophages
may be of donor origin; however, these passenger
macrophages usually disappear early after transplan-
tation. Secondly, activation of graft-resident macro-
phages leads to their production of inflammatory
mediators, resulting in a prompt migration of
recipient macrophage precursors into the graft
[56]. Infiltration of allografts by macrophages is a
prominent feature of reperfusion injury and trans-
plants undergoing acute rejection. The pool of
circulatingmonocytes available for recruitment into
allografts is reinforced by their release in large num-
bers from bone marrow as part of the generalised
response to sterile tissue injury. Thirdly, activated
macrophages can proliferate within inflamed grafts
in response to M-CSF or IL-4 stimulation.
Ischaemia-reperfusion injury
Restoration of blood flow to an ischaemic organ
graft causes cellular dysfunction, apoptosis and
necrotic cell death within the transplanted tissues
[57]. The consequent release of cellular constituents,
such as nucleic acids and heat-shock proteins,
triggers the activation of graft-resident dendritic
cells and macrophages, initiating the inflammatory
cascade [56]. Following reperfusion in experimental
models of kidney ischaemia, infiltration by macro-
phages is first observed within 30min (preceding
lymphocyte infiltration) and peaks at 24–48h [58].
This rapid influx, mediated by CCR2 and CX3CR1,
represents the earliest phase of a stereotyped
reaction in which macrophages cause further tissue
injury through the production of reactive oxygen
and nitrogen intermediates, release of extracellular
matrix-degrading enzymes, secretion of cytokines
and the activation of lymphocytes [59]. However,
the destructive tendency of macrophages after
reperfusion injury is short-lived, as both tissue-
resident and infilitrating macrophages soon begin
to exert anti-inflammatory and tissue-reparative
effects [4
&&
]. This phasic contribution of macro-
phages to both reperfusion injury and its resolution
is neatly illustrated by the effect of depleting macro-
phages using liposomal clodronate or the CD11b-
DTR conditional ablation system. Such experiments
demonstrate that depletion of macrophages prior to
renal ischaemia-reperfusion injury in mice reduces
the number of infiltratingmacrophages in the organ
at 48–96h and helps to preserve short-term renal
function [60]. However, the cost of preventing
early macrophage-mediated injury is a poorer tissue
repair response with impaired clearance of dead and
apoptotic cells [61]. A similarly dichotomous role for
macrophages in injury and repair after ischaemia-
reperfusion has been demonstrated in lung [62,63],
liver [64] and small intestine [65].
Acute allograft rejection
Macrophages are a prominent component of
inflammatory infiltrates in acutely rejecting allo-
grafts. In the case of the rejecting renal allograft,
infiltrating macrophages are to be found in the
glomerular, vascular and tubulointerstitial compart-
ments [66]. The total burden of infiltrating macro-
phages correlates with the severity of renal allograft
rejection [67] and the density of glomerular infiltra-
tion by macrophages is predictive of a worse clinical
outcome, independently of peritubular capillary
C4d deposition [68]. Infiltration of renal allografts
by macrophages within 7 days of transplantation
is likewise associated with poorer clinical outcomes
[69,70] and the presence of CX3CR1-expressing
macrophages in acutely rejecting kidney allografts
is associated with resistance to steroid treatment
and worse outcomes at 1 year [71]. Gene expression
profiling studies of clinically indicated biopsies from
renal allografts corroborate these histopathological
findings, in that, high expression of macrophage-
associated transcripts (especially M2-polarised
macrophage-associated transcripts) correlates with
T cell-mediated rejection [72]. Importantly, these
studies show that macrophage infiltration is a
feature of canonical T cell-mediated acute rejection,
so is not merely a secondary consequence of
antibody-mediated rejection. Macrophages enter
acutely rejecting allografts in response to a wide
range of chemotactic stimuli, including CCL2,
CCL3, CCL7 and osteopontin [73–75]; in the case
Tolerance induction
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of antibody-mediated rejection, C4d deposition also
recruits macrophages [76]. In the acutely rejecting
allograft, macrophages serve as direct effectors
of tissue injury, but also aggrevate the adaptive
immune response through their presentation of
alloantigen and secretion of T cell-stimulatory cyto-
kines. In kidney transplantation models, macro-
phage depletion generally reduces the severity of
acute rejection episodes, preserving function of
the allograft and limiting lymphocytic infiltrates
[77,78].
Chronic allograft injury
Precisely what governs the restoration of normal
tissue homeostasis after an inflammatory episode
is not well understood; in particular, the factors
determining whether macrophages return to a
quiescent, tissue-resident phenotype or persist in
a chronically activated state are unknown [6].
Nevertheless, this decision is integral to long-term
allograft outcomes because chronically activated
macrophages play a profibrotic role and are
central to the development of chronic transplant
arteriopathy [79]. In general terms, the profibrotic
response of macrophages can be characterised as a
sterotyped response to chronic or repetitive injury
[80]. In transplantation, the initiating insult is
mediated by alloantigen-reactive T cells, but may
later become a self-perpetuating condition. Studies
of chronic allograft rejection have identified numer-
ous mechanisms by which profibrotic macrophages
may be induced; however, activation of myofibro-
blasts and vascular smooth muscle cells through
secretion of cytokines, direct deposition of fibrotic
matrix, and the promotion of Th2 and Th17
responses are common end pathways [79,81].
Evidence for the involvement of macrophages
in chronic allograft injury comes from both
experiments in animal models and correlative his-
topathological studies. Interstitialmacrophage infil-
trates are a feature of progressive glomerulosclerosis
in the F344-to-LEW rat model of chronic rejection
[82]. Using the same model, the presence of glomer-
ular and vascular macrophage infiltrates was
associated with glomerulosclerosis, tubular atrophy,
interstitial fibrosis and arterial intimal proliferation
[83,84]. In renal transplant biopsies from patients
undergoing chronic rejection, infiltration of peritu-
bular capillaries by macrophages is particularly
associated with C4d deposition [76]. Profibrotic
macrophages produce various mediators, including
PDGF, IGF-1 and TGF-b1, which directly activate
myofibroblasts and are; therefore, essential for
normal wound healing [79]. In chronic allograft
injury, these same factors play detrimental roles;
for instance, macrophages within the thickened
intima of arteries with chronic transplant arterio-
pathy secrete high levels of PDGF, which drives
the proliferation of intimal smooth muscle cells
[85]. It has been suggested that macrophages within
chronically rejecting allografts generally adopt an
M2-polarised phenotype and promote Th2-type
responses [4
&&
]. IL-13 produced by Th2 cells, in
turn, drives macrophages to synthesise TGF-b1
and thereby promote fibrosis [86]. Profibrotic
macrophages can also generate IL-1b, so inducing
IL-17 production by Th17 cells, which promotes
fibrosis, especially in the lung [87–90].
Although macrophages play a clear role in
initiating and perpetuating fibrotic reactions, they
are also implicated in the prevention and reversal of
fibrosis [6]. Removal of dead cells and other debris
from inflammed tissues by macrophages eliminates
the stimulus for further inflammation. Remodelling
of extracellular matrix by collagen-degrading
enzymes produced by macrophages is vital to the
restoration of normal tissue structure. Production of
anti-inflammatory mediators, especially IL-10, by
macrophages dampens adaptive immune responses
and curtails fibrotic reactions [91]. Therefore, as is
the case in reperfusion injury and acute rejection,
whether allograft-infiltrating macrophages exert a
beneficial or detrimental effect in chronic allograft
injury depends on their particular state of activation
and the pathological condition of the tissue in
which they reside.
SUPPRESSOR MACROPHAGES AS A
THERAPEUTIC TARGET
As an abundant, broadly distributed class of cells
which serve indispensible roles in the amplification
and attenuation of innate and adaptive immune
responses to solid organ transplants, macrophages
represent attractive therapeutic targets. It is perhaps
unsurprising that many anti-inflammatory and
immunosuppressive drugs in current clinical use
exert pharmacologically important effects through
their general action on macrophages or their pro-
ducts, including glucorticorticoids, mTOR inhibitors
and TNFa-blocking antibodies. The development of
agents for selective targeting of macrophages in
particular activation states could have important
clinical implications. We can consider three general
strategies for promoting beneficial immunoregula-
tory and tissue-repair processes while preventing
detrimental macrophage-mediated processes. These
general strategies are depletion of graft-damaging
macrophages, in-situ inductionof suppressormacro-
phage subsets, and ex vivo-generation of regulatory
macrophages for re-administration to patients.
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Macrophage depletion
As discussed above, studies inmice have proven that
depletion of monocytes and macrophages can limit
the development of various allograft pathologies.
Presently, no antibodies capable of depletingmacro-
phages from tissues are clinically available, less so
antibodies which specifically target inflammatory
macrophage subpopulations while sparing suppres-
sor macrophages, but efforts to develop such agents
are underway [92]. In particular, the possibility of
using antibodies against CSF-1R to either deprive
macrophages of tonic M-CSF signalling or to bring
about their direct killing has generated much recent
interest [35
&&
,93]. An alternative strategy for deplet-
ing macrophages in tissues is to prevent their
recruitment: one particularly promising approach
is blockade of the CCR1, CCR2 and CCR5 chemo-
kine receptors with monoclonal antibodies or small
molecule inhibitors [94–97].
Manipulation of macrophage activation
states
The strategy of driving macrophages within tissues
towards a suppressor phenotype is not far-fetched.
Indeed, many drugs in routine clinical use influence
the polarisation state of macrophages, albeit un-
specifically. Of the immunosuppressive drugs
commonly used in solid organ transplantation, glu-
cocorticoids and mTOR inhibitors have well docu-
mented effects on the maturation state of dendritic
cells and macrophages [98–100]. Interestingly,
mycophenolate mofetil (MMF) affects macrophages
in several important respects, including limiting
their ability to migrate into inflamed sites, restrict-
ing their maturation, inhibiting LPS-induced IL-12
production, and preventing expression of IL-1b
while inducing IL-1Ra expression [101].
Administration of intravenous immunoglo-
bulin (IVIg) is a first-line treatment in certain acute
immunologically mediated conditions and has a
profound effect on the behaviour of macrophages
[102]. IVIg stimulates the inhibitory FcgRIIb recep-
tor, which leads to induction of the IL-10 expression
and a regulatory phenotype in macrophages [103–
105]. More experimentally, the immunosuppressive
properties ofmesenchymal stem cells (MSCs) appear
to relate, at least in part, to their ability to induce
IL-10 production by macrophages [106]. Several
clinical trials of MSCs as an immunomodulatory
therapy in solid organ transplantation are currently
underway and are, in a sense, trials of amacrophage-
targeting treatment [107].
Angiotensin II is generated locally by macro-
phages and fibroblasts, and plays an important role
in fibrotic processes through stimulation of TGF-b1
production and induction of fibroblast differen-
tiation into collagen-secreting myofibroblasts [79].
Furthermore, angiotensin II enhances TGF-b1 sig-
nalling by increasing SMAD2 expression and pro-
moting the nuclear translocation of phosphorylated
SMAD3. In the F344-to-LEW rat model of chronic
renal allograft rejection, blockade of the angiotensin
II type 1 receptor (AT1R) with losartan decreases
macrophage infiltration of allografts, prevents
glomerulosclerosis and reduces tubulointerstitial
injury [108].
REGULATORY MACROPHAGE
PREPARATIONS AS THERAPEUTIC
AGENTS
Pharmacological manipulation of macrophage
activation states in vivo is a subtle art: an altogether
more direct approach is to isolate monocytes and
differentiate them to suppressormacrophages under
controlled tissue culture conditions before admin-
istering them to patients as cell-based therapies.
Cell-based immunomodulatory therapy is still very
much in its infancy, although we are now witness-
ing a concerted international effort to bring such
treatments into clinical practice (www.onestudy.
org). Our group, at the cutting-edge of this effort,
has pioneered the use of regulatory macrophages as
a means of promoting allograft acceptance in solid
organ transplant recipients. The feasibility of this
approach was demonstrated in two clinical trials,
the TAIC-I and TAIC-II studies, in which crude
cell preparations containing regulatory macro-
phages were administered to a total of 20 patients
[5
&&
,109–112].
TAIC-I and TAIC-II clinical studies
The TAIC-I study (www.clinicaltrials.gov:
NCT00223093) conducted by Fa¨ndrich and col-
leagues was designed as a phase I trial to assess
the clinical feasibility and tolerability of administer-
ingdonor-derivedMreg-containing cell preparations
to deceased-donor renal transplant recipients [109].
Ten patientswere recruited to the study and received
between 0.5 and 7.5106 donor-derived cells/kg,
administered by central venous infusion 5 days post-
transplant. No acute complications of the infusion
and no later adverse reactions relating to the cell
infusion were observed. Thus, the TAIC-I trial
demonstrated the clinical feasibility of producing
and administering suppressor macrophages to
kidney transplant patients.
The TAIC-II study (www.clinicaltrials.gov:
NCT00223067) aimed to assess the feasibility,
safety and immunological effects of administering
Tolerance induction
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donor-derived M reg-containing cell preparations
to living-donor renal transplant recipients [110].
Five patients were enrolled in the TAIC-II study
and received between 1.7 and 10.4106 cells/kg,
5 days prior to transplantation. Four patients were
successfully minimised to low-dose tacrolimus
monotherapy. No rejection occured in two of five
patients. One patient underwent a rejection episode
at 36 weeks after reduction of tacrolimus treatment
to less than 2ng/ml for 6 weeks. The two remaining
patients experienced acute rejection episodes only
after complete cessation of immunosuppression
for two and 34 weeks. In mixed lymphocyte reac-
tions, all of the patients exhibited attenuated donor-
specific responses, but not third-party responses.
Patients MM and CA
Since these early clinical trials, we have arrived
at a detailed understanding of the derivation,
phenotype and T cell-suppressive functions of in
vitro-derived human regulatory macrophages. This
knowledge has inspired methodological advances
in regulatory macrophage manufacture, leading to
a purer and more homogeneous cell product, which
has now been applied to two further living-donor
renal transplant recipients with encouraging results
[5
&&
].
The first of these patients, MM, a 23 year-old
female with renal failure owing to IgA nephropathy,
was transplanted with a kidney donated by her
58 year-old mother. Donor and recipient had only
single HLA-B and DR mismatches. Six days prior to
transplantation, 8.0106 donor-derived M regs/kg
were administered to MM by slow central venous
infusion under cover of 1mg/kg per day azathio-
prine. Conventional treatment with steroids and
tacrolimus was commenced at the time of transplan-
tation. Azathioprine was discontinued from 8 weeks
posttransplant and steroids were tapered to cessa-
tion by 14 weeks. Thereafter, MM was maintained
on tacrolimus monotherapy with trough levels
of less than 6ng/ml. Protocol biopsies at 8 and
24 weeks showed no signs of rejection. At 3 years,
MM was in a stable clinical condition and received
tacrolimus 2mg BD with trough levels of 4–5ng/ml
as her sole maintenance immunosuppression.
The second patient, CA, a 47 year-old man
received a fully mismatched kidney from a 40 year-
old living, unrelatedmaledonor.CAwas treatedwith
7.1106 donor-derived M regs/kg, 7 days prior
to transplantation under cover of 1mg/kg per day
azathioprine. At the time of transplantation, con-
ventional treatment with tacrolimus and steroids
was initiated. Protocol biopsies at 8, 24 and 52weeks
showed no signs of rejection. At 3 years, CA had
stable renal function and is now being maintained
with sustained-release tacrolimus 5mg OD with a
trough tacrolimus level of 2.7ng/ml.
A pattern of peripheral blood gene expression
associated with a drug-free, tolerant state in renal
transplant recipients has been defined by the
IOT-RISET consortium [113]. In order to assess the
immunological impact of M reg therapy on patients
MM and CA, expression of the ten most dis-
criminatory gene markers of tolerance identified
by the IOT-RISET group was assessed in serial blood
samples taken from both patients [5
&&
]. Over the first
year posttransplant, the pattern of expression of
these markers gradually converged upon the IOT-
RISET signature, suggesting that MM and CA might
have achieved a degree of immunological regulation
against their donors.
THE FUTURE OF REGULATORY
MACROPHAGE THERAPY IS BRIGHT
Macrophages are phenotypically and functionally
plastic effector cells with the potential to exacerbate
or attenuate allograft pathology. A number of drugs
in routine clinical use can profoundly influence
macrophage activity, but their actions are not
macrophage-specific. Agents in preclinical and
clinical development for depleting or modulating
the phenotype of particular macrophage popu-
lations hold great therapeutic promise; however,
targeting drug treatments to the correct phase of
allograft injury will not be without its challenges.
In principle, ex-vivo production of regulatory
macrophages for use as therapeutic agents solves
many difficulties of pharmacologically altering
macrophages in vivo. Early-stage clinical trials of
M reg therapy in renal transplantation have proven
the feasibility of treating patients with donor-
derived M regs and the clinical outcomes have
been encouraging. In our opinion, M reg therapy
has significant therapeutic potential and warrants
further clinical investigation.
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INTRODUCTION
Transferring immunoregulatory cells from a tolerant donor to 
nontolerant individual as a means of establishing tolerance in the 
recipient is a common technique in experimental immunology, 
but its clinical application is only now receiving serious  attention.1 
Several classes of immunoregulatory cells are currently being 
developed as adjunct immunosuppressive agents for use in 
solid organ transplantation, including several types of regulatory 
T cells2–4 and suppressive myeloid cells.5–8 One particularly prom-
ising candidate cell type is the human regulatory  macrophage.9 
The regulatory macrophage (M reg) phenotype relects a unique 
state of macrophage diferentiation, distinguished from mac-
rophages in other activation states by its mode of derivation, 
robust phenotype, and potent suppressor function.10 M regs 
prevent mitogen-stimulated T cell proliferation in vitro through 
IFN-γ–induced indoleamine 2,3-dioxygenase activity, as well as 
mediating a contact-dependent deletion of activated T cells.11 
In addition, M regs drive the development of activated induced 
regulatory T cells (iTreg) that, in turn, suppress the proliferation 
of efector T cells and inhibit the maturation of dendritic cells 
(Walter et al. unpublished data). Therefore, it is speculated that 
when M regs are administered to a transplant recipient, they initi-
ate a feed-forward loop of allospeciic regulation.
M reg-containing cell preparations have been administered to a 
total of 19 kidney transplant recipients in a series of case studies 
and two early-phase clinical trials.12–15 While these pilot studies do 
not provide conclusive evidence of the safety or eicacy of M reg 
treatment in renal transplantation, they do demonstrate the feasi-
bility of delivering donor-derived M reg therapy to renal transplant 
recipients.16 A further two living-donor kidney transplant recipients 
have now been treated with ~8.0 × 106 cells/kg bodyweight (BW) of 
highly puriied donor-derived M regs.11 These patients are now more 
than 5 years posttransplantation with stable renal function, receiv-
ing only low-dose tacrolimus monotherapy as maintenance immu-
nosuppression. A newly developed therapeutic cell product con-
taining M regs (known as Mreg_UKR) conforms to our expectations 
of a clinically applicable drug product. A further clinical trial of M 
reg therapy in living-donor renal transplantation is now authorized 
within the framework of the ONE Study (www.onestudy.org). This 
trial (ONEMreg12; EudraCT Nr.: 2013-000999-15; ClinicalTrials.gov: 
NCT02085629) aims to treat 16 patients with donor-derived Mreg_
UKR at a dose of 2.5–7.5 × 106/kg BW under cover of 500 mg/day 
MMF on day 7 prior to surgery.17
Although cell-based medicines are quite diferent in nature from 
chemically synthesized drugs, many of the same general consid-
erations apply to their clinical use. In order to use any therapeutic 
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agent safely and efectively, clinicians must know about its phar-
macological properties and how these predict eicacy and safety 
in individual patients.18 Speciically, clinicians must know about the 
pharmacokinetics (i.e., absorption, tissue distribution, metabolism, 
and elimination) and therapeutic dose-range of a drug, as well as 
having an understanding of its mechanism of action and potential 
adverse efects. These clinical considerations are now relected in 
European Law19–21 and guidance issued by the European Medicines 
Agency.22
Current European Medicines Agency guidelines on cell-based 
medicinal products (CBMPs) stipulate that novel cell products must 
be subjected to conventional toxicological and safety pharmacol-
ogy studies.23 Toxicology studies are principally concerned with 
deining the relationship between drug exposure and its adverse 
efects, usually taking structural changes to tissues upon postmor-
tem examination as their major endpoint. Accordingly, a key objec-
tive of toxicological studies is deining the maximum tolerated dose 
of a drug in single and repeat doses. In contrast, safety pharmacol-
ogy studies seek to predict whether a drug is likely to be found 
unsafe when administered to patients at therapeutic doses and 
thereby aim to prevent such occurrences. Within this remit, safety 
pharmacology studies try to predict the possible occurrence of rare 
adverse events.24 In practical terms, this entails showing whether a 
drug is safe or unsafe using a core battery of pharmacological tests 
to assess adverse reactions afecting the central nervous, cardio-
vascular, respiratory, and other organ systems.25 A general require-
ment for toxicological and safety pharmacology studies in the drug 
development process are now codiied in International Conference 
on Harmonisation (ICH) guidelines (CPMP/ICH/539/00).26
This article presents the results of preclinical studies into the 
pharmacokinetics, acute and chronic toxicity, carcinogenicity, and 
safety pharmacology of Mreg_UKR, which were presented to the 
German National Competent Authority, the Paul Ehrlich Institute 
(www.pei.de) as part of a successful application for authorization 
to conduct the ONEmreg12 clinical trial. As an academic research 
group with no prior experience in drug development, we consulted 
an independent regulatory afairs advisor to devise a preclinical 
safety testing strategy that complied with all relevant regulatory 
obligations. This strategy was endorsed by the Paul Ehrlich Institute 
at a scientiic advice meeting. On the basis of this advice and our 
own interpretation of European Medicines Agency guidelines,23 a 
clinical trial application was lodged with the competent authority, 
which incorporated the pharmacokinetic, acute toxicity, chronic 
toxicity, and carcinogenicity studies presented in this article. This 
application was initially rejected owing to shortcomings in the clini-
cal protocol and all three principal sections of the Investigational 
Medicinal Product Dossier. Notably, the Authority commented on 
the inadequacy of our biochemical and clinical investigations of 
mice treated with Mreg_UKR; hence, the safety pharmacology stud-
ies presented in this article were performed. In response to its cri-
tique, a revised clinical trial application was submitted to the Paul 
Ehrlich Institute and was granted approval.
The preclinical studies described in this article found no evidence 
of acute or chronic adverse reactions to therapeutic doses of Mreg_
UKR; accordingly, they present no impediment to the further devel-
opment of Mreg_UKR as a pharmaceutical agent. However, this 
work brings into question the relevance of applying animal-into-
animal (homologous) and human-into-animal (heterologous) safety 
testing strategies to CBMPs. In particular, this article illustrates how 
easily preclinical pharmacokinetic and safety pharmacology studies 
could lead to false conclusions about the probable pharmacological 
properties of CBMPs in human recipients. Hence, a major conclusion 
of this work is that previous clinical experience from exploratory 
trials should be aforded far greater importance in assessing the 
potential clinical risk proile of Mreg_UKR therapy than preclinical 
animal experiments. By extension, we argue that there is a case for 
conducting small-scale exploratory clinical studies of novel CBMPs 
without extensive preclinical safety investigation, especially when 
similar CBMPs were already administered patients without adverse 
efects.
RESULTS
Tissue distribution and survival of Mreg_UKR in NSG mice
The eventual distribution of Mreg_UKR after intravenous infusion 
relects their passive and active migration to diferent sites, their 
engraftment in those tissues, as well as their death and elimination. 
To track the survival and tissue distribution of M regs in vivo, human 
cells were injected into NSG mice and their presence in blood, 
spleen, bone marrow, liver, and lungs was assessed by low cytom-
etry on days 1–7 postinjection. Recipients were randomized to 
two treatment groups, which received either 5 × 106 viable M regs 
or vehicle-only. Prior to detection by low cytometry, M regs were 
enriched from dissociated tissues by positive selection of CD11b+ 
cells with magnetic selection beads. Notably, this method of 
detection gives only qualitative information about the presence 
or absence of M regs in a tissue. M regs present in mouse tissues 
were identiied by low cytometry as living human CD45+ cells that 
coexpressed CD11b and HLA-DR. In previous work, we have shown 
that human M regs are homogeneously CD45+ CD11b+ HLA-DR+ 
CD14−/low and CD16−/low in phenotype.11 To assess the stability of the 
M reg_UKR phenotype after administration to mice, expression of 
CD14 and CD16 by living M regs recovered from mouse tissues was 
also investigated.
Human M regs were detectable in lung, blood, and liver for up to 
7 days postinfusion (Figure 1). It was not possible to reliably detect 
human M regs at any time point in spleen and bone marrow, either 
because human M regs were not present or because they were 
indiscriminable from the large populations of mouse macrophages 
present in those tissues. M regs retained their CD11b+ HLA-DR+ 
CD14−/low phenotype throughout the 7-day observation period. 
In  contrast, M  regs upregulated CD16 expression within 1 day of 
infusion, which possibly relects the absence of human immuno-
globulins in NSG mice.27
Clinical observation of NMRI-nude mice after Mreg_UKR injection
Fifteen age-matched, male NMRI-nude mice were randomized to 
three treatment groups of ive animals. NMRI-nude mice are con-
genitally athymic, so are efectively T-cell deicient, but produce 
functionally normal B cells. Hence, NMRI-nude mice were chosen 
for safety pharmacology studies because they are incapable of 
T cell-mediated rejection of xenogeneic cells, while still being able 
to mount innate immune and IgM responses that might contribute 
to adverse reactions.
Recipient mice were anesthetized and fully anticoagulated with 
60 IU heparin prior to slow (30–180 seconds) intravenous injection 
of M regs via the tail vein. For injection, M regs were suspended in 
Ringer’s lactate solution plus 5% human albumin. Mice in treatment 
group 1 received 1 ml vehicle-only. Mice in groups 2 and 3 received 
106 or 107 viable M regs suspended in a volume of 1 ml, respec-
tively. These cell doses corresponded to 34.0 ± 3.1 × 106 cells/kg 
BW and 356.8 ± 31.9 × 106 cells/kg BW, respectively. Recipient mice 
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Figure 1 Distribution and fate of Mreg_UKR in NSG mice. Recipient mice were given 5 × 106 viable M regs or vehicle-only by slow intravenous injection. 
The tissue distribution of M regs was then assessed on days 1 to 7 post-injection by flow cytometry. Human M regs defined by expression of human 
CD45, CD11b and HLA-DR were detected in lung, blood and liver at all timepoints. Although the engrafted M regs remained CD14-, CD16 expression 
was regained by day 1. Data are representative of at least two animals per timepoint from at least two independent experiments.
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were closely observed for 3 hours following Mreg_UKR injection to 
assess their clinical responses, particularly with regard to respiratory 
rate and rhythm. Over the subsequent 7 days, recipient mice were 
checked daily for constitutional signs of adverse drug reactions and 
BW changes were recorded.
No acute adverse reaction to Mreg_UKR doses of 106 or 107 cells 
was detected. In particular, no deaths occurred following intra-
venous cell infusion, no change in respiratory rate or rhythm was 
detected, and no dyspnea, hemoptysis, or cyanosis was observed. 
This is perhaps a reassuring result because one theoretical con-
cern with infusion of M regs, which have a diameter of 15–30 μm, is 
obstruction of pulmonary vessels by single cells or cell aggregates.18 
Recipient mice in all groups recovered from general anesthesia 
within 30 minutes, and none showed signs of distress upon waking. 
At 3 hours postinfusion, mice from all treatment groups were nor-
mally active, and an abbreviated clinical examination revealed no 
respiratory or neurological abnormalities. No signiicant diference 
in weight gain between treatment groups was observed over the 
7-day study (Figure 2). No delayed reactions, as assessed by changes 
in behavior or constitutional signs, were observed over the 7-day 
follow-up period, and no deaths occurred.
At 7 days postinfusion, mice in all treatment groups were nor-
mally active and showed no grossly unusual behavior. Speciically, 
recipient mice were examined using an adaptated version of Irwin’s 
comprehensive observational assessment, which assesses behav-
ioral, neurological, and autonomic responses to drug treatments.28 
No clinically relevant diferences in performance between treat-
ment and control groups were detected (Table 1). No signs of der-
matological disease were observed, although a few animals in each 
treatment group bore bite-marks. There was no sign of disturbed 
bowel function or rectal prolapse in any of the animals. Respiratory 
rate was not diferent between the treatment groups and respira-
tory rhythm was regular in all recipients (Table 1).
Postmortem examination of NMRI-nude mice on day 7 after 
Mreg_UKR injection
Upon thoracotomy under anesthesia, heart rate was not signiicantly 
diferent between the treatment groups and cardiac contraction was 
organized and regular in all recipients (data not shown). The lungs 
appeared pink and uniformly well perfused. No gross pathological 
changes were evident in the Mreg_UKR-treated or control mice. 
Speciically, there was no sign of myocardial infarction or distension 
of the atria, ventricles or pulmonary arterial trunk in any animals. 
The abdomen contained no ascites, blood, tumors, or adhesions 
in any recipients or controls. The large and small intestines, spleen, 
urinary bladder, kidney, liver, pancreas, kidneys, and great vessels of 
all animals appeared grossly normal. No other gross abnormalities 
were noted. Organ weights were not signiicantly diferent between 
Mreg_UKR-treated and untreated recipients (Table 2).
Histological sections of brain, lung, heart, liver, spleen, duodenum, 
right colon, and kidney were prepared from paraformaldehyde-
ixed, parain-embedded tissues and stained with hematoxylin and 
eosin. Tissue sections were evaluated blindly. No microscopic tissue 
pathology associated with Mreg_UKR administration was observed 
(Figure 3).
Biochemical investigation of NMRI-nude mice on day 7 after 
Mreg_UKR injection
Given that Mreg_UKR distributed primarily to liver, recipient 
mice were investigated for markers of liver injury: serum albumin 
(Figure 4a) and alkaline phosphatase (Figure 4b) levels were not sig-
niicantly diferent between treatment groups; however, a marginal 
increase in serum aspartate transaminase (AST) was observed in 
group 3 (Figure 4c). The biological relevance of such a small difer-
ence serum AST levels is presently unknown. Notably, among the 
21 patients treated with M reg-containing cell products, who are 
all more than 5 years posttreatment, no incidents of disturbed liver 
function tests were reported. Serum alkaline phosphatase is also a 
marker of increased bone resorption and serum albumin levels are 
typically reduced as part of the acute phase response; therefore, no 
biochemical evidence was found of increased bone turnover or sys-
temic inlammation caused by Mreg_UKR. To investigate the possi-
bility that Mreg_UKR afect renal function by embolising (in the form 
of individual cells, cell aggregates, dead cells, or immune complexes) 
to renal glomeruli, serum creatinine levels were measured as an indi-
cator of iltrative capacity: no diferences were observed between 
treatment groups (Figure 4d). Glucose levels are a sensitive, albeit 
very unspeciic, parameter to screen for adverse drug reactions: 
Hypoglycemia might result from sepsis, disturbances of the hypo-
thalamic–pituitary–adrenal axis resulting in reduced glucocorticoid 
production or disturbed insulin production (or IGF-2 production); 
hyperglycemia may result from pituitary, adrenal, or pancreatic dys-
function or could indicate ischemic disease or infections. No signii-
cant changes in glucose levels were observed (Figure 4e).
Immunogenicity of allogeneic mouse M regs in immunocompetent 
recipients
To formally assess the risk of humoral sensitization by M regs, 
donor-speciic anti-major histocompatibility complex class I anti-
body responses were measured in BALB/c mice that received C3H 
cardiac allografts after preoperative treatment with donor strain-
derived M regs. As previously published, no accelerated allograft 
lost was observed in the M reg-treated recipients, indicating that 
M reg administration on day 8 prior to transplantation did not sen-
sitize recipients.10 Here, sera were harvested from mice 7 days after 
heart transplantation, and their alloantibody content was measured 
by low cytometry cross-match. Consistent IgG responses were 
detected in transplanted mice without M reg treatment; in con-
trast, mice treated with 5 × 106 donor-derived M regs 8 days prior 
to transplantation had signiicantly lower levels of antidonor IgG 
Figure 2 Weight gain in NMRI-nude mice was unaffected by human 
regulatory macrophages (Mreg_UKR) treatment. NMRI-nude mice were 
allocated to three groups of five animals. Mice received injections of 
either 106 or 107 viable human M regs resuspended in Ringer’s lactate 
solution plus 5% human serum albumin and 60 U heparin, or were 
given a vehicle-only injection. No significant difference in weight 
gain was observed over a 7-day observation period after Mreg_UKR 
administration. (Filled symbols indicate bodyweight on day 0; unfilled 
symbols indicate bodyweights on day 7.)
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(Figure 5). No antidonor IgM response was detected in either the 
control or M reg-treated group (data not shown). Therefore, there is 
no evidence that intravenous injection of allogeneic mouse M regs 
caused humoral sensitization.
Chronic toxicity studies in immunodeicient mice
Malignant disease after treatment with Mreg_UKR might, in princi-
ple, arise either as consequence of transferring neoplastic cells or as 
consequence of transferred cells promoting growth of autochtho-
nous tumors.18 Neoplastic cells within Mreg_UKR products might 
originate from the donor, arise during in vitro culture or emerge 
after transfer into the recipient. Not only the therapeutically active 
cells within a cell product may lead to malignant disease but also 
cellular contaminants pose a risk of malignant transformation. In 
theory, immunosuppressive cell therapies might also promote 
recipient malignancies either by facilitating the growth of autoch-
thonous tumors or by suppressing immune responses against can-
cerous cells.
To formally assess the risk of M regs causing malignancy or other 
chronic pathologies, conventional carcinogenicity and chronic toxic-
ity studies were performed in immunodeicient mice. The purpose of 
this GLP-compliant study was to determine the chronic single-dose 
toxicity and tumorigenicity of M reg-containing cell preparations. 
Seventy-ive male and 75 female C.B-17-scid mice were divided into 
three experimental groups (Table 3). Mice in group 1 served as vehi-
cle-only controls. Mice in group 2 received M regs at a BW-adjusted 
dose (5 × 106 cells/ kg BW) corresponding to the intended treatment 
dose in humans, whereas mice in group 3 received an eightfold excess 
cell dose (4 × 107 cells/ kg BW). After treatment with M reg-containing 
Table 1 Clinical examination of NSG mice treated with 
Mreg_UKR
Vehicle-only 106 M regs 107 M regs
Behavioral
 Spontaneous activity
  Sleep 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
  Body position 5.2 P0 5.6 P0 5.6 P0
  Locomotor activity 2.0 ± 0.0 2.0 ± 0.0 2.8 ± 1.1
  Bizarre behavior 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
 Motor-affective response
  Alley progression (cm) 35.5 ± 14.7 43.9 ± 20.5 45.0 ± 22.3
  Transfer arousal 4.0 ± 0.0 4.0 ± 0.0 3.2 ± 1.8
  Touch-escape 3.6 ± 0.9 4.0 ± 0.0 4.4 ± 0.9
  Positional struggle 2.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0
  Grasp irritability 0.8 ± 0.4 0.8 ± 0.4 1.0 ± 0.7
  Provoked biting 3.2 ± 1.8 2.4 ± 2.2 2.0 ± 2.0
  Provoked freezing 1.0 ± 0.0 0.8 ± 0.4 1.0 ± 0.0
  Finger approach 4.8 ± 1.1 5.2 ± 1.1 5.2 ± 1.1
  Positional passivity 3.2 ± 1.1 3.6 ± 1.7 2.4 ± 0.9
  Vocalization (events) 0.0 ± 0.0 0.6 ± 0.9 0.6 ± 0.9
  Urination (events) 0.2 ± 0.4 0.2 ± 0.4 0.2 ± 0.4
  Defecation (events) 2.4 ± 2.1 1.0 ± 1.7 4.0 ± 1.9
 Sensory-motor response
  Visual placing 6.0 ± 0.0 6.0 ± 0.0 5.6 ± 0.9
  Tail-pinch 2.6 ± 2.3 1.0 ± 0.0 2.4 ± 1.5
  Toe-pinch reflex 5.6 ± 0.9 5.6 ± 0.9 6.0 ± 0.0
  Corneal reflex 5.2 ± 1.1 4.8 ± 1.1 5.6 ± 0.9
  Pinna reflex 2.4 ± 0.9 2.4 ± 0.9 3.6 ± 0.9
  Startle 2.8 ± 1.1 5.2 ± 1.8 4.0 ± 1.4
Neurological
 Posture
  Pelvic elevation 4.0 ± 0.0 4.4 ± 0.9 4.4 ± 0.9
  Tail elevation 2.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0
  Limb rotation 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0
 Muscle tone
  Body tone 6.0 ± 0.0 6.0 ± 0.0 6.0 ± 0.0
  Abdominal tone 4.0 ± 0.0 4.4 ± 0.9 5.2 ± 1.1
  Limb tone 2.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0
  Grip strength 6.0 ± 0.0 5.6 ± 0.9 4.8 ± 01.8
  Wire maneuver 0.4 ± 0.9 0.8 ± 1.8 0.4 ± 0.9
 Equilibrium and gait
  Righting reflex 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
  Ataxic gait 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
  Hypotonic gait 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
  Other gait impairment 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
  Total gait incapacity 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
 CNS excitation
  Tremors 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
  Twitches 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
  Convulsions 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Autonomic
 Eyes
  Palpebral closure 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
  Exopthalmos 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
 Secretion and excretion
  Lacrimation 1.2 ± 2.7 0.0 ± 0.0 0.2 ± 0.4
  Salivation 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
  Diarrhea 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
 General
  Hypothermia 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
  Skin color 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0
  Resp. rate 6.0 ± 0.0 6.0 ± 0.0 6.0 ± 0.0
 Toxicity
  Acute death (events) 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
NMRI-nude mice were allocated to three groups of five animals. Mice 
received injections of either 106 or 107 viable human M regs resuspended 
in Ringer’s lactate solution plus 5% human serum albumin and 60 U 
heparin, or were given a vehicle-only injection. Seven days after Mreg_UKR 
administration, recipient mice underwent clinical examination to identify 
possible signs of neurological impairment. No significant differences were 
found. Values represent mean ± SD.
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cell preparations, follow-up observations were made over 295 days. 
These studies showed no abnormal clinical or pathological indings 
that could be ascribed to M reg exposure. Speciically, clinical and 
postmortem examination on day 295 after M reg administration 
revealed no abnormalities of growth, tumor formation, biochemical 
or hematological disturbances, or any histopathological changes in 
any of the organs or tissues examined (data not shown).
DISCUSSION
The manufacture and application of medicinal products is strictly 
regulated to ensure an appropriate balance of risk and beneit to 
patients. Under European Union (EU) Law, CBMPs are governed by 
a legislative framework enacted through EU Regulation 1394/2007/
EEC on Advanced Therapy Medicinal Products (ATMPs)19 and an 
amendment of Directive 2001/83/EEC on the Community code 
relating to medicinal products for human use.20,21 At once, this 
legislation both recognizes the inherent di culties of studying 
cell-based therapies as pharmacological agents, but also imposes 
exacting standards for preclinical characterization of cell products, 
comparable to those applied to conventional pharmaceuticals.23 
Complying with these strict regulatory requirements is challenging, 
especially for academic centers with limited resources29,30; more-
over, the scientiic value of the required safety studies is doubtful, 
as the Committee for Advanced Therapies (CAT) itself recognizes.31
Pharmacokinetic and safety pharmacology studies are performed 
during nonclinical drug development to assess drug exposure and 
to identify any possible unwanted drug efects, including rare 
adverse reactions. Information from such studies is then used to 
predict safe drug doses for early-phase trials in humans. However, 
as the results presented in this article illustrate, it is questionable 
whether preclinical safety testing in animals is a meaningful way 
of investigating immunologically active CBMPs. A core problem is 
one of interspecies incompatibility: either a cell product of human 
origin is tested in animals, which may lack biological relevance, or 
an analogous animal cell is tested, which does not give direct evi-
dence about the safety of the human cell product. This article high-
lights the problems of applying animal-into-animal (homologous) 
and human-into-animal (heterologous) safety testing strategies to 
CBMPs. In our opinion, preclinical safety testing in animal models 
provides such poor-quality information that it is largely unhelpful in 
judging the probable safety proile of CBMPs in patients. Speciically, 
our conidence in the safety of administering Mreg_UKR to humans 
is not greatly increased by the safety studies presented here, or 
by previous studies in mice10 and miniature swine,32 despite no 
adverse efects having been identiied. Accordingly, we argue that 
far greater emphasis should be placed on previous clinical experi-
ence with identical and closely related cell products when assessing 
probable clinical safety of novel CBMPs.
Table 2 Postmortem of NSG mice treated with Mreg_UKR
Heart (mg) Lungs (mg) Liver (mg) Left kidney (mg) Spleen (mg) Brain (mg) Small  
intestine (mm)
Large  
intestine (mm)
Vehicle-only 176.2 ± 39.0 180.2 ± 21.4 1491.0 ± 252.6 229.0 ± 38.5 100.6 ± 27.8 374.2 ± 57.4 455.0 ± 16.9 98.0 ± 6.0
106 M regs 186.0 ± 17.1 202.6 ± 15.4 1588.0 ± 81.8 238.2 ± 18.9 91.6 ± 23.2 337.4 ± 47.1 470.3 ± 28.4 98.3 ± 11.3
107 M regs 189.0 ± 33.3 173.4 ± 18.9 1508.4 ± 141.1 244.6 ± 35.1 132.2 ± 81.8 369.0 ± 40.8 459.6 ± 12.8 100.4 ± 18.0
NMRI-nude mice were allocated to three groups of five animals. Mice received injections of either 106 or 107 viable human M regs resuspended in Ringer’s lactate 
solution plus 5% human serum albumin and 60 U heparin, or were given a vehicle-only injection. Seven days after Mreg_UKR administration, recipient mice were 
killed and organ weights or sizes were recorded. No significant differences were found. Values represent mean ± SD.
Figure 3 Histopathological survey of tissues from human regulatory macrophages (Mreg_UKR)-treated NMRI-nude mice. NMRI-nude mice were 
allocated to three groups of five animals. Mice received injections of either 106 or 107 viable human M regs resuspended in Ringer’s lactate solution 
plus 5% human serum albumin and 60U heparin, or were given a vehicle-only injection. Seven days after Mreg_UKR administration, recipient mice 
were killed and tissues were harvested for histopathological examination. Three micrometer sections were cut from paraformaldehyde-fixed, paraffin-
embedded tissues and then stained with hematoxylin and eosin. No tissue pathology associated with Mreg_UKR administration was observed. 
Representative images of liver and lung, the tissues in which M regs principally accumulate, are shown (Bar = 50 μm).
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What can be concluded from the absence of adverse reactions in 
animals?
Few immunologists would contend that animal experiments are not 
valuable in proof-of-principle demonstrations of the eicacy of new 
immunotherapies. Why then should we be critical about the value of 
safety pharmacology and toxicology studies, which use very similar 
models and techniques as those used for primary and secondary 
pharmacodynamic studies? One reason is that pharmacodynamic 
studies aim to detect particular biological efects that, in order to be 
regarded as therapeutically promising, should be relatively large and 
accrue to all recipients; by contrast, safety pharmacology studies aim 
to detect any adverse biological efects, which may be relatively small 
or restricted to only a subset of recipients. Self-evidently, proving the 
absence of detrimental efects requires more sensitive technical and 
statistical approaches than proving the presence of a beneicial efect.
Before examining the particular case of Mreg_UKR, it is useful 
to examine the logic of safety testing in animals. In general, it is 
argued that if a drug has an adverse efect in animal models then 
it is highly likely to elicit the same adverse reaction in patients; by 
extension, if a drug does not cause a given adverse reaction in ani-
mals, then it is correspondingly unlikely to elicit that reaction in 
humans. Clearly, this form of analogical reasoning hinges on the 
biological relevance of the animal model to the human system. In 
the case of chemically synthesized, small-molecule drugs acting 
at deined pharmacological targets, it may be uncontroversial to 
accept that its properties in animals are a correct analogy for its 
actions in humans; however, in the case of immunologically active 
CBMPs, this is often not obviously true. Human and mouse M regs 
are derived by analogous processes, express very similar pheno-
types, and suppress efector T cell function; however, human and 
mouse M regs are not absolutely alike in phenotype and, whereas 
iNOS is indispensible for mouse M reg-mediated suppression of 
T-cell proliferation, it has no proven role in human M reg-mediated 
suppression.10,11 Thus, mouse and human M regs are equivalent 
cell types, but are not absolutely  identical; it follows, for every 
Figure 4 Biochemical investigation of NMRI-nude mice after human regulatory macrophage (Mreg_UKR) treatment. NMRI-nude mice were allocated 
to three groups of five animals. Mice received injections of either 106 or 107 viable human M regs resuspended in Ringer’s lactate solution plus 5% 
human serum albumin and 60 U heparin, or were given a vehicle-only injection. Seven days after Mreg_UKR administration, recipient mice were killed 
and serum levels of albumin, alkaline phosphatase, aspartate transaminase, creatinine and glucose were investigated. No signficant differences were 
observed between treatment groups, except for a marginal increase in aspartate transaminase levels in mice treated with 107 M regs (Kruksall–Wallis 
test; 107 Mreg_UKR versus vehicle-only, *P = 0.036).
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Figure 5 Assessing the immunogenicity of allogeneic mouse M regs 
in mice. BALB/c mice were either treated with 5 × 106 C3H-derived M 
regs (n = 4) or received no cells (n = 3). Eight days later, all mice were 
given a heterotopic heart transplant from a C3H donor. None of the 
transplants failed before day 7. On day 7, sera were harvested from 
all mice for measurement of antidonor IgG and IgM antibody titers by 
flow cytometry crossmatch. Mice treated with M regs 8 days before 
transplantation registered significantly lower levels of antidonor IgG 
than untreated controls (Mann–Whitney U-test; *P < 0.001). Gray line 
indicates limit of detection..
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pharmacological property studied using mouse M regs, it must 
be shown that human M regs possess a truly analogous property. 
Likewise, tolerogenic dendritic cell (DC), regulatory T  cells and 
mesenchymal stem cells from mice and humans are divergent in 
phenotype and efector mechanisms, so the same argument could 
apply to safety testing of all these cell types.
Another way of interpreting preclinical safety studies is to 
regard them as a means for drug developers to screen-out poten-
tially harmful cell products at a relatively early stage. This is a prag-
matic approach, which concerns itself only with positive evidence 
of adverse reactions that lead to the conclusion that a product is 
likely to be unsafe in humans. If this is the purpose of preclinical 
safety studies, then it is crucial to recognize that inding a product 
is “not unsafe” is not the same as saying that it is “safe”; importantly, 
it follows that it is not valid to claim that screening for unsafe cell 
products increases the probable clinical safety of administering 
cell products found to be “not unsafe” to patients.
It is perhaps counterintuitive to think that extensive preclinical 
safety testing might not actually increase our conidence in the 
likely clinical safety of a cell product, but the conclusion can be 
proven by example. It is striking to note that mouse-into-mouse 
or human-into-mouse safety preclinical studies would not identify 
life-threatening acute hemolytic reactions as a consequence of ABO 
incompatible transfusion of erythrocytes.33,34 Similarly, in the ield 
of adoptive transfer of antigen-speciic T cells as a cancer therapy, 
there are many examples of “on-target, of-tumor” adverse efects, 
especially ocular and central nervous system (CNS) autoimmune 
reactions, that were not detectable in mice, but caused very serious 
complications in patients.35 Also, in the ield of embryonic stem cell 
transplantation, several groups have produced neural, neuronal or 
glial progenitors from human embryonic stem cells that were not 
tumor-forming in animals,36 but gave rise to multifocal brain tumors 
in humans.37 These three cases illustrate general reasons for unreli-
able safety conclusions from preclinical testing, which are: reactions 
caused by antigens unique to human cell products; reactions caused 
by antigens unique to human recipients; and, reactions caused by 
the failure of human tumors to properly engraft in animals. To this 
general list, we might also add insidious adverse reactions (e.g., 
immune complex deposition or ibrotic diseases) that may not pres-
ent within a conventional 18-month toxicology study,38 as well as 
infectious diseases that cannot be transmitted to rodents.
The EMA committee for human medicinal products’ guidelines 
(CHMP/410869/2006) on human cell-based medicinal products 
advocates a risk-based approach to safety pharmacology and toxi-
cology studies.39 The risk-based approach demands a focused inves-
tigation of possible adverse reactions predicted from the known 
pharmacodynamic and pharmacokinetic properties of that drug. 
For the most part, immunoregulatory cell types used as CBMPs are 
naturally occurring components of the immune system; therefore, 
possible adverse reactions elicited by such cells are predictable 
because they primarily relate to excessive immunological activity, 
triggering of unwanted immune responses, an abnormal distribu-
tion of cells, or dysregulated cell growth. A detailed risk assessment 
of Mreg_UKR administration to living-donor kidney transplant 
recipients has been published elsewhere.18 On the basis of this risk 
assessment, preclinical studies with Mreg_UKR concentrated upon 
the risk of pulmonary embolic disease and whether M regs cause 
nonspeciic tissue injury at sites of accumulation. No clinically rele-
vant detrimental efect was observed when Mreg_UKR were admin-
istered intravenously to NSG mice, either at therapeutic or supra-
therapeutic doses. Speciically, the cell infusion had no apparent 
impact on respiratory, cardiac, renal, or neurological function. No 
gross or microscopic pathology was observed as a result of M reg 
administration, either at 7 or 295 days postinjection. On the basis of 
these negative results, there are no safety grounds for terminating 
development of Mreg_UKR as a CBMP; however, we regard this as a 
very weak conclusion with no deinite implications for the manage-
ment of patients receiving Mreg_UKR therapy.
Table 3 Chronic toxicity studies of M reg-containing cell preparations in C.B-17-scid mice
Group Cohort Cell dose 
(cells/kg)
N Cell density 
(cells/100 μl)
Administration Cotreatment Mortality
(ml/kg) Route ♂ ♀ Total
1 1 0 13 ♂ — 5 i.v. None 4/13 9/13 13/26
13 ♀
2 0 12 ♂ — 5 i.v. None 11/12 7/12 18/24
12 ♀
2 1 5 × 106 13 ♂ 1 × 105 5 i.v. None 2/13 6/13 8/26
13 ♀
2 5 × 106 12 ♂ 1 × 105 5 i.v. None 11/12 3/12 14/24
12 ♀
3 1 4 × 107 13 ♂ 8 × 105 5 i.v. None 4/13 8/13 12/26
13 ♀
2 4 × 107 12 ♂ 8 × 105 5 i.v. None 10/12 7/12 17/24
12 ♀
i.v. intravenously.
Seventy-five males and 75 females C.B-17-scid mice were divided into three experimental groups. Mice in group 1 served as vehicle-only controls. Mice in Group 2 
received a bodyweight-adjusted dose of 5 × 106 cells/kg. Mice in group 3 received 4 × 107 cells/kg. After treatment with M reg-containing cell preparations, follow-up 
observations were made over 295 days.
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So, what useful information can be drawn from safety pharmacol-
ogy and toxicology studies of CBMPs? To answer this question, we 
have to establish which properties of our animal models represent 
correct analogies to the human condition: We are only entitled to 
draw safety conclusions regarding adverse species-nonspeciic 
efects to which animals and humans are equally susceptible. As 
already mentioned, the major unwanted secondary pharmacody-
namic efects and toxicities of immunologically active CBMPs are 
most likely to result from their inluence over recipient immune 
responses; unfortunately, it is precisely these complicated and spe-
ciic immunological interactions that are poorly modeled in ani-
mals.40–42 On the contrary, adverse reactions that afect systems that 
are highly conserved between animals and man can be usefully stud-
ied in animal models. Pulmonary embolism (PE) of Mreg_UKR is one 
such example of an analogous adverse reaction, since the diameter 
of pulmonary vessels and BW-adjusted pulmonary vessel numbers 
are very similar in all mammals. Accordingly, we can be somewhat 
reassured by the absence of PE in experimental mice, which implies 
that PE caused by Mreg_UKR in humans is unlikely at equivalent cell 
doses.18
How should the potential immunogenicity of CBMPs be assessed?
In the context of solid organ transplantation, treatment with donor-
derived M regs has a superior allograft-protective efect compared 
to recipient-derived M regs.10 However, sensitization is an inherent 
risk of administering allogeneic cells to a patient, which in solid 
organ transplant recipients could lead to accelerated transplant 
rejection.43 ICH S6 recommendations on the preclinical safety 
evaluation of biotechnology-derived pharmaceuticals recognize 
the limitations of studying the immunogenicity of biopharma-
ceuticals intended for human use in animals.44 Speciically, these 
guidelines acknowledge that induction of an antibody response 
in animals is not predictive of antibody formation in humans. In 
our experiments, it would clearly have been meaningless to assess 
the immunogenicity of human M regs in immunocompetent or 
immunodeicient mice; therefore, we investigated the potential 
of allogeneic mouse M regs to exacerbate or attenuate antibody 
responses in mice receiving an allogeneic heart transplant (i.e., a 
homologous test system). These experiments showed that pretrans-
plant M reg treatment signiicantly diminished humoral responses 
against allogeneic cardiac allografts, presumably by suppressing 
T-cell responses. Nonetheless, the conclusion that allogeneic M reg 
exposure does not normally elicit alloantibodies in mice cannot 
be neatly extrapolated to the human situation. Mouse and human 
M regs, although equivalent cell types, are not absolutely identical in 
phenotype, so may be diferently immunogenic. Additionally, there 
may be preparation-related factors (e.g., dead cell content or manu-
facturing process-related contaminants) or recipient-related factors 
(e.g., concurrent inlammation or donor–recipient HLA-mismatches) 
that inluence the immunogenicity of infused M regs in patients. 
Overall, these experiments provided no evidence that administer-
ing Mreg_UKR to patients is likely to cause humoral sensitization; 
however, they do not provide strong support for the conclusion that 
Mreg_UKR are unlikely to cause sensitization in patients.
ICH S6 recommendations on the preclinical safety evaluation of 
biotechnology-derived pharmaceuticals advise that toxicity stud-
ies in nonrelevant species (i.e., species in which the test substance 
is not pharmacologically active) may be misleading and are dis-
couraged.44 Therefore, we are bound to ask whether our choice of 
animal models afected the strength of safety conclusions drawn 
about Mreg_UKR. Speciically, would testing Mreg_UKR in large 
animal models have provided better evidence of safety? It is fair to 
assume that human M regs should be more similar to M regs from 
species with a closer evolutionary relationship to humans than 
M regs derived from more distantly related species. On this basis, 
one might expect safety testing of Mreg_UKR in large animals to 
be generally more informative than rodent experiments. However, 
experimental group sizes needed to detect clinically relevant 
adverse efects are often impractical in relevant large animal mod-
els. This is certainly true when considering the risk of sensitization: 
Historical rates of sensitization of patients receiving donor-speciic 
blood transfusion prior to kidney transplantation under cover of 
azathioprine were 7–16%; therefore, it would necessary to observe 
18–42 animals to have a 95% probability of detecting one or more 
sensitization event. Thus, while large animal experiments certainly 
provide the most convincing evidence of the eicacy of novel 
CBMPs, their actual value in toxicological and safety pharmacology 
studies is much less certain.
What can be learnt from pharmacokinetic studies in animals?
The EMA committee for human medicinal products’ guidelines on 
human CBMPs recognize that conventional absorption, distribu-
tion, metabolism, and excretion studies are not usually relevant to 
CBMPs.22 However, these same guidelines mandate that pharma-
cokinetic studies of CBMPs should be carried out to demonstrate 
 tissue distribution, viability, traicking, growth, phenotype, and any 
alteration in phenotype due to factors in the tissue environment. 
After intravenous administration to NSG mice, human M regs par-
titioned to the lungs, blood, and liver, where a detectable fraction 
persisted up to 7 days. M regs were not found in spleen or bone 
marrow, either owing to technical limitations in their detection or 
because the cells were absent from those tissues.
Tellingly, the distribution of human M regs in NSG mice is not consis-
tent with the distribution of human M regs in humans, since in previ-
ous work, we reported that 111In-labeled M regs migrated via the blood 
from the lung to the liver, spleen, and bone marrow. Clearly, studying 
the distribution and survival of human M regs in NSG mice is unhelp-
ful in predicting the pharmacokinetics of human M regs in patients. 
There may be many reasons for the discrepant behavior of human 
M regs in mouse and man, including species-speciic diferences 
in soluble mediators and adhesion molecules. Notably, when 
transferred into mice, human M regs are deprived of tonic M-CSF-
stimulation, which is vital for macrophage survival in vivo; hence, 
the lifespan of human M regs in patients may be underestimated 
from this mouse model.45 On the contrary, because NSG mice lack 
any efective means of rejecting M regs, the NSG mouse model may 
overestimate the lifespan of allogeneic M regs in an immunocompe-
tent human recipient. The possible use of more sophisticated animal 
models, such as transgenic mice that better support engraftment 
of human M regs, does not address the fundamental problem that, 
without irst characterizing the pharmacokinetics of human cells in 
human recipients, we cannot know whether their distribution and 
survival in a mouse is an accurate representation. The corollary of not 
knowing whether human M reg survival in immunodeicient mice is 
representative of their survival in humans is that only a weak inter-
pretation of the absence of chronic adverse efects observed in our 
chronic toxicity and tumorigenicity study can be given.
Are there alternatives to safety pharmacology and toxicology 
studies in animals?
If, owing to interspecies diferences, pharmacological and toxico-
logical studies with mouse or human M regs are liable to produce 
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unreliable safety conclusions, how could the application of Mreg_
UKR to patients ever be justiied? Elsewhere we have argued that 
the likely clinical complications of administering cell products to 
patients are predictable and mitigable.18 There is now a substantial 
literature concerning the administration of therapeutic cell prepara-
tions (including regulatory T cells,46 tolerogenic DCs,47 M regs,8 and 
mesenchymal stem cells)48 to patients for a variety of indications. 
In our opinion, these clinical experiences constitute a much more 
meaningful basis for assessing the safety proile of other novel cell-
based therapies than safety pharmacology and toxicology studies in 
animals. Explicitly stated, any pharmacological diferences between 
alternative preparations of the same immunoregulatory cell type 
are generally less important, at least from a safety perspective, than 
the pharmacological diferences between the same immunoregula-
tory cell type from humans and animals. Therefore, greater coni-
dence in the likely clinical safety of a novel immunoregulatory cell 
product can be taken from previous studies with similar prepara-
tions of the same class of immunoregulatory cell type in humans 
than from preclinical testing in animals. By extension, we argue that 
previous clinical experience with immunoregulatory CBMPs is a reli-
able basis for predicting safe doses of similar CBMPs; furthermore, 
patient safety information obtained about an immunoregulatory 
CBMP in one clinical indication is arguably a reliable basis for judg-
ing its likely safety proile in other indictions. The obvious conclu-
sion of this argument is that the growing body of clinical safety data 
relating to immunoregulatory CBMPs largely obviates the need for 
further safety testing of existing and new CBMPs in animal models.
In a recent article, members of the Paul Ehrlich Institute advo-
cated two possible ways to circumvent the centralized European 
Marketing Authorization procedure pertaining to ATMPs.49 In the 
irst case, they suggest that some ATMPs could be reclassiied as 
transplants or transfusion products, which are less stringently regu-
lated under the Tissues and Cells Directive (Directive 2004/23/EC).50 
Speciically, cell products which have not undergone substantial 
manipulations and are intended for homologous use are contend-
ers for classiication as non-ATMPs. In the second case, they advo-
cate the use of the Hospital Exemption Rule, a provision made 
under Article 28 of the EU Regulation on ATMPs for products pre-
pared on a nonroutine basis for a speciied patient to be excluded 
from the central authorization requirements for ATMPs.19 Notably, 
the Hospital Exemption Rule can be used by National Authorities as 
a regulatory tool for supporting the development and availability 
of eligible ATMPs, perhaps guiding a particular product into routine 
manufacturing and then later into central marketing authorization.49
In summary, this article presents three lines of argument against 
the need for further preclinical safety studies of CBMPs in animal 
models. Firstly, safety pharmacology and toxicity testing of immu-
nologically active CBMPs in heterologous or homologous animal 
models is questionably relevant to humans and may lead to mis-
leading safety conclusions. Secondly, past clinical experiences with 
CBMPs are more informative about the probable safety of similar 
CBMPs in patients than preclinical safety testing in animal mod-
els. Thirdly, the burden of conducting preclinical pharmacokinetic, 
safety pharmacology, and toxicology studies may be great enough 
to deter development of novel CBMPs. Accordingly, we take a 
nuanced view of preclinical safety testing of CBMPs in animals: On 
the one hand, focused investigation of particular adverse reactions 
in genuinely analogous systems is valuable and, perhaps, there is 
a case for screening studies with truly novel cell products; on the 
other hand, it is evident that preclinical safety studies do not gen-
erally increase our conidence in the likely safety of CBMPs when 
administered to patients. Therefore, we contend that there is an 
urgent need for a debate about the acceptability of trialing novel 
CBMPs in small-scale exploratory clinical studies with only minimal 
preclinical safety data, especially when similar CBMPs have been 
previously applied to patients without adverse efects.
MATERIALS AND METHODS
Manufacture of Mreg_UKR
Leucapheresis products used as starting material for Mreg_UKR generation 
were produced under a manufacturing license issued by the Regierung von 
Oberbayern (DE_BY_04_MIA_2013_0177/53.2 – ZAB – 2677.1 204). Mreg_
UKR were produced under a separate manufacturing license (DE_BY_04_
MIA_2013_0187/53.2–2677.1 A 220-O) by Apceth GmbH (Ottobrunn, 
Germany) according to a proprietary standard operating procedure, which 
was adapted from previously published protocols.51
Administration of Mreg_UKR to immunodeicient mice
Animal experiments were performed in accordance with permission Nr. 
54-2532.1-10/12 granted by the Regierung von Oberbayern. NMRI-nude 
(NMRI-Foxn1nu) mice were obtained from Charles River (Sulzfeld, Germany) 
and NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice were bred in-house. Animals 
were kept in individually ventilated cages and fed a conventional diet. 
Recipient mice were anesthetized during Mreg_UKR infusion using 3.6 mg 
Xylazine plus 27.3 mg ketamine in 1000 μl 0.9% NaCl, given by intraperito-
neal injection at 40 μl per 10 g BW. Immediately prior to injection, the con-
centration of M regs in Mreg_UKR products was adjusted to 106 or 107 viable 
cells/ml in Ringer’s lactate solution plus 5% human serum albumin. Cell 
suspensions were injected through a 27-gauge needle into the tail vein of 
recipient mice over 30–180 seconds.
Clinical examination of Mreg_UKR recipients
Recipient mice were observed over 7 days for signs of adverse reactions to 
Mreg_UKR. Changes in BW were monitored. Behavioral, neurological, and 
autonomic responses to recipient mice were examined using an adaptive 
version of Irwin’s comprehensive observational assessment.28
Postmortem investigation of NMRI-mice after Mreg_UKR exposure
Recipient mice were killed on day 7 by thoracotomy and exsanguina-
tion under anesthesia. Organs were removed, weighed, and prepared for 
 histology. Three micrometer histological sections were cut from parain-
embedded tissues and stained with hematoxylin and eosin according to 
standard protocols. Sera were sent for analysis by the Institute of Clinical 
Chemistry at University Hospital Regensburg using routine diagnostic assays.
Flow cytometry to detect M regs in tissues from NSG mice
Recipient mice were killed on days 1 to 7 after M reg injection. Human leu-
cocytes were recovered from tissues by physical (spleen and bone marrow) 
or enzymatic digestion (lung and liver) according to previously described 
methods.10 Single-cell suspensions were passed through a 40-μm mesh (BD 
Biosciences, Heidelberg, Germany) before enrichment of CD11b+ leuco-
cytes by positive human/mouse CD11b magnetic bead selection (Miltenyi, 
Bergisch-Gladbach, Germany) on an AutoMACS Pro device (Miltenyi).
Assessing the immunogenicity of mouse M regs in a cardiac 
transplant model
Abdominal heterotopic heart transplants from C3H donors into BALB/c recipi-
ents were performed as previously described in accordance with permission 
Nr. 54-2532.1-28/09.10 Graft rejection was deined as cessation of palpable car-
diac contractions with veriication by direct inspection of the allograft after 
laparotomy. Mouse M regs were generated as previously described. Recipient 
mice either received no additional treatment or received 5 × 106 donor-
derived M regs on day 8 prior to transplantation. M regs were resuspended 
in 1 ml phosphate-bufered saline containing 62 U heparin and administered 
by slow injection into the tail vein. Sera from all mice were harvested on day 
7 posttransplant, and alloantibody levels were measured by low cytom-
etry cross-match. Briely, C3H splenocytes were stimulated in overnight 
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culture with concanavalin A. Aliquots of 0.5 × 106 stimulated splenocytes were 
blocked with mouse FcR blocking reagent (Miltenyi) before incubation for 90 
minutes on ice with 50 µl of test serum diluted by 1:500 in Dulbecco’s modi-
ied phosphate-bufered saline. Nonimmune sera from naive BALB/c mice 
were used as a negative control. After incubation, splenocytes were stained 
with antimouse IgG-FITC, antimouse IgM-APC, and anti-CD3-PE (antibodies 
from eBioscience, Frankfurt, Germany). For analysis, the CD3+ T cell popula-
tion was gated, and geometric mean luorescence intensity was determined 
(FlowJo v7.6.5, Miltenyi).
Chronic toxicity studies of M reg-containing cell preparations in 
C.B-17-scid mice
Responsibility for conducting good laboratory practice-compliant chronic 
toxicity studies was outsourced to a contract research organization (Aurigon 
Life Science, Gräfeling, Germany).
Statistics
Statistical analyses and curve itting were performed with GraphPad soft-
ware (La Jolla, CA). Values given in histograms and tables represent mean 
± SD. The Mann–Whitney U-test was used for nonparametric comparisons 
between two groups. The Kruksall–Wallis test was used for nonparametric 
comparisons among three groups.
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Cutting Edge: Immunological Consequences and
Trafficking of Human Regulatory Macrophages
Administered to Renal Transplant Recipients
James A. Hutchinson,*,† Paloma Riquelme,*,† Birgit Sawitzki,†,‡ Stefan Tomiuk,†,x
Patrick Miqueu,†,{ Maaz Zuhayra,‖ Hans H. Oberg,# Andreas Pascher,** Ulf Lu¨tzen,‖
Uwe Janßen,†,x Christiane Broichhausen,* Lutz Renders,†† Friedrich Thaiss,‡‡
Ernst Scheuermann,xx Eberhard Henze,‖ Hans-Dieter Volk,†,‡ Lucienne Chatenoud,†,{{
Robert I. Lechler,†,‖‖ Kathryn J. Wood,†,## Dieter Kabelitz,# Hans J. Schlitt,*
Edward K. Geissler,*,† and Fred Fa¨ndrich†,***
Regulatory macrophages (M regs) were administered
to two living-donor renal transplant recipients. Both
patients were minimized to low-dose tacrolimus mono-
therapy within 24 wk of transplantation and subse-
quently maintained excellent graft function. After cen-
tral venous administration, most M regs remained
viable and were seen to trafﬁc from the pulmonary vas-
culature via the blood to liver, spleen, and bone marrow.
By 1 y posttransplantation, both patients displayed pat-
terns of peripheral blood gene expression converging
upon the IOT-RISET signature. Furthermore, both pa-
tients maintained levels of peripheral blood FOXP3 and
TOAG-1 mRNA expression within the range consistent
with nonrejection. It is concluded that M regs warrant
further study as a potential immune-conditioning ther-
apy for use in solid-organ transplantation. The results of
this work are being used to inform the design of The
ONE Study, a multinational clinical trial of immuno-
modulatory cell therapy in renal transplantation. The
Journal of Immunology, 2011, 187: 000–000.
C
onditioning the response of organ transplant recipi-
ents to donor alloantigen using cell-based therapies is
now becoming a clinically feasible strategy, and, as
the potential risks are better understood and minimized, such
approaches are gaining credibility. Compared to longer
established techniques, such as donor-specific blood trans-
fusion and bone marrow transplantation, newer methods in-
volving the ex vivo induction, expansion, and purification of
tolerance-promoting cells offer the substantial advantages that
the quality and dose of cell products can be tightly controlled.
Moreover, by expansion or induction of cells in culture and
by specifically purifying tolerogenic cell types, the number of
viable suppressor cells administered to the patient can be
maximized, and the dangers of sensitization and graft-versus-
host reactions may be reduced.
Efforts in our laboratory to develop a cell product for
promoting transplant tolerance in the clinical setting have
focused on a type of suppressor macrophage, the human reg-
ulatory macrophage (M reg) (1–7). M regs exhibit a number
of properties that might make them particularly suitable for
clinical purposes, in particular, the cells are fully differenti-
ated and potently T cell suppressive (8). M regs derive from
CD14+ peripheral blood monocytes in the absence of other
cell types when monocytes are cultured for 6 d in medium
supplemented with human AB serum before stimulation
with IFN-g for a further 24 h. Cell populations generated
in this manner are homogeneously CD142/lowHLA-
DR+CD802/lowCD86+CD162CD64+TLR22TLR42 and
CD1632/low (8).
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This report describes the treatment of two living-donor renal
transplant recipients with preoperative infusions of donor-
derived M regs. Both patients were successfully weaned to
low-dose tacrolimus monotherapy within 24 wk of transplan-
tation and remain in excellent clinical condition. Throughout
their follow-up, the patients were intensively monitored using
cutting-edge immunomonitoring assays provided by the Eu-
ropean Union Framework Program 6 Reprogramming the
Immune System for the Establishment of Tolerance (RISET)
consortium, including flow cytometry, serial gene expression
profiling, and analysis of TCR Vb usage by peripheral blood
T cells. The two patients are now 3 y posttransplantation with
stable graft function and receive minimal maintenance im-
munosuppression.
Materials and Methods
Ethics
In a modification of the TAIC-II trial protocol (http://www.clinicaltrials.gov,
NCT00223067), two patients were treated with M reg therapy at the dis-
cretion of two senior consultants as “individueller heilversuch” (individual
healing attempts). The patients and their donors gave full, informed, written
consent to the procedure and follow-up investigations. Human leukocytes for
experimental use were obtained with approval of the local ethics committee
(ethics vote 09/100) and informed consent of the donors.
In vitro characterization of human M regs
M regs were prepared according to published methods (1). For flow cytometry,
harvested M regs were resuspended in ice-cold staining buffer (Dulbecco’s
modified PBS, 1% BSA, and 0.1% NaN3) and blocked for 30 min with 10%
FcR block (Miltenyi Biotec) before staining with fluorochrome-conjugated
primary Abs for 1 h. 7-aminoactinomycin D exclusion was used for live/dead
discrimination. To assess the T cell-suppressive capacity of M regs, CFSE-
labeled CD3+ T cells and M regs were set in direct coculture for 5 d. Sub-
sequently, T cell proliferation and absolute numbers were assessed by flow
cytometry, as described elsewhere (1). The mechanism of M reg-mediated
T cell suppression was investigated in direct 1:1 M reg/T cell cocultures. 1-
methyl-D/L-tryptophan (1-D/L-MT; Sigma-Aldrich), an inhibitor of IDO,
was completely dissolved in 5N HCl with gentle heating and agitation, before
adjusting the solution to pH 7.2.
Production of M regs for infusion into patients
M regs for administration to patients were prepared under strict GMP con-
ditions according to an adaptation of a previously published method (1).
Briefly, donor PBMC were obtained by leucapheresis and Ficoll density
gradient separation. Plastic-adherent PBMC were plated at a density of 35 3
106 monocytes/175 cm2 culture flask (Cell+ T175 flask; Sarstedt) in 30 ml
RPMI 1640-based medium without phenol red (Lonza) supplemented with
10% human AB serum (Lonza), 2 mM L-glutamine (Lonza), 100 U/ml
penicillin, 10 mg/ml streptomycin (Lonza), and recombinant human M-
CSF (R&D Systems) at a final concentration of 5 ng/ml carried on 0.1%
human serum albumin (Aventi). The cells were cultured for 6 d with com-
plete medium exchanges on days 1, 2,and 4. On day 6, cultures were stim-
ulated with 25 ng/ml recombinant human IFN-g (Imukin; Boehringer
Ingelheim). On day 7, the adherent cell fraction was recovered by trypsin-
EDTA treatment (TrypLE Express without Phenol Red; Invitrogen) followed
by gentle scraping. M regs from all flasks were pooled and resuspended in
a physiological saline solution containing 5% human albumin for infusion.
Clinical management of patients CA and MM
M regs were administered to patients CA and MM in the context of an
immunosuppressive protocol comprising tacrolimus, steroids, and azathio-
prine. To reduce the risk of preoperative infusion of M regs sensitizing
recipients, infusions were given under cover of 2 mg/kg/d azathioprine,
commencing 3 d prior to administration of M regs and continuing for 8 wk
postoperatively (9). M regs were administered 6 (MM) or 7 (CA) d prior to
transplantation by central venous infusion. From the day of transplantation
onwards, the patients were immunosuppressed with tacrolimus and steroids;
steroids were weaned over the first 10 wk postoperatively, leaving the patients
with maintenance tacrolimus monotherapy, aiming for trough serum levels
between 4 and 8 ng/ml.
Radiological investigations
Radiological investigations were performed by the Department of Nuclear
Medicine at Universita¨tsklinikum Schleswig-Holstein according to standard
clinical protocols. For short-term cell tracking studies, patient MM received
a total of 5 3 107 M regs labeled with 45 MBq [111In]-oxine (Covidien).
Single photon emission computed tomography (SPECT) images were inter-
preted by an expert radiologist.
Gene expression profiling
Gene expression profiling data have been deposited in the National Center
for Biotechnology Information/Gene Expression Omnibus (http://www.ncbi.
nlm.nih.gov/geo/) with accession numbers GSE14655 and GSE24172.
Statistics
Reported values are mean6 SD in all cases. All n-values signify the number of
independent biological replicates using cells from separate donors. Error bars
shown in Fig. 1 represent SEM. A paired t test was used for all significance
testing. Statistical treatment of microarray data is described in the text and
figure legends.
Results
Production and quality control of clinical M reg preparations
A basic scientific understanding of the development, func-
tion, and possible immunological role of naturally occurring
counterparts of the human M reg has lead to an optimized
method of cell production for clinical purposes. The quality of
M reg preparations produced by this method can be tightly
specified in terms of cell surface phenotype, cell morphology,
and potency in suppressing mitogen-driven T cell responses.
Specifically, M regs are consistently CD142/low-HLA-
DR+CD802/lowCD86+CD162TLR22 and CD1632/low (Fig.
1A).
M regs suppress T cell responses in vitro
To assess the T cell-suppressive capacity of M regs, a flow
cytometric assay was used to quantify mitogen-driven CD4+
and CD8+ T cell proliferation and, in parallel, to make ab-
solute counts of T cells in direct coculture with M regs. T cells
cultured alone did not proliferate and, by the fifth day of
culture, 17 6 6.5% of CD4+ and 22.1 6 11.1% of CD8+
T cells had died spontaneously (Fig. 1B, 1C). Direct coculture
of M regs with allogeneic T cells did not stimulate an MLR
reaction, nor did M regs rescue cocultured lymphocytes. The
strong proliferation of both CD4+ and CD8+ T cells ob-
served after PHA stimulation was profoundly suppressed by
coculture with allogeneic M regs (Fig. 1B). Strikingly, fewer
CD4+ and CD8+ T cells remained in coculture with M regs
when stimulated with PHA (p , 0.001 and p = 0.009, re-
spectively), which points to an M reg-mediated elimination
of activated T cells (Fig. 1C). This disappearance of T cells
during M reg cocultures is most likely due to phagocytosis of
dying T cells by M regs because examination of M regs by
transmission electron microscopy after coculture with T cells
revealed the presence of numerous phagolysosomes (Supple-
mental Fig. 1). Suppression of T cell proliferation by M regs
was observed at M reg/T cell ratios .1:8 (Fig. 1D). Inhibi-
tion of IDO activity with 1 mM 1-D/L-MT restored the
ability of T cells cocultured in the presence of allogeneic M
regs to proliferate in response to PHA (Fig. 1E).
Administration of M regs to patient MM
Patient MM, a 23-y-old female with renal failure owing to IgA
nephropathy, received a kidney transplant from her 58-y-old
mother, with whom she had single HLA-B and HLA-DR
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mismatches. CMV and EBV serology was negative in donor
and recipient. Six days prior to transplantation, MM was given
4.3 3 108 viable donor-derived M regs (an equivalent of
8.0 3 106 cells/kg) by central venous infusion under cover of
1 mg/kg/d azathioprine (Fig. 2A, Supplemental Fig. 2).
Transplantation was without complications and initial graft
function was satisfactory, in that serum creatinine levels had
fallen to 1.4 mg/dl within 1 wk. Azathioprine was discon-
tinued from week 8 postoperatively without adverse effect,
and steroid therapy was discontinued by week 14, after which
MM was maintained on tacrolimus monotherapy. Protocol
biopsies at 8 and 24 wk posttransplantation showed no signs
of rejection. Currently, MM is 3 y posttransplantation and in
a stable clinical condition on tacrolimus 2 mg twice daily with
trough levels of 4 to 5 ng/ml.
Profiling of peripheral blood TCR Vb usage showed no
mono- or oligoclonal T cell expansion, which is indicative of
T cell nonreactivity to the transplanted kidney (Supplemental
Fig. 3A) (10). Peripheral blood TOAG-1 mRNA expression
levels are usually reduced during acute rejection of kidney
allografts, but MM consistently maintained levels of TOAG-1
expression similar to healthy controls (Supplemental Fig. 3B)
(11). No anti-HLA Abs, which were assayed on a monthly
basis, were detected following the administration of M regs.
Trafficking of [111In]-labeled M regs in patient MM
Knowing the fate of M regs after administration to a patient
is central to any understanding of their potential immuno-
modulatory effects in vivo. Therefore, 5 3 107 (12%) of the
4.3 3 108 M regs given to patient MM were labeled with 45
MBq [111In] oxine and administered at the same time as the
unlabeled M regs. Immediately after the infusion, a whole-
body SPECT study was performed and again at four later
time points (Fig. 2B). Initially, the M regs were seen to be
FIGURE 1. Phenotypic and functional attributes of M regs in vitro. A, M regs are uniquely identified by the CD142/lowHLA-DR+CD802/low
CD86+CD162TLR22 and CD1632/low phenotype. Expression ranges of these cell-surface Ags by M regs were determined in cell preparations from six normal
healthy donors (mean6 SD). Unfilled trace, specific staining; filled trace, isotype control. B, Over 5 d in direct 1:1 coculture, M regs did not stimulate allogeneic
T cell proliferation and were suppressive of PHA-stimulated T cell responses (n = 12). C, Absolute quantification of CD4+ and CD8+ T cell numbers in 5-d
1:1 cocultures with allogeneic M regs suggest that M regs eliminated activated T cells. D, Suppression of T cell proliferation by M regs was observed at M reg/T
cell greater ratios .1:8. E, 1-D/L-MT, an inhibitor of IDO, disinhibited the mitogen-stimulated proliferation of T cells in 1:1 cocultures with M regs (n = 3).
*p , 0.05.
The Journal of Immunology 3
 o
n
 July 30, 2011
w
w
w
.jimmunol.org
D
ow
nloaded from
 
trapped in the lungs, but after 2.5 h, cells were detected in
circulation and had begun to accumulate in the liver and
spleen. Twenty-two hours after M reg administration, the
signal from the lung fields had much diminished, the cells
having accumulated in the liver, spleen, and hematopoietically
active bone marrow. The absence of signal from the patient’s
urinary tract throughout the investigation indicates that the
majority of infused M regs remained alive (12).
Administration of M regs to patient CA
Patient CA was an athletic 47-y-old male patient with severe
chronic renal failure owing to nephrosclerosis as a consequence
of long-standing arterial hypertension. CA was transplanted
with a kidney from an unrelated 40-y-old living donor (Fig.
3A). Donor and recipient were fully HLA mismatched (do-
nor: HLA-A3, 2; HLA-B41, 55; HLA-DR11, 13; recipient:
HLA-A2, 2; HLA-B7, 35; HLA-DR4, 14), and both were
CMV positive. One week prior to transplantation, a total of
7.5 3 108 viable donor-derived M regs (equivalent to 7.1 3
106 cells/kg) were administered to CA by slow central venous
infusion (Supplemental Fig. 2). No evidence of impaired
pulmonary perfusion caused by M reg administration was
found (Fig. 3B). Seven days later, the patient underwent
transplantation without complications. Serum creatinine lev-
els gradually declined over the subsequent 10 wk to ,2 mg/
dl. Azathioprine treatment was stopped after the 8th week
postoperatively, and steroids were discontinued by the 10th
week, leaving the patient with tacrolimus as his sole mainte-
nance therapy. Protocol biopsies taken at weeks 8, 24, and 52
showed no signs of acute cellular rejection, although occa-
sional clusters of CD20+ B cells of unknown pathological
significance were observed (data not shown). At 36 mo
posttransplantation, CA had stable renal function with a cre-
atinine of 1.43 mg/dl. Patient CA is being maintained on
once-daily 5 mg sustained-release tacrolimus (Advagraf;
Astellas Pharma) monotherapy; at 36 mo, his trough tacro-
limus level was 2.7 ng/ml.
After administration of M regs, but prior to transplanta-
tion, the expression of TOAG-1 mRNA in the peripheral
blood of CA increased 5.5-fold (Supplemental Fig. 3B). A sim-
ilar increase in TOAG-1 was observed in patient MM after
M reg treatment. As observed in MM, patient CA’s expres-
sion of FOXP3 mRNA began to rise from the fourth week
postoperatively (Supplemental Fig. 3B), which corresponded
FIGURE 2. Administration of M regs to patient MM. A, The management and clinical course of patient MM. B, Anterior-posterior scintigrams reconstructed
from SPECT imaging data show the distribution of 111In-labeled M regs at various intervals after administration by central venous infusion: 1, M regs were
initially trapped in the pulmonary vasculature; 2, by 2.5 h postinfusion, M regs were detected in circulation; 3 and 4, within 4.5 h, M regs had begun to
accumulate in the liver and spleen; 5, on the day after M reg administration, the majority of M regs had exited the lungs and were no longer detectable in the
blood; 6 and 7, M regs also accumulated in hematopoietically active bone marrow.
FIGURE 3. Administration of M regs to patient CA. A, The management and clinical course of patient CA. B, Total of 7.53 108 viable donor-derived M regs
were administered to CA by slow central venous infusion using a giving set with a 200-mm cell filter. During and after infusion, the patient displayed no
symptoms or signs of pulmonary embolism. To directly assess the degree to which M reg infusion might have impaired pulmonary perfusion, CA was investigated
by ventilation and perfusion scintigraphy, both before and after M reg administration. Prior to cell administration, there was no evidence of a ventilation or
perfusion defect: the perfusion fraction to the right lung was 59% and 41% to the left (L). After cell infusion, no localized or generalized perfusion defect was
noted, and the perfusion fraction for each lung was unaltered.
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to a small increase in the number of circulating T regs ob-
served by flow cytometry (Supplemental Fig. 4).
Serial analysis of Indices of Tolerance marker gene expression in the
peripheral blood of patients MM and CA
A pattern of gene expression in peripheral blood that correlates
with a drug-free, tolerant state in kidney transplant recipients
has been defined by the Indices of Tolerance (IOT) research
network (13). Using the RISET 2.0 Agilent custom micro-
array platform (Agilent Technologies), serial analyses of gene
expression in the peripheral blood of patients MM and
CA were performed (Fig. 4). The dataset from MM and CA
was then compared with the dataset obtained from the cohort
of kidney transplant recipients studied by IOT. Expression
profiles of the 10 most discriminatory biomarkers of toler-
ance identified by the IOT study were extracted from the
complete quantile normalized, log2-transformed dataset.
From this data, pairwise correlation coefficients were calcu-
lated comparing the medians of the IOT-tolerant patient
group with MM and CA at each separate time point, and
heatmaps of reporter-wise median-centered log2 data were
generated.
Throughout her postoperative course, the profile of gene
expression displayed by patient MM was very similar to that
of the tolerant patient group. Patient CA followed a different
course, upregulating SH2D1B, HS3ST1, TCL1A, FCRL1,
FCRL2, and CD79b and downregulating SLC8A1 and TLR5
only later in the follow-up period. In consequence, CA initially
most resembled the group of chronically rejecting and stably
immunosuppressed patients, but after week 32 closely re-
sembled the clusters of patients classified as tolerant or healthy
controls.
Discussion
Several alternative cell types are now approaching the point of
preclinical development that might allow them to be properly
investigated as adjunct immunosuppressive therapies in early-
stage clinical trials, including certain tolerogenic DC subsets,
regulatory T cells, mesenchymal stem cells, and M regs. Yet
clinical studies using cellular therapies in transplantation re-
main controversial because many in the field doubt the clinical
practicality of such therapies and their safety. It is certainly
true that administration of cell preparations to patients is
not without potential complications, but these risks can be
minimized by refining cell production and clinical monitor-
ing of the recipient: in both these respects, we have learned
much from the cases of MM and CA.
Should we be surprised by the clinical outcomes of MM and
CA? Although a high proportion of renal transplant recipients
with stable graft function several years after transplantation
may be weaned to tacrolimus monotherapy, quite a different
situation pertains to our patients. Both MM and CA under-
went an early, rapid reduction in immunosuppression, such
that both received tacrolimus monotherapy by 14 and 10 wk,
respectively, and were further minimized to 4–6 ng/ml trough
tacrolimus levels by 24 wk. At 3 y posttransplantation, patient
CA is clinically stable with once-daily 5 mg sustained-release
tacrolimus, and patient MM is being stably maintained with
tacrolimus 2 mg twice daily. Despite their early minimization
of immunosuppressive therapy, neither patient MM nor CA
underwent an acute rejection episode during the 3-y follow-
up period. Shapiro et al.’s study (14) remains a benchmark
trial of minimized tacrolimus monotherapy in renal transplant
recipients: In this study, 150 patients were treated with 5 mg/
kg antithymocyte globulin with bolus prednisone as induction
and were subsequently treated with tacrolimus monotherapy.
Under this regimen, 37% of patients underwent acute re-
jection by 4 mo. After the fourth month, 113 patients un-
derwent a stepwise minimization of tacrolimus dosing; these
patients were followed up for a mean of 11 6 5.4 mo, during
which time 23% of patients underwent acute rejection. Other
studies with the aim of establishing renal transplant patients
on tacrolimus monotherapy after antithymocyte globulin in-
duction (15) or alemtuzumab induction (16) achieved similar
outcomes in terms of acute rejection rates and the proportion
of patients tolerating monotherapy. Despite receiving no
conventional induction therapy, neither MM nor CA un-
derwent acute rejection or showed any signs of subclinical
rejection at their last protocol biopsy. From clinical experience,
for the patients to have tolerated such an abrupt weaning of
FIGURE 4. Using the RISET 2.0 Agilent
custom microarray platform, serial analyses of
gene expression in the peripheral blood of patients
MM and CA were performed. The resulting
dataset was then compared with that obtained
from the IOT-RISET patients. Expression profiles
of the 10 most discriminatory biomarkers of
tolerance identified by the IOT-RISET study are
presented. The color coding of the heatmaps
represents reporter-wise median-centered log2
ratios of the combined IOT, CA, and MM
datasets: red, relative upregulation; green, relative
downregulation; black, no differential regulation.
The convergence over time of patient MM and
CA’s marker gene expression upon the tolerance-
associated IOT-RISET gene signature is best ap-
preciated by considering pairwise Pearson corre-
lation coefficients comparing the medians of
the IOT-RISET drug-free, tolerant patient group
with MM and CA at each sampling time point
(bottom right panel).
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immunosuppression is a surprising result and suggestive of
attenuated antidonor reactivity.
Serial analyses of the immunological status of the two
patients, especially by gene expression profiling, support the
contention that the reactivity of MM and CA against their
grafts was attenuated. As time progressed, the expression
pattern of the IOT-RISET gene set in MM and CA tended
toward that of a group of tolerant kidney transplant recipients
or healthy untransplanted individuals (13). The frequency of
individuals displaying the IOT-RISET gene signature among
the cohort of stably immunosuppressed patients on calci-
neurin inhibitor monotherapy studied by IOT-RISET was
only 14.7%. Considering that this group of patients were all
6 to 9 years after transplantation and had been purposefully
selected for their stable clinical state, we can reasonably expect
the frequency of patients displaying the IOT-RISET gene
signature within the general pool of renal transplant recipients
to be lower.
Could selection of MM and CA have biased our in-
terpretation of their clinical outcomes? Patient CA was fully
mismatched against his unrelated donor. Patient MM, who
received a kidney from her 58-y-oldmother, was at risk for being
presensitized against noninherited maternal Ags (17). There-
fore, neither donor-recipient pair could be said to be especially
more likely to have a better outcome than the general pool of
living-donor transplant recipients.
After systemic administration, humanM regs could influence
recipient responses against donor alloantigen by multiple
mechanisms: M regs might have direct effects on alloreactive
and regulatory T cells or may act indirectly through a systemic
release of cytokines or alloantigen. At the cellular level, though,
it has been shown that M regs profoundly suppress mitogen-
stimulated T cell proliferation in vitro and that this activity is
partly mediated by the tryptophan-catabolizing enzyme IDO.
In mice, IDO is indispensable for maintaining maternal tol-
erance of allogeneic conceptuses (18) and participates in the
establishment of allograft tolerance by adoptive transfer of T
regs (19). Therefore, it is at least plausible that human M regs
might influence responses to allografts through the action of
IDO.
Central to any understanding of the possible mechanisms
by which M regs might act is the question of whether they
transiently or stably engraft in the recipient or die shortly after
administration. Tracking studies with 111In-labeled cells in
patient MM revealed that donor-derived M regs migrated to
specific sites and remained viable for at least the first 30 h
posttransfusion, although their fate beyond this time is not
known. However, given that M regs are believed to be fully
differentiated, postmitotic cells, it must be assumed that they
cannot establish a permanent state of chimerism.
In conclusion, these pilot case studies demonstrate the
feasibility of treating renal transplant recipients with M regs.
Reassuringly, no unexpected adverse reactions were observed
in either patient. Tracking M regs has provided us with a
preliminary description of their distribution after infusion,
which is essential information in the assessment of any new
therapeutic agent. Taken together, the clinical outcomes of the
patients and their peripheral blood gene expression profiles
must be seen as promising results, albeit of a preliminary
nature. We are still years away from proving any clinical ef-
ficacy of M reg treatment as an adjunct immunosuppressive
therapy, which could only be properly demonstrated in a large-
scale clinical trial. However, it is our opinion that further
clinical trials of M reg treatment as an adjunct therapy aimed
at establishing renal transplant recipients on minimal, calci-
neurin inhibitor-based maintenance immunosuppression are
warranted. This concept is now being carried forward within
The ONE Study, a European Union-funded multinational
clinical trial.
Acknowledgments
We thank patients M.M. and C.A. for willing and generous cooperation
with our studies. We also thank Martina Mattha¨i, Ingrid Berg, Tina Jansen,
Hebke Hinz, Prof. Gro¨ne, Dr. Felix Braun, Dr. Corinna von Forstner, and
Prof. Andreas Humpe.
Disclosures
The authors have no financial conflicts of interest.
References
1. Hutchinson, J. A., P. Riquelme, E. K. Geissler, and F. Fa¨ndrich. 2011. Human
regulatory macrophages. Methods Mol. Biol. 677: 181–192.
2. Riquelme, P., F. Go¨vert, E. K. Geissler, F. Fa¨ndrich, and J. A. Hutchinson. 2009.
Human transplant acceptance-inducing cells suppress mitogen-stimulated T cell
proliferation. Transpl. Immunol. 21: 162–165.
3. Hutchinson, J. A., B. G. Brem-Exner, P. Riquelme, D. Roelen, M. Schulze, K. Ivens,
B. Grabensee, O. Witzke, T. Philipp, L. Renders, et al. 2008. A cell-based approach
to the minimization of immunosuppression in renal transplantation. Transpl. Int. 21:
742–754.
4. Hutchinson, J. A., P. Riquelme, B. G. Brem-Exner, M. Schulze, M. Mattha¨i, L. Renders,
U. Kunzendorf, E. K. Geissler, and F. Fa¨ndrich. 2008. Transplant acceptance-inducing
cells as an immune-conditioning therapy in renal transplantation. Transpl. Int. 21: 728–
741.
5. Hutchinson, J. A., D. Roelen, P. Riquelme, B. G. Brem-Exner, O. Witzke, T. Philipp,
M. Mattha¨i, F. Go¨vert, F. H. Claas, E. Westphal, et al. 2008. Preoperative treatment
of a presensitized kidney transplant recipient with donor-derived transplant
acceptance-inducing cells. Transpl. Int. 21: 808–813.
6. Hutchinson, J. A., F. Go¨vert, P. Riquelme, J. H. Bra¨sen, B. G. Brem-Exner, M. Mattha¨i,
M. Schulze, L. Renders, U. Kunzendorf, E. K. Geissler, and F. Fa¨ndrich. 2009. Ad-
ministration of donor-derived transplant acceptance-inducing cells to the recipients of
renal transplants from deceased donors is technically feasible. Clin. Transplant. 23: 140–
145.
7. Brem-Exner, B. G., C. Sattler, J. A. Hutchinson, G. E. Koehl, K. Kronenberg, S. Farkas,
S. Inoue, C. Blank, S. J. Knechtle, H. J. Schlitt, et al. 2008. Macrophages driven to
a novel state of activation have anti-inflammatory properties in mice. J. Immunol. 180:
335–349.
8. Hutchinson, J. A., P. Riquelme, E. K. Geissler, and F. Fandrich. 2009. Macro-
phages driven to a novel state of activation have tolerogenic properties in kidney
transplant recipients. Am. J. Transplant. 9: 657.
9. Anderson, C. B., G. A. Sicard, and E. E. Etheredge. 1982. Pretreatment of renal
allograft recipients with azathioprine and donor-specific blood products. Surgery 92:
315–321.
10. Miqueu, P., N. Degauque, M. Guillet, M. Giral, C. Ruiz, A. Pallier, C. Braudeau,
G. Roussey-Kesler, J. Ashton-Chess, J. C. Dore´, et al. 2010. Analysis of the pe-
ripheral T-cell repertoire in kidney transplant patients. Eur. J. Immunol. 40: 3280–
3290.
11. Sawitzki, B., A. Bushell, U. Steger, N. Jones, K. Risch, A. Siepert, M. Lehmann,
I. Schmitt-Knosalla, K. Vogt, I. Gebuhr, et al. 2007. Identification of gene markers
for the prediction of allograft rejection or permanent acceptance. Am. J. Transplant.
7: 1091–1102.
12. Andreesen, R., C. Scheibenbogen, W. Brugger, S. Krause, H. G. Leser, S. Kopf,
H. Engler, C. Schu¨michen, and G. W. Lo¨hr. 1991. A new approach to adoptive
immunotherapy of cancer using tumorcytotoxic macrophages grown from periph-
eral blood monocytes. Cancer Detect. Prev. 15: 413–421.
13. Sagoo, P., E. Perucha, B. Sawitzki, S. Tomiuk, D. A. Stephens, P. Miqueu, S. Chapman,
L. Craciun, R. Sergeant, S. Brouard, et al. 2010. Development of a cross-platform
biomarker signature to detect renal transplant tolerance in humans. J. Clin. Invest.
120: 1848–1861.
14. Shapiro, R., M. L. Jordan, A. Basu, V. Scantlebury, S. Potdar, H. P. Tan, E. A. Gray,
P. S. Randhawa, N. Murase, A. Zeevi, et al. 2003. Kidney transplantation under a
tolerogenic regimen of recipient pretreatment and low-dose postoperative immu-
nosuppression with subsequent weaning. Ann. Surg. 238: 520–525, discussion 525–
527.
15. Tan, H. P., D. Kaczorowski, A. Basu, J. McCauley, A. Marcos, J. Donaldson, M. Unruh,
P. Randhawa, A. Zeevi, and R. Shapiro. 2005. Steroid-free tacrolimus monotherapy
after pretransplantation thymoglobulin or Campath and laparoscopy in living donor
renal transplantation. Transplant. Proc. 37: 4235–4240.
6 CUTTING EDGE: HUMAN REGULATORY MACROPHAGES
 o
n
 July 30, 2011
w
w
w
.jimmunol.org
D
ow
nloaded from
 
16. Tan, H. P., J. Donaldson, A. Basu, M. Unruh, P. Randhawa, V. Sharma, C. Morgan,
J. McCauley, C. Wu, N. Shah, et al. 2009. Two hundred living donor kidney
transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year
follow-up. Am. J. Transplant. 9: 355–366.
17. Burlingham, W. 2001. The blood transfusion effect. In Pathology and Immunology of
Transplantation and Rejection. S. Thiru, and H. Waldmann, eds. Blackwell Science,
Oxford, United Kingdom, p. 92.
18. Munn, D. H., M. Zhou, J. T. Attwood, I. Bondarev, S. J. Conway, B. Marshall,
C. Brown, and A. L. Mellor. 1998. Prevention of allogeneic fetal rejection by
tryptophan catabolism. Science 281: 1191–1193.
19. Cobbold, S. P., E. Adams, C. A. Farquhar, K. F. Nolan, D. Howie, K. O. Lui,
P. J. Fairchild, A. L. Mellor, D. Ron, and H. Waldmann. 2009. Infectious tol-
erance via the consumption of essential amino acids and mTOR signaling. Proc.
Natl. Acad. Sci. USA 106: 12055–12060.
The Journal of Immunology 7
 o
n
 July 30, 2011
w
w
w
.jimmunol.org
D
ow
nloaded from
 
R E V I E W
Clinical management of patients receiving cell-based
immunoregulatory therapy
James A. Hutchinson,1 Norbert Ahrens,2 Paloma Riquelme,1 Lisa Walter,1 Michael Gruber,3
Carsten A. Böger,4 Stefan Farkas,1 Marcus N. Scherer,1 Christiane Broichhausen,1 Thomas Bein,1
Hans-J. Schlitt,1 Fred Fändrich,5 Bernhard Banas,4 and Edward K. Geissler1
Administering immunoregulatory cells as medicinal
agents is a revolutionary approach to the treatment of
immunologically mediated diseases. Isolating, propagat-
ing, and modifying cells before applying them to
patients allows complementation of specific cellular
functions, which opens astonishing new possibilities for
gain-of-function antigen-specific treatments in autoim-
munity, chronic inflammatory disorders, and transplanta-
tion. This critical review presents a systematic
assessment of the potential clinical risks posed by cell-
based immunotherapy, focusing on treatment of renal
transplant recipients with regulatory macrophages as a
concrete example.
T
ransferring immunoregulatory cells from a tol-
erant donor to nontolerant recipient as a means
of establishing tolerance in the recipient is a
well-known technique in experimental immu-
nology,1 but its clinical application is only now receiving
serious attention.2 At present, several immunoregulatory
cell types are reaching the point of preclinical develop-
ment, which will allow them to be investigated as immu-
nosuppressive agents in early-phase clinical trials,
including regulatory T cells,3 tolerogenic dendritic cells,4
and regulatory macrophages (M regs).5 A broad spectrum
of immunologic conditions may be amenable to treat-
ment with cell-based immunoregulatory therapies,
including T-cell-mediated autoimmune disease,6 chronic
inflammatory conditions,7 graft-versus-host disease
(GVHD),8 and transplant rejection.9 In these cases, cell-
based immunoregulatory therapies might reduce or
obviate the need for general immunosuppressive therapy,
so sparing patients its attendant complications. Because
the kind of immunologic tolerance supported by regula-
tory cells (as opposed to purely deletional or anergic
mechanisms) is dominant and self-sustaining, there exists
the staggering possibility that cell-based immunotherapy
may offer a curative option in diseases that would other-
wise require long-term general immunosuppressive
therapy.
One particularly promising candidate cell type for use
as an adjunct immunosuppressive agent in transplanta-
tion is the M reg. The M reg reflects a unique state of mac-
rophage differentiation, which is distinguished from
macrophages in other activation states by its robust phe-
notype and potent T-cell suppressor function.10 A newly
developed therapeutic cell product containing M regs
(known as Mreg_UKR) conforms to our expectations of a
clinically applicable drug product in most respects.11
Human M regs potently suppress mitogen-stimulated
T-cell proliferation in vitro, which can be attributed to
interferon (IFN)-γ–induced indoleamine 2,3-dioxygenase
activity, as well as contact-dependent deletion of activated
T cells.10 In addition, M regs drive the development of acti-
vated induced regulatory T cells that, in turn, suppress the
proliferation of effector T cells and inhibit the maturation
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of dendritic cells (L. Walter, submitted for publication).
Therefore, when M regs are administered to an allogeneic
recipient, it is hypothesized that a feed-forward loop of
immunologic regulation is initiated leading to the long-
term immunologic acceptance of a foreign transplant.
M reg–containing cell preparations have been admin-
istered to a total of 19 kidney transplant recipients in a
series of case studies and two early-phase clinical trials
(Table 1).10,12-15 While these pilot studies do not provide
conclusive evidence of the safety or efficacy of M reg treat-
ment in renal transplantation, they demonstrate the feasi-
bility of this technique. An additional two living-donor
kidney transplant recipients have now been treated with
approximately 8.0 × 106 cells/kg of purer donor-derived
M regs.10 These two patients are now more than 5 years
posttransplantation with stable renal function on low-dose
tacrolimus monotherapy as their sole maintenance immu-
nosuppression. An additional clinical trial of M reg therapy
in living-donor renal transplantation now has regulatory
approval within the framework of the ONE Study (http://
www.onestudy.org). This trial (ONEMreg12, EudraCT 2013-
000999-15) aims to treat 16 patients with donor-derived
Mreg_UKR at a dose of 2.5 × 106 to 7.5 × 106/kg body weight
(BW) under cover of 500 mg/day mycophenolate mofetil
on Day 7 before surgery.
IDENTIFICATION OF CLINICAL RISKS
ASSOCIATED WITH M REG THERAPY
Although cell-based medicines are quite different in
nature from chemically synthesized drugs, many of the
same general considerations apply to their clinical use.11
An essential step in the safe implementation of any cell-
based immunosuppressive treatment is an assessment of
its associated risks and understanding how those risks
relate to particular properties of the cell product.16 Natu-
rally, evaluation of the risks associated with immunosup-
pressive cell therapy depends on the nature of the
therapeutic cell type, the quality of the cell product, the
route and timing of cell administration, and the condition
and concomitant treatments of the recipient. This article
examines the risk profile of Mreg_UKR treatment as a par-
ticular example of the risks of immunoregulatory cell
therapy in living-donor renal transplantation. The follow-
ing risk–benefit assessment has been adapted from the
ONEMreg12 clinical trial application, which was approved
by the Paul Ehrlich Institute (http://www.pei.de) on
December 17, 2013. Although some risk factors and asso-
ciated risks discussed here are unique to the administra-
tion of M regs to transplant recipients, others are of
generic importance. The authors hope that this article
might serve as template for other groups wishing to estab-
lish M reg therapy or other cell-based immunosuppres-
sive therapies.
The type and rate of complications caused by
Mreg_UKR have not yet been accurately assessed in clini-
cal trials. Nevertheless, the limited available clinical evi-
dence, as well as preclinical studies and theoretical
considerations, serve as an adequate basis for a thorough
risk assessment. In discussing the potential risks associ-
ated with M reg therapy, it is helpful to categorize them as
immunologic, physiologic, malignant, or infectious
(Table 2). Generally speaking, the potential complications
of administering any immunoregulatory cell-based
therapy overlap with those of Mreg_UKR therapy; never-
theless, it is valuable to consider possible differences
between the safety profiles of alternative immu-
noregulatory cell products.
Potential immunologic complications of
M reg therapy
The immunologic complications of M reg therapy are
broadly similar to those associated with blood transfu-
sions.17 When administering allogeneic cells to a trans-
plant recipient, sensitization against donor antigens and
the risk of accelerated graft rejection is a major concern;
vice versa, transferring recipient-reactive immunologic
effector cells might also cause disease. Additionally, non-
specific reactions, such as massive cytokine release, may
be responsible for adverse reactions.
Sensitization against donor antigens
With a mouse heterotopic heart transplant model, donor-
derived M regs were found to afford a greater graft-
protective effect than recipient- or third party-derived
M regs.18 Administration of M regs before transplantation
was more effective than posttransplant treatment, which
is consistent with our current understanding of the func-
tion of M regs in promoting T-cell regulation. Accordingly,
our clinical studies of M reg therapy have focused on
the use of donor-derived cells given preoperatively.10
TABLE 1. Overview of clinical studies with human M regs
Study Number Total cell number Cells/kg BW Reference
Patient KW 1 1.1 × 106 Hutchinson et al.15
TAIC-I Study 12 0.9-5.0 × 108 1.0-5.0 × 106 Hutchinson et al.12
Patient FR 1 4.8 × 109 6.9 × 107 Hutchinson et al.14
TAIC-II Study 5 1.4-5.9 × 109 1.7-10.4 × 107 Hutchinson et al.13
Patients MM and CA 2 4.3-7.5 × 108 7.0-8.0 × 106 Hutchinson et al.10
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Deliberate preoperative challenge of transplant recipients
with donor alloantigen carries a risk of priming donor-
reactive T cells19 and B cells,20 potentially leading to accel-
erated graft rejection. Induction of donor-specific
antibody production is especially undesirable because
preformed donor antibody could lead to hyperacute,
acute, or chronic rejection. There is an important historical
precedent for patients being sensitized by pretransplant
exposure to donor antigen in the form of HLA-disparate
blood transfusions.21 Pretransplant challenge of prospec-
tive transplant recipients with donor-specific blood trans-
fusions (DSTs) used to be common practice in renal
transplantation and was associated with fewer acute rejec-
tion episodes and improved allograft survival when donor
and recipient shared at least one HLA-DR antigen.22 Unfor-
tunately, DST was also associated with a relatively high rate
of sensitization, so the practice was largely abandoned
after the introduction of cyclosporin. Sensitization rates in
prospective kidney transplant recipients receiving DST
without concomitant immunosuppression ranged from
8% to 29%, but this could be reduced by cotreatment with
azathioprine to 7% to 16%.23
Recent studies performed by Ezzelarab and
colleagues24 in rhesus macaque monkeys are impor-
tant in assessing the potential risk of monocyte-
derived antigen-presenting cells (APCs) of donor origin in
causing alloantigenic sensitization. This group generated
maturation-resistant, T-cell-suppressive dendritic cells
(so-called DCregs) by differentiating monocytes in the
presence of vitamin D3 and interleukin (IL)-10. Allogeneic
kidney transplant recipients were treated with 3.5 × 106 to
10 × 106 donor-derived DCregs/kg on Day −7 before trans-
plantation under cover of belatacept and rapamycin. After
transplantation, belatacept was continued for 10 or 56
days, and rapamycin treatment was continued for 180
days. DCreg treatment prolonged allograft survival com-
pared to untreated control animals. Importantly, neither
anti-donor immunoglobulin (Ig)G nor IgM antibodies
were observed in the sera of the six DCreg-treated recipient
monkeys. These data indicate that transfusing relatively
high numbers of donor-derived myeloid APCs does not
necessarily lead to sensitization, although the experiment
was not large enough to detect the rates of sensitization
observed in clinical studies of DST.
Sensitization rates observed in DST-treated patients
are likely to overestimate the risk of sensitization in
patients treated with Mreg_UKR. The composition of
whole blood products and Mreg_UKR preparations are
very different: A 200-mL DST comprises 0.8 × 109 to
2.2 × 109 white blood cells (WBCs; of which 2%-10% are
monocytes), 0.8 × 1012 to 1.3 × 1012 red blood cells (RBCs),
and 30 × 109 to 80 × 109 platelets; by contrast, M reg prepa-
rations are homogeneous and a single treatment dose of
2.5 × 106 to 7.5 × 106 M regs/kg represents a total dose of
1.25 × 108 to 7.5 × 108 cells. Importantly, the WBC fraction
of a DST contains many potentially activatory APCs,
whereas the Mreg_UKR product is an essentially pure
preparation of suppressive cells.10 Additionally, classical
DST protocols often involved multiple rounds of treat-
ment and the risk of sensitization increased with each
rechallenge: In a series of 61 patients, the rate of sensiti-
zation after a first DST was 5%, but this increased to 10%
after a second DST was given 2 months later. To avoid any
cumulative risk of sensitization with multiple treatments,
Mreg_UKR will only be given as one-time therapy at 7 days
before transplantation.
TABLE 2. Overview of possible adverse reactions to Mreg_UKR
Class of adverse effect Description of adverse effect Evidence
Immunologic Sensitization against donor alloantigen Theoretical
Type I hypersensitivity reactions Theoretical
Type II hypersensitivity reactions Theoretical
Type III hypersensitivity reactions Theoretical
Mild febrile reactions Theoretical
GVHD Theoretical
TRALI Theoretical
Physiologic PE (overt or subclinical) Preclinical toxicology
Infusion-related circulatory overload Theoretical
Hypotension due to bradykinin activation Theoretical
Paradoxical embolism Theoretical
Biochemical changes Elevated LDH Theoretical
RBC lysis causing elevated free Hb and Hp Theoretical
Elevated TAT complexes or D-dimer Theoretical
Elevated K+ (consequence of K+ infusion) Theoretical
Elevated BNP, D-dimer, troponin due to PE Theoretical
Infectious diseases Local or systemic infection by opportunistic bacteria, viruses, fungi, or parasites owing to
compromised immunity through generalized immunosuppression
Theoretical
Malignant disease
Iatrogenic disease
Promotion of autochthonous tumor growth Theoretical
Allograft dysfunction or rejection owing to reduction in immunosuppressive therapy Theoretical
Allograft dysfunction owing to biopsy Theoretical
Allograft dysfunction owing to surgical complications Theoretical
Other Higher rate of noncompliance with immunosuppressive therapy Previous experience
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In previous clinical studies, none of the 12 patients
treated postoperatively and the nine patients treated
preoperatively with M regs (or M reg–containing cell
preparations) developed measurable donor antibody
responses and none showed signs of antibody-mediated
rejection.10,12-15 Taken together, these preclinical and clini-
cal data suggest that the risk of sensitization against
alloantigen as consequence of Mreg_UKR admin-
istration is low. Nevertheless, as a precautionary measure,
patients receiving Mreg_UKR should be treated with
mycophenolate mofetil 250 mg BD from the day of cell
infusion until transplantation. Additionally, patients will
be screened for donor-specific antibody on the day before
transplantation and surgery will be cancelled if there is
evidence of de novo reactivity.
In a broader context, several groups working with
immature dendritic cells have shown that recipient-
derived cells (with or without donor antigen pulsing)
have tolerogenic properties.4 In addition, most groups
working with therapeutic nTreg and Tr1 preparations use
cells of recipient origin. Using recipient-derived cells cir-
cumvents any risk of anti-donor sensitization; however,
at least in the case of M regs and DCregs, the far greater
efficacy of donor-derived cells in promoting allograft sur-
vival appears to outweigh the possible risk of
sensitization.
Antibody-mediated hypersensitivity and
nonspecific reactions
Discussion of Type I, Type II, and Type III hypersensitivity
reactions and nonspecific adverse immunologic reactions
are presented as Appendix S1 (available as supporting
information in the online version of this paper).
Transfusion-associated GVHD
GVHD is an extremely rare complication of blood transfu-
sions, characterized by fever, hepatic dysfunction, gastro-
intestinal disturbances, pancytopenia, and rash.25 Despite
its rarity, because transfusion-related GVHD is fatal in
approximately 90% of cases, it deserves special consider-
ation. GVHD is caused by alloreactive donor T cells that
cannot be rejected by the recipient. Immunocompromised
recipients and recipients of transfusions from donors with
closely matched HLA types are especially susceptible to
transfusion-related GVHD because they are less capable of
eliminating donor T cells. We note that an HLA-
homozygotic recipient given T-cell-containing cell prepa-
rations from a haploidentical, HLA-heterozygotic donor
represents a particularly high-risk constellation. To miti-
gate the risk of GVHD, the Mreg_UKR manufacturing
process uses CD14+ monocytes enriched by magnetic
bead sorting as a starting material, thereby largely exclud-
ing T cells and other WBCs from the preparation.26 Never-
theless, as it is impossible to remove all donor T cells from
M reg preparations, there may be a very small residual risk
of GVHD. As a basis for assessing the risk of GVHD after
infusing T cells into an allogeneic recipient, we must turn
to the extensive literature on preemptive donor lympho-
cyte infusion (pDLI) as a treatment for hematologic malig-
nancy.27 In a meta-analysis of pDLI, CD3+ T-cell doses
greater than 100 × 106 cells/kg were found to be associated
with an increased risk of GVHD.28 In the case of unrelated
donors, CD3+ T cell doses of ≥10 × 106 cells/kg were asso-
ciated with a higher risk of GVHD.28 In a typical M reg cell
product, contamination with CD3+ T cells is consistently
less than 1%, which implies a maximum exposure of
0.075 × 106 CD3+ T cells/kg in M reg recipients; this
equates to approximately 100-fold fewer T cells than typi-
cally used for pDLI. Therefore, the risk of GVHD as a result
of Mreg_UKR is considered to be extremely low.
In a broader context, reaction of autologous
immunoregulatory cell products against a recipient is
extremely unlikely, especially in the case of self-derived
tolerogenic DCs. However, there are concerns that trans-
fused T regs could lose their suppressive capacity and dif-
ferentiate into graft-reactive effector T cells if restimulated
in an inflammatory environment.29 It is well documented
that nTregs can redifferentiate into Th17 cells,30 but con-
version into Th1,31 Th2,32 and TfH33 cells has also been
reported. Various strategies to avoid nTreg products
becoming potentially pathogenic effector cells have been
proposed, including selection of the CD45RA+ subset
that is completely demethylated at the Treg-specific
demethylated region (TSDR) of the FOXP3 gene, limiting
the number of divisions undergone by T regs in vitro, and
performing T reg expansion in the presence of rapamycin
and/or vitamin D3.34 Little is known about the behavior of
nTregs (or other regulatory T-cell products) after infusion
into patients and, of course, it is not possible to control the
fate of nTregs in vivo. Of significant concern are experi-
ments in mice that show Foxp3 expression in T regs is
unstable under inflammatory conditions and that T regs
can spontaneously redifferentiate into a IFN-γ– and IL-17–
producing T cells that exacerbate autoimmune disease.
Transfusion-related acute lung injury
Discussion of transfusion-related acute lung injury
(TRALI)-like reactions is presented as Appendix S1.
Potential physiologic complications of
M reg therapy
Potential physiologic complications of preoperative M reg
administration to renal transplant recipients include
embolization of cellular aggregates or cellular debris, fluid
overload, and biochemical disturbances owing to release
of cellular constituents.
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Pulmonary embolism
When a cell product is administered systemically by intra-
venous (IV) infusion, the potential for embolism of cells,
aggregates of cells, or debris to the pulmonary vasculature
is a major concern. Pulmonary vascular obstructions
caused by cell infusion may be widespread throughout the
pulmonary tree and are more likely to affect small
end-arteriolar branches or capillaries than larger vessels;
therefore, pulmonary embolism (PE) after cell infusion is
unlikely to present with classical clinical signs of throm-
boembolic PE. Depending on its extent, PE may be a life-
threatening condition and all possible measures must be
taken to avoid its occurrence.
Human M regs in suspension are approximately
spherical and have a diameter of 15 to 30 μm. In humans,
an estimated 2.8 × 1011 individual capillary segments are
distributed between 108 alveoli.35 Human pulmonary cap-
illaries have a mean diameter of 7.5 ± 2.3 μm, whereas
partially muscular and nonmuscular arterioles associated
with respiratory bronchioles have internal diameters
ranging from 15 to 150 μm.36 Rigid polystyrene particles
with a diameter of greater than 10 μm cannot pass
through the lung vasculature, whereas the majority of par-
ticles less than 6 μm in diameter pass within 48 hours.37
Polymorphonuclear leukocytes (PMNs), which have a
mean diameter of 6.8 ± 0.8 μm, take 60 to 100 times longer
than RBCs to transit through the lung capillary bed owing
to their size.38 Because of hydrostatic pressure, capillaries
toward the lung bases are dilated and offer less resistance
to the passage of PMNs; importantly, this effect is suffi-
cient to cause a relative retention of PMNs in the upper
lung vasculature.35 On this evidence, it seems probable
that passage of single M regs traveling through the pulmo-
nary vasculature may be resisted by pulmonary capillaries
and it is conceivable that aggregates of M regs might
obstruct small end-arterioles.
What might be the clinical consequence of adminis-
tering a treatment dose of 2.5 × 106 to 7.5 × 106 viable
cells/kg on pulmonary perfusion? Studies performed in
adult dogs after lung embolization with 22-μm aggregated
albumin particles revealed no significant increase in mean
pulmonary arterial pressure (PAP) when up to approxi-
mately 9 × 106 particles were administered.39 In contrast,
administration of approximately 3.5 × 106 polystyrene
beads with a mean diameter of 58.9 ± 5.2 μm to dogs
caused an increase in mean PAP, increased shunt fraction,
and reduced cardiac output.40 Particles with a mean diam-
eter of 116.6 ± 13.1 μm likewise caused an increase in
mean PAP, shunting, and reduced cardiac output and was
ultimately fatal in some cases.40 The mean lethal dose of
splenocytes in heparinized dogs is 4.5 × 108 cells/kg BW
and the mean lethal dose of adult hepatocytes in dogs is
1.7 × 108 cells/kg BW.41 Recently, Kobayashi and col-
leagues42 found that slow IV infusion of 107 mesenchymal
stem cells/kg BW into heparinized miniature swine
caused a 30 mmHg increase in PAP. Therefore, infusion of
approximately 108 cells or cell-sized particles per kilogram
can be lethal in large animals and infusion of approxi-
mately 107 cells or cell-sized particles per kilogram can
cause a significant increase in PAP.
In conclusion, it is possible that slow infusion of
2.5 × 106 to 7.5 × 106 M regs/kg BW could increase pulmo-
nary vascular resistance, thereby increasing PAP; however,
recipients with normal right-heart function are unlikely to
be symptomatically compromised by M reg infusion. As a
precautionary measure, patients receiving Mreg_UKR
should be fully anticoagulated with high-molecular-
weight heparin to reduce the risk of intrapulmonary
coagulation resulting from vascular stasis. In a general
sense, the risk of any given therapeutic cell type adminis-
tered by IV injection causing PE depends on the size of the
cells, their adherence to pulmonary vascular endothe-
lium, their propensity to aggregate into clusters, and
perhaps the degree of contamination with activated
thrombocytes. Without experimental evidence, one might
imagine that patients would tolerate higher doses of
nTregs, which have a diameter of approximately 8.5 μm
when quiescent, better than myeloid cells, such as M regs
and tolerogenic DCs, which are larger.
Circulatory overload and biochemical disturbances
Discussion about infusion-related circulatory overload
and biochemical disturbances is presented as Appendix
S1.
Potential for transmission of malignant disease
Malignant disease after treatment with an immunosup-
pressive cell product might, in principle, arise either as
consequence of transferring neoplastic cells or as conse-
quence of transferred cells promoting growth of
autochtonous tumors.43 Neoplastic cells within the cell
product might originate from the donor or arise during in
vitro culture or after transfer into the recipient. Impor-
tantly, not only the therapeutically active cells within a cell
product might cause malignant disease, but the cellular
contaminants may also pose a risk. Immunosuppressive
cell therapies might promote recipient malignancies
either by directly influencing the growth of malignant cells
or by suppressing immune responses against cancerous
cells.
Human M regs are prepared from isolated
CD14+ blood monocytes. Blood monocytes stem from a
myelomonocytic precursor in marrow, known as the pro-
myelocyte. As the promyelocyte differentiates into a blood
monocyte, it passes through a series of intermediate
stages, gradually losing promyelocyte characteristics and
gaining features of mature monocytes. Blood monocytes
are the immediate precursors of interstitial histiocytes,
connective tissue macrophages, and various specialized,
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tissue-specific macrophage populations. Malignancies
can arise from cells at any stage of myelomonocytic devel-
opment, although malignancies of primitive forms are
very much more common than those of blood monocytes
and macrophages.44 In our view, it is extremely unlikely
that a myelogenous leukemia could be transmitted from a
donor with an undiagnosed malignancy to a recipient
through Mreg_UKR treatment. Likewise, we consider the
risk of inadvertently isolating malignant cells from pro-
spective donors with any other undetected malignancy as
negligible. Division of human M regs during in vitro gen-
eration cannot be reliably detected, so it appears that
M regs are fully differentiated postmitotic cells. Although
the possibility of there being a small fraction of M regs
with some proliferative potential cannot be absolutely
excluded, it is our opinion that the general non-
proliferative condition of M regs means that the likelihood
of them undergoing neoplastic transformation during
culture is very low.
The arguments presented above for the low risk of
malignancy after Mreg_UKR equally apply to tolerogenic
DC preparations. Proliferating T cells accumulate genetic
aberrations, both in vivo and in vitro, but the pathologic
relevance of such mutations are unclear. nTreg-derived
malignancies do occur naturally, notably in approximately
50% of patients with cutaneous T-cell lymphoma;45 never-
theless, this is a very rare condition. To the best of the
authors’ knowledge, there is no evidence that nTregs
expanded using any common clinical protocol are immor-
talized by the procedure; moreover, we know of no toxico-
logic studies showing that ex vivo expanded nTregs give
rise to T-cell malignancies in immunodeficient animal
models.
Potential for transmission of infectious diseases
Transmission of viral, bacterial, or fungal disease through
the application of cell products is a potential risk of any
cell therapy.46 Hypothetically, there are three potential
sources of infective contaminants that must be controlled,
namely, pathogens from the cell donor, microbial con-
taminants of culture reagents or materials, and adventi-
tious agents introduced during the manufacturing
process. Therefore, we are concerned not only with
excluding primary pathogens and opportunistic patho-
gens of transplant recipients, but also adventitious agents
which may be favored by the cell product manufacturing
process. Guidelines issued by the Amsterdam Forum pre-
scribe that all potential live kidney donors are screened for
cytomegalovirus and Epstein-Barr virus, hepatitis B virus
(HBV) and hepatitis B virus (HCV), human immunodefi-
ciency virus (HIV) and human T-lymphotropic virus 1 and
2, Treponema pallidum, Toxoplasma gondii, and urinary
tract infections. When indicated by the patient’s history or
other investigations, screening for human herpes virus 8
and herpes simplex virus, Mycobacterium tuberculosis,
Salmonella typhi, Brucella spp., Trypanosoma cruzi,
malaria, schistosome, and strongyloides infections should
also be undertaken. To exclude the presence of pathogens
in the leukapheresis product used as starting material for
the generation of Mreg_UKR, testing will be performed for
HBV, HCV, HIV, and T. pallidum. Microbiologic control of
Mreg_UKR preparation is performed on a manufacturing
intermediate using the BacTAlert system, which detects
aerobic and nonaerobic bacteria and fungi. Sterility of the
final product is ascertained by testing a membrane filtrate
from the Mreg_UKR culture medium and washing solu-
tions. In addition, testing for endotoxin and mycoplasma
contamination are performed to pharmacopoieal stan-
dards. Together, the measures taken to avoid transmission
of infectious diseases with the Mreg_UKR product repre-
sent a stringent approach to ensuring microbiologic
safety. With appropriate microbiologic screening of inter-
mediate and final cell products, there is no reason to think
that any particular immunoregulatory cell product is
more or less likely to transmit infectious diseases than
Mreg_UKR.
RISK–BENEFIT BALANCE OF CELL
THERAPY IN TRANSPLANTATION
Were it possible to maintain the acceptable rates of rejec-
tion achieved with conventional calcineurin inhibitor–
based immunosuppression, but avoid the toxicity of such
treatment by dose minimization, we would expect to sub-
stantially reduce the morbidity and mortality of renal
transplant recipients. One possible route to achieving this
goal is to strengthen regulatory immune responses against
donor alloantigens, which might lead to a lower overall
requirement for maintenance immunosuppression. This
is precisely what we hope may be achieved with
Mreg_UKR or other cell-based immunosuppressive
therapies.
Compared to standard therapy, patients in the forth-
coming ONEmreg12 trial will receive lower doses of
tacrolimus and will be weaned from mycophenolate
mofetil completely, if no clinical or histologic signs of
rejection are evident. In consequence, M reg–treated
patients established on low-dose maintenance tacrolimus
monotherapy should benefit from better glomerular filtra-
tion rates, less neurotoxicity, fewer opportunistic infec-
tions, and a reduced incidence of adverse cardiovascular
events. Aside from probable reductions in patient morbid-
ity and mortality, reducing immunosuppressive therapy
should reduce the cost of drugs given to transplant recipi-
ents and the costs incurred by treating complications of
generalized immunosuppression. Similar therapeutic
benefits may be anticipated with other immunoregulatory
cell products with a very similar safety profile to
Mreg_UKR. The ONEmreg12 trial takes a relatively conser-
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vative approach to minimization of tacrolimus dosing;
however, if patients in this study were to show a promising
immunologic profile, more radical reductions in mainte-
nance immunosuppression might be considered in future
clinical trials, with even greater potential benefits.
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ABSTRACT 
 
Human regulatory macrophages (M regs) represent a unique and stable state of macrophage 
activation, characterized by a potent T cell-suppressive capacity and DHRS9 expression. These 
cells have already been investigated as an immunosuppressive cell-based therapy in renal 
transplantation with promising preliminary results. This article examines the phenotypic and 
functional changes imposed by M regs on allogeneic T cells, which were characterized by flow 
cytometry, microarray and secondary suppression assays. M reg-exposed CD4+ T cells were 
induced to express FoxP3, CD25, CTLA4, OX40, GITR, ICOS, EBI3 and BTNL8. These M reg-
induced iTregs suppressed T cell proliferation and inhibited dendritic cell maturation. 
Generation of iTregs by M regs depended upon indoleamine 2,3-dioxygenase and B7-signalling, 
but was unaffected by tacrolimus or rapamycin. These data support the concept that pre-
transplant treatment of recipients could engender a pro-tolerogenic immunological milieu and 
hint at a feed-forward mechanism by which this favorable state could be perpetuated. 
 
Keywords:   Cell therapy; M reg; T reg; EBI3; BTNL8; DHRS9. 
Word count:  3983  
Reviewer link:  The gene expression data presented in this article have been submitted to 
the National Center for Biotechnology Information/Gene Expression Omnibus: 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=bhyjdugmkkecwre&acc=GSE49369 
 
 
 
HIGHLIGHTS 
 The human regulatory macrophage represents a unique and stable state of macrophage 
activation. 
 DHRS9 is a novel marker that discriminates M regs from other monocyte-derived 
macrophage types. 
 M regs drive CD4+ T cells to become Foxp3+ iTregs through IDO- and B7. 
 BTNL8 is a novel, specific marker of T cells that have directly interacted with M regs. 
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INTRODUCTION 
 
Transferring immunoregulatory cells from an immunologically tolerant donor to non-tolerant 
individual as a means of establishing tolerance in the recipient is a common technique in 
experimental Immunology, but its clinical application is only now receiving serious attention (1). 
Several classes of immunoregulatory cells are currently being developed as adjunct 
immunosuppressive agents for use in solid organ transplantation, including different types of 
regulatory T cell and suppressive myeloid cells (2). One particularly promising candidate cell 
type is the human regulatory macrophage (3-5). Preclinical experiments in a heterotopic mouse 
heart transplant model have demonstrated the capacity of mouse M regs to prolong allograft 
survival (6). A single iv dose of 5x106 donor-strain M regs at 8 days prior to transplantation 
significantly prolonged allograft survival in unconditioned, non-immunosuppressed recipients. 
Importantly, this graft-protective effect was not simply due to alloantigen exposure, but was 
mediated by inducible nitric oxide synthase-expressing cells. Following iv injection into mice, 
allogeneic M regs were initially trapped in the pulmonary vasculature, but rapidly redistributed 
to other peripheral organs, especially the liver and spleen, but not lymph nodes, where they 
persisted for up to 4 weeks. Similar pharmacokinetics were observed in one patient after 
administration of 111Indium oxine-labelled cells (5). Thus, M regs appear to be relatively short-
lived after transfer, but are nevertheless capable of exerting a therapeutic benefit that endures 
beyond their lifespan.  
 
In principle, donor-derived M regs might influence the response of recipient T cells against 
alloantigen in two ways: Infused M regs might interact directly with recipient T cells to anergise 
or delete antigen-specific effector T cells, or induce regulatory T cells; alternatively, M regs 
might give-up donor antigen to recipient antigen presenting cells that then modify the recipient 
T cell response (1). Of course, these two general mechanisms are not mutually exclusive and M 
regs might contribute actively or passively to both. The tolerogenic properties of alloantigen 
administered by intravenous injection without adjuvant are well-documented and it is highly 
probable that presentation of M reg-derived antigens by recipient APCs (via the indirect or semi-
direct pathway) contributes to the therapeutic benefit of M reg treatment (7). Previous 
observation that prolongation of allograft survival through M reg treatment depends upon active 
properties of M regs is not inconsistent with the idea that M regs exert suppressive effects 
through recipient APCs, as one function of M regs may be to die and release donor antigen into a 
suitably self-conditioned environment (6). On the other hand, the high likelihood that M regs act, 
at least in part, through recipient APCs does not negate the possibility that M regs might interact 
directly with recipient T cells to suppress or regulate their reactivity to donor alloantigen. 
Clearly, determining whether direct interaction between M regs and recipient T cells occurs, and 
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what therapeutic consequences this interaction may have, is critical to our further 
understanding of the suppressive activity of M regs. 
 
This article examines the phenotypic and functional changes wrought upon T cells exposed to M 
regs in vitro with a view to identifying properties that might serve as specific markers of T cells 
that have interacted with M regs. A comparative characterisation of T cells cultured with M regs 
or under control conditions revealed that M regs drove T cells to become FoxP3+ iTregs, which 
were uniquely identified by butyrophilin-like protein 8 (BTLN8) expression. Patients receiving 
M reg therapy in the forthcoming ONEmreg12 trial (EudracCT-Nr.: 2013-000999-15) will be 
monitored for T cells expressing BTNL8 as a putative measure of pharmacodynamic effect. 
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MATERIALS AND METHODS 
Generation of M regs and IFN-γ-Mφ 
CD14+ monocytes were isolated from Ficoll-prepared PBMC and positive-selection using anti-
CD14 microbeads (Miltenyi, Bergisch-Gladbach). Monocytes were plated in 6-well Cell+ plates 
(Sarstedt, Nümbrecht) at 106 cells/well in RPMI-1640 (Lonza, Cologne) containing 10% heat-
inactivated human AB serum (Lonza), 2 mM Glutamax (Invitrogen, Karlsruhe), 100 U/mL 
penicillin (Lonza), 100 ug/mL streptomycin (Lonza), and rhM-CSF (R&D Systems, Wiesbaden-
Nordenstadt) at 25 ng/ml carried on 0.1% human albumin (CSL-Behring, Hattersheim-am-
Main). On day 6 of culture, cells were stimulated for 18 hours with 25 ng/mL rh)FNγ ȋChemicon, 
Billerica, MA). IFN-γ-Mφ were generated under identical conditions, except 10% human serum 
was substituted with 10% FCS. 
 
Coculture of M regs and T cells 
On day 7 of culture, M reg and IFN-γ-Mφ medium was exchanged with serum-free X-vivo-10 
medium (Lonza) supplemented with 2 mM Glutamax and 25 ng/mL rhM-CSF. MACS-sorted CD3+ 
T cells were added to macrophages at a 1:1 ratio for 5 days. For transwell experiments, inserts with Ͳ.Ͷ μm pore size were used (Greiner-BioOne, Frickenhausen). Where indicated, cocultures 
were performed in the presence of tacrolimus (Astellas, Munich), 1-methyl-L-tryptophan 
(Sigma), recombinant CTLA-4-Ig fusion protein (Bio X Cell, West Lebanon, NH) or control human 
immunoglobulin (CSL-Behring). 
 
Flow cytometry 
Surface staining (Table S1) was performed at 4°C in DPBS/1% BSA/0.02% NaN3/10% FcR-block 
(Miltenyi). Foxp3 Fixation-and-Permeabilization buffers (eBioscience) were used for 
intracellular staining. Dead cells were excluded with 7-AAD (BD-Biosciences) or Aqua-
LIVE/DEAD (Invitrogen). 
 
Western blotting, immunoprecipitation and protein sequencing 
SDS-PAGE and immunoblotting were performed using conventional methods. Protein A/G-
sepharose (Sigma-Aldrich) was used to immunoprecipitate the ASOT1 antigen before 
sequencing by MALDI-MS (Proteome-Factory, Berlin). 
 
Rabbit polyclonal anti-serum against DHRS9 
Rabbit polyclonal antisera were raised against a peptide corresponding to residues 85-105 of 
human DHRS9 (CTDPENVKRTAQWVKNQVGEKG). 
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Microarrays 
Highly-purified populations of CD4+ or CD8+ T cells were isolated using a FACS-Aria flow-sorter 
(BD-Biosciences).  Total RNA was extracted using an RNeasy-Plus Mini-Kit (Qiagen, Hilden). 
Assessment of RNA quality, labeling and hybridization to 8x60K Agilent Whole-Human-Genome-
Oligo-Microarrays was performed according to published methods10. Fluorescence signals from 
hybridized microarrays were detected using Agilent’s Microarray Scanner System ȋG2505C, 
Agilent-Technologies, Palo Alto). The Agilent Feature Extraction Software 10.7.3.1 was used to 
extract the microarray image files. Background-corrected intensity-values were quantile-
normalized and log2-transformed. Only reporters with at least three valid signal intensity values 
in at least one sample group were considered. For visualisation in heatmap format, the log2 
intensity values were median-centered for each reporter. One-way ANOVA was performed using 
GeneSpring-GX v.11.5.1 (Agilent). 
 
qPCR 
SuperScript-III (Invitrogen) was used for reverse-transcription. qPCR was performed with a 
LightCycler™ real-time PCR system using the FastStart DNA Master SYBR Green I kit (Roche-
Diagnostics, Penzberg). DHRS9 qPCR primers: ͷ’-TGACCGACCCAGAGAATGTCAA-͵’ and ͷ’-
GCCGGGAACACCAGCATTATT-͵’. Specificity was confirmed by amplicon sequencing (MWG-
Biotech, Ebersberg). 
 
TSDR methylation analysis 
CD4+ T cells were positively isolated by MACS. Genomic DNA was extracted with the QIAamp 
DNA blood mini-kit and bisulfite-treated (EpiTect, Qiagen) before real-time PCR quantification of 
Foxp3 TSDR (29). 
 
Statistics  
Statistical analyses and curve-fitting were performed with GraphPad software. As indicated, 
values given in histograms either represent mean±SD, mean±SEM or median±MADM. A Mann-
Whitney test was used for all significance tests. 
Human M regs generate iTregs Walter et al.  
 _______________________________________________________________________________________________________________________________________________________ 
 
 
   
   Page 7 of 20  
   
RESULTS 
 
The steady-state phenotype of human M regs 
Human M regs derive from purified CD14+ blood monocytes when cultured at a density of 105 
cells/cm2 in RPMI-1640 supplemented with 10% human AB serum (HABS) and 25 ng/ml M-CSF 
for six days prior to stimulation with IFN- for a further 18 hours. M regs generated in this 
manner are consistently CD14-/low HLA-DR+ CD80-/low CD86+ CD16- TLR2- and CD163-/low (Fig.1a). 
In culture, M regs exhibit a very distinctive morphology with the cells adopting a tessellating, 
epithelioid morphology to form almost confluent monolayers (Fig.1b). Individual M regs are 
large, densely granular cells with a prominent central body and a thin cytoplasmic skirt, which 
spreads symmetrically over the surface of the culture vessel, reaching diameters of up to ͷͲ μm. 
Ultrastructural examination of M regs by transmission electron microscopy confirmed the 
impression of a large, flattened cell adhering very closely to the underlying surface (Fig.1c-f). 
 
Human M regs only arise in human serum 
IFN-γ-stimulated macrophages (IFN-γ-Mφ) are generated by growing monocytes under identical 
conditions to M regs, but with substitution of FCS for HABS. Notably, IFN-γ-Mφ did not acquire 
the marker phenotype (Fig.1g) or typical morphology (Fig.1h) of M regs. As previously reported, 
M regs efficiently suppress mitogen-stimulated allogeneic CD4+ and CD8+ T cell proliferation in 
1:1 cocultures (5); however, IFN-γ-Mφ were found to be significantly less suppressive under the 
same conditions (Fig.1i). IFN-γ-Mφ exhibited general characteristics of M1-polarised 
macrophages, including promotion of Th1-cytokine production by cocultured T cells (Fig.S1). 
Therefore, it appears the phenotype and suppressive function of human M regs is a feature of 
human monocytes cultivated in human serum. Because IFN-γ-Mφ are generated under very 
similar conditions from M regs, but have a different phenotype and function, IFN-γ-Mφ 
represent an appropriate and useful experimental control cell type for M regs. 
 
The M reg phenotype is distinct from previously described Mφ polarisation states  
To establish the phenotypic proximity of M regs to macrophages in previously described states 
of activation, a panel of macrophage types was generated for comparison with M regs in terms of 
their morphology, cell-surface markers, cytokine production, and global gene expression 
profiles. M regs were readily distinguished from all these other macrophages by their 
characteristic morphology (Fig.2a) and distinct cell-surface phenotype (Fig.2b). M regs and the 
panel of comparator macrophages were also distinguished by their cytokine and chemokine 
production profiles (Fig.2c).  
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DHRS9 expression uniquely identifies M regs amongst comparator Mφ types 
ASOT1, a monoclonal antibody raised in mice against human M regs, reacted strongly against M 
regs, but not other macrophages (Fig.3a). By immunoprecipitating and sequencing its antigen, 
the ASOT1 mAb was shown to recognise DHRS9, a little-studied retinol dehydrogenase of the 
SDR family (8-10) (Fig.3b). Quantitative PCR confirmed that DHRS9 mRNA expression was 
restricted to M regs within the panel of comparator macrophages (Fig.3c). Importantly, DHRS9 
mRNA expression was not extinguished by lipopolysaccharide treatment of M regs. A rabbit 
polyclonal antibody generated against an N-terminal epitope of DHRS9 reacted against a protein 
of ~35-kD immunoprecipitated by ASOT1 (Fig.3d). As a commercially-available monoclonal 
antibody (clone 3C6) which recognises DHRS9 also reacted with the same protein detected by 
the rabbit antibody, it is concluded that both ASOT1 and the rabbit polyclonal antibody 
recognise DHRS9. Using this rabbit pAb, DHRS9 protein expression was shown to be unique to M 
regs (Fig.3e). PCR analysis showed that M regs express all the necessary enzymes to convert Ⱦ-
carotene and retinol to retinoic acid (Fig.3f). Naturally-occuring DHRS9+ macrophages were 
detected in human spleen (Fig.3g). 
 
M regs induce T cell-suppressive T cells 
That administration of M regs affords allograft-protective effects that persist beyond the lifespan 
of the M regs implies the establishment of recipient regulatory T cell responses. As a first step in 
testing this hypothesis, the impact of exposure to M regs on allogeneic T cell phenotype and 
function was investigated in coculture experiments (Fig.4a). When unstimulated, polyclonal 
human T cells were cocultured with equal numbers of allogeneic M regs for 5 days, no bias was 
seen in the CD4/CD8 ratio compared to IFN-γ-Mφ-cocultured T cells (Fig.4b). CD25 was 
significantly up-regulated by CD4+ T cells after M reg-coculture compared to IFN-γ-Mφ-coculture 
(Fig.4c). To gauge their suppressive capacity, M reg-cocultured T cells were re-isolated and set in 
culture with autologous CFSE-labelled responder T cells. In such assays, proliferation of 
responder T cells stimulated with plate-bound anti-CD3 was relatively inhibited by M reg-
cocultured T cells (Fig.4d). 
 
M reg-cocultured T cells inhibit monocyte-derived DC maturation 
To test whether M reg-cocultured T cells inhibit DC maturation, allogeneic M reg-cocultured 
CD4+ T cells were flow-sorted and added at a 2:1 ratio to immature monocyte-derived DCs (mo-
DC) from the same donor as the M regs. These T cell-cocultured mo-DCs were matured with 
TNFȽ over 2 days and then expression of maturation markers was assessed. CD4+ T cells from M 
reg cocultures inhibited the upregulation of CD80 and CD83 by maturing mo-DCs (Fig.4e). 
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M reg coculture drives CD4+ T cells to become activated iTregs  
To better characterise the influence of M reg co-culture on T cells, whole-genome gene 
expression profiling by microarray was performed. M regs and IFN-γ-Mφ were generated from 
monocytes of 5 healthy donors. Polyclonal CD3+ T cells were isolated from a further 5 unrelated, 
healthy, HLA-discrepant donors and were added into direct co-culture with M regs or IFN-γ-Mφ, 
or were cultured alone for 5 days without stimulation. Following co-culture, CD4+ and CD8+ T 
cells were FACS-sorted and total RNA was extracted. In addition, freshly isolated CD3+ T cells 
were also sorted into CD4+ and CD8+ fractions for RNA isolation. These RNA samples gave rise to 
a microarray dataset comprising triplicate samples of eight cell types produced by single-colour 
hybridisations. From this dataset, genes that were highly (>20-fold) and significantly (p<0.01 
after Benjamini-Hochberg correction for multiple testing) differentially expressed in any two of 
the four sample sets were identified by one-way ANOVA (Fig.5a). By presenting these 
differentially expressed genes as a hierarchically clustered heatmap, it was evident that T cells 
cocultured with either M regs or IFN-γ-Mφ are more similar to one another than to either fresh 
T cells or T cells cultured alone; however, many notable differences between M reg-cocultured 
CD4+ T cells and IFN-γ-Mφ-cocultured CD4+ T cells were discovered. 
 
Discriminatory gene analyses identified a large number of reporters up- and down-regulated in 
M reg-cocultured T cells compared to IFN-γ-Mφ-cocultured T cells (Table S2). Enriched among 
those genes up-regulated in M reg-exposed CD4+ T cells were T reg-associated markers, such as 
CD25, CTLA4, TNFRSF4/OX40, TNFRSF18/GITR, ICOS and LAG3. Notably, EBI3 was 18.6-fold 
up-regulated in M reg-cocultured CD4+ T cells compared to IFN-γ-Mφ-cocultured T cells. EBI3 
encodes one subunit of heterodimeric cytokines IL-27 and IL-35, which are both principally 
regarded as immunosuppressive cytokines (11). FOXP3 was also significantly up-regulated in M 
reg-cocultured CD4+ T cells compared to all control conditions (Fig.5b), but key transcriptional 
regulators of Th1, Th2, and Th17 differentiation, namely TBX21/TBET, GATA3, and RORC, were 
not differentially expressed between M reg-cocultured CD4+ T cells and controls (data not 
shown). 
 
Flow cytometry demonstrated a relative up-regulation of FoxP3, CD25, CTLA4, OX40, GITR, 
CD28, PD1 and ICOS by M reg-cocultured CD4+ T cells compared to IFN-γ-Mφ-cocultured CD4+ T 
cells or T cells cultured alone (Fig.5c). Some M reg-cocultured CD4+ T cells expressed LAG3, but 
LAG3 expression was not entirely coextensive with OX40 expression. FoxP3+ T cells represented 
50±8 % of M reg-cocultured CD4+ T cells and these were predominantly CD45RA- (Fig.5c). M 
reg-cocultured T cells secreted ~4-fold more IL-10 than IFN-γ-Mφ-cocultured T cells during a 
24-hour restimulation with anti-CD3, although the absolute amounts of IL-10 produced were 
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small (Fig.5d). Only marginally more cell-surface TGF-Ⱦ-expressing T cells were detected after M 
reg-coculture than after IFN-γ-Mφ-coculture (Fig.5e). Analysis of the methylation status of Treg-
specific demethylated region (TSDR) of the FOXP3 gene in M reg-cocultured CD4+ T cells 
revealed only 5.3% demethylation, which was not different to that found in CD4+ T cells cultured 
alone (Fig.5f). This low degree of TSDR methylation proves that M reg-cocultured CD4+ T cells 
are not nTregs. Therefore, we conclude that M regs are capable of driving the development of 
allogeneic T cells into activated iTregs, which are characterised by a FoxP3+ CD25+ CTLA4+ 
OX40+ GITR+ CD28+ PD1+ ICOS+ CD45RA- CD62L-/low CCR7-/low and CD127-/low phenotype. Because 
the expression of Foxp3 in M reg-generated iTregs may only be transient, its stability was 
investigated in iTregs cultured for 10 days without further restimulation (Fig.5g). FoxP3 
expression decayed slowly over this period, such that 64%±26 of the initial pool of FoxP3+ T 
cells was present at day 10. In this context, it is interesting to note that M reg cocultured CD4+ T 
cells expressed relatively high levels of SOCS2 mRNA, which has been shown to stabilise the 
phenotype of FoxP3+ T regs (12) (Table S1). 
 
Generation of activated iTregs by M regs is B7- and IDO-dependent 
Induction of iTregs by M regs was not alloantigen-dependent, as no difference in iTreg 
generation was observed between allogeneic and autologous cocultures (Fig.6a). Nevertheless, 
transwell separation of M regs and T cells in coculture demonstrated the need for direct physical 
interaction for M reg-driven iTreg development (Fig.6b). By blocking B7-mediated signaling 
using 10 μg/ml CTLA4-Ig, it was shown that iTreg generation by M regs is substantially 
dependent upon the B7 costimulatory pathway (Fig.6c). Because T cell suppression by M regs is 
principally IDO-mediated, the effect of blocking IDO activity with 1-methyltryptophan was also 
examined. Generation of T regs in cocultures treated with 1mM 1-L-MT was significantly 
reduced, but not completely abolished (Fig.6d). RO41-5253, an antagonist of the retinoic acid 
receptor-alpha, did not affect iTreg generation (Fig.6e). Importantly, from a translational 
perspective, neither 10 ng/ml tacrolimus nor 10 ng/ml rapamycin prevented iTreg development 
in the presence of M regs (Fig.6f&g). Taken together, these results show that M regs drive an 
antigen non-specific, but B7- and contact-dependent induction of iTregs through an IDO-
dependent mechanism that is unaffected by therapeutically-relevant concentrations of 
tacrolimus or rapamycin. 
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BTNL8 is a marker of iTregs arising in M reg cocultures 
With the intention of identifying novel markers of iTregs generated by coculture with M regs, we 
re-examined the list of genes highly and significantly up-regulated in M reg-cocultured T cells 
(Fig.7a). The 10 most discriminatory reporters included 5 genes encoding proteins with known 
function (CYS1, OXCT2, RET, GNG4 and EBI3), one cell-surface receptor of uncharacterized 
function (BTNL8), two predicted proteins of unknown function (SEC14L6 and C11orf96) and 
one lincRNA (represented by reporters A_19_P00316371 and A_19_P00810403). Of these 
discriminatory genes, Butyrophilin-like protein 8 (BTNL8) stood out as a potential marker of M 
reg-generated iTregs of possible immunological importance (13). BTNL8 belongs to the 4-
member butyrophilin-like gene family, which is closely related to the butyrophilin family, both 
of which families are structurally and functionally related to the B7-costimulatory molecules 
(Fig.7b). 
  
The specific up-regulation of BTNL8 mRNA expression in M reg-cocultured T cells observed by 
microarray studies was corroborated by qPCR using primers specific for both the BTN-like and 
B7-like variants (Fig.7c). Using isoform-specific primer sets and sequencing of amplicons, it was 
shown that M reg-cocultured T cells express only the B7-like variant of BTNL8 (data not shown). 
A selection of polyclonal antibodies raised against the extracellular portion of full-length BTNL8 
is commercially available; however, none of these reagents are well-characterised. Therefore, 
the specificity of two pAbs were assessed by IP-Western (Fig.7d). BTNL8 was precipitated from 
lysates of M reg cocultured T cells using a goat pAb (sc-245053). As a negative control, Ⱦ-actin 
was precipitated using a goat pAb (sc-1616). BTNL8 protein was then detected by Western blotting using either the goat Ƚ-BTNL8 pAb or a rabbit Ƚ-BTNL8 pAb (PA5-24933). In agreement 
with the PCR data, both blotting antibodies detected a precipitated protein at ~37-kD, but no 
protein at 57-kD. Therefore, we can be confident that M reg-cocultured T cells express the B7-
like isoform of BTNL8, but not the BTN-like variant, and that both the goat and rabbit pAbs are 
reactive with this isoform. Western blotting using the goat Ƚ-BTNL8 pAb revealed strongest 
expression of a 37-kD isoform of BTNL8 in M reg-cocultured T cells, compared to IFN-γ Mφ-
cocultured T cells or T cells cultured alone (Fig.7e). Likewise, Western blotting using the rabbit Ƚ-BTNL8 pAb revealed much stronger BTNL8 expression in M reg-cocultured T cells than in IFN-γ Mφ-cocultured T cells (Fig.7f). To demonstrate cell-surface expression of BTNL8, CD4+ T cells 
were stained with goat Ƚ-BTNL8 pAb and analysed by flow cytometry (Fig. 7g). By this approach, 
M reg-cocultured CD4+ T cells were shown to uniformly express cell-surface BTNL8, in contrast 
to control CD4+ T cells.  
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 DISCUSSION 
This work seeks to identify particular characteristics of human CD4+ T cells acquired through 
direct contact with M regs. Through IDO-dependent mechanisms, M regs potently suppress 
mitogen-stimulated T cell proliferation and drive conventional T cells to a regulatory phenotype. 
Regulatory T cells arising from M reg-cocultures exhibit many typical properties of in vitro- 
induced T reg (iTreg), including a FoxP3+ CD25+ CTLA4+ OX40+ GITR+ CD28+ PD1+ and ICOS+ 
phenotype and the capacity to inhibit mitogen-stimulated proliferation of responder T cells (15). 
Suppressive FoxP3+ T cells have been generated in vitro by various means, most commonly by 
treatment with exogenous TGF-Ⱦ or coculture of T cells with DCs or macrophages that produce 
TGF-Ⱦ (16;17). Such TGF-Ⱦ-induced iTreg typically express TGF-Ⱦ themselves, which accounts 
for their suppressive function (18). Similarly, activation of T cells in the presence of IL-10, or in 
coculture with IL-10-producing DCs, generates regulatory T cells that act through IL-10 
production (19). In contrast to these TGF-Ⱦ- and IL-10-dependent regulatory T cells, M reg-
induced T regs produce little IL-10 or TGF-Ⱦ and no clear evidence was found that either 
cytokine contributes to their suppressive activity. Thus, although it cannot be claimed that M 
reg-induced T reg are a novel type of T reg, these cells are sufficiently distinctive that, were an 
increase in phenotypically similar T regs observed in M reg-treated patients, it would point to a 
direct effect of M regs on recipient T cells in vivo. 
 
In previous work, M regs were found to suppress mitogen-driven T cell proliferation through the 
action of IDO (5). Here, it was shown that IDO activity also contributes to the generation of 
iTregs in M reg cocultures. The principal candidate mechanism for IDO-dependent induction of T 
regs is ligation of the aryl hydrocarbon receptor (AHR) by tryptophan metabolites generated 
through the action of IDO (20;21). A second possibility is that tryptophan degradation products 
might exert effects through G protein-coupled receptor 35 (GPR35), which microarray analyses 
found was 9.3-fold up-regulated in M reg-cocultured T cells compared to IFN-γ Mφ-cocutured T 
cells (22). Notably, the demonstration that iTreg generation was inhibited by CTLA4-Ig and 
required M reg-T cell contact argues that IDO activity alone is not sufficient to account for iTreg 
induction by M regs.  
 
The overarching objective of this work was to identify unique markers of CD4+ T cells that have 
encountered M regs. In this context, expression of the B7-like isoform of BTNL8 is potentially 
useful, but it is also an intriguing receptor from a basic scientific perspective (13). The 
butyrophilin and butyrophilin-like proteins are B7-related costimulatory molecules (as are 
CTLA-4, ICOS, etc.) and probably serve as negative regulators of immune responses. The human 
genome encodes four BTNL genes (designated BTNL2, -3, -8 and -9) of which only BTNL2 and 
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BTNL9 have clear orthologues in mice (23). Ig-fusion proteins of mouse Btnl1, Btnl2 and Btnl9 
have T cell-suppressive properties in vitro through unknown counter-receptors (24-26); 
however, there is sparse information about the functions of human BTNL family members. In 
particular, human BTNL8 has received very little attention. BTNL8 is predicted to be type-I 
membrane protein with an extracellular region comprising an IgV and IgC domain (13). Various 
isoforms of BTNL8 have been reported, including a 57-kD isoform, which incorporates an 
intracellular B30.2 domain that is lacking from the 37-kD isoform. Expression of both BTNL8 
mRNA splice variants was previously reported in neutrophils and eosinophils, but was not 
detectable in freshly-isolated T cells, B cells, NK cells or monocytes (23;27). Here, BTNL8 was 
found to be a highly discriminatory marker of M reg-cocultured CD4+ T cells, which leads us to 
speculate that BTNL8 could limit T cell activation during inflammatory responses through a 
negative feedback loop (28). 
 
If ex vivo-generated allogeneic human M regs were capable of modifying recipient T cells in vivo 
in a similar fashion as they do in vitro, this would help to explain persistence of the therapeutic 
effects of M regs beyond their lifespan. In this regard, it is interesting that M reg-induced T regs 
were capable of preventing the full maturation of monocyte-derived DCs in response to TNFȽ. 
Thus, although M regs and M reg-induced T regs may only be transient populations, it is 
conceivable these cells might initiate a feed-forward regulatory loop that is perpetuated by 
recipient DCs and T regs. Flow cytometry and qPCR assays to measure the frequency of OX40+ 
LAG3+ T cells and BTNL8-expression by T cells in peripheral blood have now been established. It 
is hoped that monitoring these parameters in patients treated with M regs during the 
ONEmreg12 trial will corroborate our in vitro findings, thereby demonstrating a 
pharmacodynamic effect of M reg therapy in a clinical setting. 
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FIGURE LEGENDS 
 
Figure 1: The steady-state phenotype of human M regs. (a) Human M regs exhibit a CD14-/low 
HLA-DR+ CD80-/low CD86+ CD16-/low TLR-/low CD163-/low cell-surface phenotype 
(data representative of n=3 donors). (b) M regs in culture acquire a distinctive 
morphology (bar = ͷͲ μmȌ. (c-f) Transmission electron micrographs of M regs 
that show a close adherence to the culture surface, active nuclei with abundant 
fine chromatin, numerous cell processes, lipid inclusions [L], and bilaminar 
annular structures [] within the cytoplasm that resemble confronting cisternae. 
(g) IFN-γ-stimulated macrophages (IFN-γ Mφ) are generated by growing 
monocytes under identical conditions to M regs, but with substitution of FCS for 
HABS. In contrast to M regs, IFN-γ Mφ are CD14+ HLA-DR++ CD80+ CD86+ CD16+ 
TLR+ CD163+ (data representative of n=3 donors). (h) IFN-γ Mφ are readily 
distinguished from M regs by their irregular, elongated form ȋbar = ͷͲ μmȌ. (i) In 
direct 1:1 co-cultures, M regs strongly suppress PHA-stimulated CD4+ and CD8+ T 
cell proliferation, whereas equal numbers of IFN-γ Mφ do not (n=3; CD4+: 
p=0.036; CD8+: p=0.036). 
 
Figure 2: Within the spectrum of previously described states of macrophage polarisation, the 
human M reg phenotype is unique. (a) M regs are reliably distinguished from 
macrophages in other polarisation states by their characteristic morphology in 
culture. (b) Human M regs can be distinguished from all other macrophage types 
by a constellation of four cell-surface markers: CD14-/low CD16- TLR2-/low and 
CD163- (n=6; values are mean ± SD). (c) The 24-hour constitutive cytokine 
secretion profile of M regs was typical of neither M1- or M2-polarised Mφ (n=6). 
M regs constitutively produced relatively small amounts of TNF-Ƚ and )L-6, and 
did not secrete detectable amounts of IL-12p40. M regs expressed detectable 
levels of TGF-Ⱦ and relatively greater amounts of )L-1Ra than most other 
macrophage types, but notably less IL-10. 
 
Figure 3: DHRS9 expression uniquely identifies the M reg phenotype. (a) The ASOT1 mAb 
recognised an antigen expressed by M regs, but not other macrophage types. (b) 
An antigen of ~35 kD was specifically precipitated by ASOT1. This precipitated 
antigen was identified by mass spectrometry as DHRS9. (c) Strong DHRS9 mRNA 
expression was detected in M regs, but not other macrophage types (n=6). (d) 
ASOT1 precipitated an antigen which was also recognised by an anti-DHRS9 
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rabbit pAb and an anti-DHRS9 mouse mAb, confirming that ASOT1 recognises 
DHRS9. (e) Immunoblotting with a rabbit anti-DHRS9 pAb demonstrated that 
DHRS9 expression at the protein level distinguishes M regs from other 
macrophage types. (f) The SDR family of retinol dehydrogenases, which can be 
classified as NAD+ or NADP+ dependent enzymes, are responsible for conversion 
of retinol to retinal (10). Retinal is further metabolised to retinoic acid by retinal 
dehydrogenases: Expression of ALDH1A1 and ALDH1A2 mRNA was detectable in M regs. Retinal is liberated from Ⱦ-carotene through the action of beta-carotene 
monooxygenases: Expression of BCO2, but not BCMO1, was detected in M regs. Therefore, M regs appear to express the necessary machinery to convert Ⱦ-
carotene and retinol to retinoic acid. (Expression of enzymes responsible for 
retinoid metabolism was detected by PCR in M regs from 3 donors: D1-3.) (g) To 
ascertain whether DHRS9-expressing macrophages occur naturally, an 
immunohistochemical staining procedure for fixed tissues was established using 
the rabbit anti-DHRS9 pAb. Immunohistochemical staining of spleen identified a 
minor population of DHRS9-expressing macrophages. Although it is not possible 
to conclude that these splenic macrophages are a physiological conterpart of the 
human M reg, the existence of naturally-occuring DHRS9+ macrophages argues 
that the DHRS9+ M reg phenotype is not purely an in vitro artefact. (Arrow; 
original magnification 400x). 
 
Figure 4: M reg-cocultured T cells inhibit T cell proliferation and mo-DC maturation. (a) 
Human M regs were cocultured for 5 days with either allogeneic or autologous T 
cells. These T cells were then analysed by flow cytometry, qPCR and microarray, 
or were used to suppress T cell proliferation or inhibit TNFȽ-stimulated DC-
maturation. (b) 5-day coculture of positively-isolated CD3+ T cells with allogeneic 
M regs at a 1:1 ratio did not affect the proportion of CD4+ and CD8+ T cells 
compared to coculture with IFN-γ Mφ (n=11). (c) 5-day coculture of positively-
isolated CD3+ T cells with allogeneic M regs at a 1:1 ratio led to a relative increase 
in the proportion of CD25+ T cells compared to coculture with IFN-γ Mφ (n=11). 
(d) Division of CFSE-labelled responder CD4+ T cells stimulated with plate-bound 
anti-CD3 was relatively inhibited by M reg-cocultured T cells, but not by control T 
cells (n=6). (e) CD4+ T cells re-isolated from M reg cocultures by FACS-sorting 
inhibited the upregulation of CD80 and CD83 by maturing mo-DCs (data 
representative of n=6). 
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Figure 5: M reg coculture drives CD4+ T cells to become activated iTregs. (a) Hierarchical 
clustering of the reporter sets returned by one-way ANOVA which were 
significantly (p<0.01) and highly differentially (>20-fold) regulated in any two of 
the comparator T cell populations. This analysis shows that T cells cocultured 
with either M regs or IFN-γ Mφ are more similar to one another than to either 
fresh T cells or T cells cultured alone; however, many notable differences 
between M reg-cocultured CD4+ T cells and IFN-γ Mφ-cocultured CD4+ T cells are 
evident. Red shading indicates a higher expression of a certain reporter in the 
respective sample compared to the median of all samples, whereas green shading 
indicates down-regulation. (b) Relative expression of a biased selection of T reg-
related genes in CD4+ T cells cocultured with allogeneic M regs or IFN-γ Mφ, or 
cultured alone (n=5; median ± MADM). (c) Confirmation by flow cytometry of 
upregulated expression of T reg-related markers by M reg-cocultured CD4+ T 
cells compared to IFN-γ Mφ-cocultured CD4+ T cells and T cells cultured alone 
(data representative of n=5 donors). (d) 24-hour secretion of IL-ͳͲ by Ƚ-CD3-
stimulated CD4+ T cells reisolated from allogeneic M reg cocultures (n=4). (e) 
Cell-surface expression of TGF-Ⱦ by CDͶ+ T cells cocultured with allogeneic M 
regs or IFN-γ Mφ ȋrepresentative of n=Ͷ donorsȌ. (f) Quantification of 
demethylation status of the T reg-specific Demethylated Region (TSDR) in CD4+ T 
cells cocultured with allogeneic M regs or IFN-γ Mφ, or cultured alone ȋn=3; 
mean ± SEM). (g) Assessment of the stability of FoxP3 expression in M reg-
induced iTregs over 7 days in culture without restimulation (n=3; mean ± SEM). 
 
Figure 6: Generation of activated iTregs by M regs is B7- and IDO-dependent. Induction of 
FoxP3+ iTregs in 5-day allogeneic M reg cocultures was assessed by flow 
cytometry. Plots are gated on live CD3+ CD4+ T cells. Quadrants were set strictly 
according to FMO-isotype controls. (a) Generation of iTregs in M reg cocultures 
was not alloantigen dependent. (b) Nevertheless, direct contact between M regs 
and T cells was necessary for the generation of FoxP3+ iTregs. (c) The 
requirement for direct interaction between M regs and T cells is partly explained 
by the dependence of FoxP3+ iTreg generation on B7-mediated signals, which 
could be inhibited with CTLA-4-Ig. (d) Generation of FoxP3+ iTregs was inhibited 
when IDO activity was blocked with 1 mM 1-L-methyltryptophan. (e) An antagonist of RARȽ did not affect FoxP3+ iTreg generation. (f) 10 ng/mL 
tacrolimus or (g) 10 ng/mL rapamycin did not affect FoxP3+ iTreg induction. 
(Data are representative of n≥͵ donors in all cases.) 
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Figure 7: BTNL8 is a marker of iTregs arising in M reg cocultures. (a) Top ten most highly 
upregulated reporters in allogeneic M reg-cocultured CD4+ T cells compared to 
IFN-γ Mφ-cocultured CD4+ T cells (n=5; median ± MADM). (b) Six putative 
alternatively-spliced isoforms of BTNL8 have been reported, ranging in predicted 
molecular weight from 37 kD to 57 kD. These isoforms can be categorized as B7-
like or BTN-like according to their structure. The BTN-like variant comprises an 
extracellular IgV and IgC domain, a transmembrane domain and an intracellular 
B30.2 domain (14). The B7-like variant share the same extracellular IgV and IgC 
domains, but owing to alternative splicing resulting in a frameshift, it possesses a 
different transmembrane region and only a short intracellular C-terminal 
domain. (c) qPCR for BTNL8 mRNA in CD4+ T cells cocultured with M regs or IFN-γ Mφ, CD4+ T cells cultured alone and freshly-isolated CD4+ T cells (n=9; mean ± 
SEM). (d) BTNL8 was precipitated from a lysate of M reg-cocultured T cells using a goat Ƚ-BTNL8 pAb and detected by Western blotting using either the Ƚ-BTNL8 pAb or a rabbit Ƚ-BTNL8 pAb. This experiment shows that the goat and rabbit 
pAbs both recognise the same 37 kD variant of BTNL8. (e) Western blot for BTNL8 using a goat Ƚ-BTNL8 pAb from T cells cocultured with allogeneic M regs 
or IFN-γ Mφ and T cells cultured alone. A band corresponding to BTNL8 was 
detected at 37 kD. (f) Western blot for BTNL8 using a rabbit Ƚ-BTNL8 pAb from T 
cells cocultured with allogeneic M regs or IFN-γ Mφ. A band corresponding to 
BTNL8 was detected at 37 kD. (g) M reg-cocultured T cells and control T cells 
were stained for analysis by flow cytometry with either a goat Ƚ-BTNL8 pAb or a rabbit Ƚ-BTNL8 pAb. 
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Figure S1: IFN‐γMφ‐cocultured T	cells expressed Th1‐type	cytokines.	
Table S1.		 Antibodies	used	for	flow	cytometry	studies.	
	
Specificity	 Supplier	 Clone	CD͵	 BD	Pharmingen	 SK͹	CDͶ	 BD	Horizon	 RPA‐TͶ	CDͺ	 BD	Pharmingen	 SKͳ	CDͳͳb	 Beckman	Coulter	 Bearͳ	CDͳͳc	 BD	Horizon	 B‐ly͸	CDͳͶ	 BD	Horizon	 MφPͻ	CDͳ͸	 BD	Pharmingen	 ͵Gͺ	CDʹͷ	 BD	Pharmingen	 M‐Aʹͷͳ	CDʹͺ	 BD	Biosciences	 Lʹͻ͵	CDͶͷ	 Beckman	Coulter	 J͵͵	CDͶͷRA	 BD	Pharmingen	 HIͳͲͲ	CDͶͷRO	 BD	Pharmingen	 UCHLͳ	CDͷ͹	 BD	Pharmingen	 NK‐ͳ	CD͸ʹL	 BD	Pharmingen	 DREG‐ͷ͸	CDͺͲ	 BD	Pharmingen	 L͵Ͳ͹.Ͷ	CDͺ͵	 BD	Pharmingen	 HBͳͷe	CDͺ͸	 BD	Pharmingen	 ʹ͵͵ͳ/FUN‐ͳ	CDͳʹ͹	 BD	Pharmingen	 HIL‐͹R‐Mʹͳ	CDͳ͵Ͷ/OXͶͲ	 Becton	Dickinson	 LͳͲ͸	CDͳͷʹ/CTLAͶ	 BD	Pharmingen	 BNI͵	CDͳ͸͵	 BD	Pharmingen	 GHI/͸ͳ	CDͳͻ͹/CCR͹	 BD	Pharmingen	 ͵Dͳʹ	CDʹʹ͵/LAG‐͵	 R&D	Systems	 Goat	polyclonal	CDʹ͹ͺ/ICOS	 eBioscience	 ISA‐͵	CDʹ͹ͻ/PDͳ	 BD	Pharmingen	 EHͳʹ.ͳ	CDʹͺʹ/TLRʹ	 eBioscience	 TLʹ.ͳ	CD͵ͷ͹/GITR	 eBioscience	 eBioAITR	Foxp͵	 eBioscience	 PCHͳͲͳ	HLA‐DR	 BD	Bioscience	 GͶ͸‐͸	LAP/TGFβͳ	 R&D	Systems	 ʹ͹ʹ͵ʹ			
 
G
e
n
e
S
y
m
b
o
l	
A
lt
e
r
n
a
ti
v
e
	na
m
e
	
F
r
e
sh
	CD
4
+
	T	
c
e
ll
s	
C
D
4
+
	T	
c
e
ll
s	c
u
lt
u
r
e
d
	al
o
n
e
	fo
r
	5d
	
IF
N
‐γ	
M
φ	c
o
c
u
lt
u
r
e
d
	CD
4
+
	T	
c
e
ll
s	
M
	re
g
	co
c
u
lt
u
r
e
d
	CD
4
+
	T	
c
e
ll
s	
fo
ld
‐ch
a
n
g
e
	(M
	re
g
	>	I
F
N
‐γ	
M
φ)
	
p
‐va
lu
e
	(t‐
te
st
	of
	M
	re
g
	vs
.	IF
N
‐γ	
M
φ)
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Table S2: A	 subset	 of	 ͵Ͳ	 T	 reg‐associated	 markers	 selected	 from	 the	 ͷ͹ʹ	 reporters	significantly	 up‐regulated	 in	 M	 reg‐cocultured	 T	 cells	 compared	 to	 IFN‐γ	 Mφ‐cocultured	T	cells.	Values	are	median	normalised	logʹ‐transformed	intensities. 
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The Journal of Immunology
Laser Ablation–Inductively Coupled Plasma Mass
Spectrometry: An Emerging Technology for Detecting
Rare Cells in Tissue Sections
Amy J. Managh,* Robert W. Hutchinson,† Paloma Riquelme,‡ Christiane Broichhausen,‡
Anja K. Wege,x Uwe Ritter,{ Norbert Ahrens,‖ Gudrun E. Koehl,‡ Lisa Walter,‡
Christian Florian,‡ Hans J. Schlitt,‡ Helen J. Reid,* Edward K. Geissler,‡
Barry L. Sharp,* and James A. Hutchinson‡
Administering immunoregulatory cells to patients as medicinal agents is a potentially revolutionary approach to the treatment of
immunologically mediated diseases. Presently, there are no satisfactory, clinically applicable methods of tracking human cells in
patients with adequate spatial resolution and target cell specificity over a sufficient period of time. Laser ablation–inductively
coupled plasma mass spectrometry (LA-ICP-MS) represents a potential solution to the problem of detecting very rare cells in
tissues. In this article, this exquisitely sensitive technique is applied to the tracking of gold-labeled human regulatory macrophages
(Mregs) in immunodeficient mice. Optimal conditions for labeling Mregs with 50-nm gold particles were investigated by exposing
Mregs in culture to variable concentrations of label: Mregs incubated with 3.5 3 109 particles/ml for 1 h incorporated an average
of 3.39 3 108 Au atoms/cell without loss of cell viability. Analysis of single, gold-labeled Mregs by LA-ICP-MS registered an
average of 1.9 3 105 counts/cell. Under these conditions, 100% labeling efficiency was achieved, and label was retained by Mregs
for ‡36 h. Gold-labeled Mregs adhered to glass surfaces; after 24 h of culture, it was possible to colabel these cells with human-
specific 154Sm-tagged anti–HLA-DR or 174Yb-tagged anti-CD45 mAbs. Following injection into immunodeficient mice, signals
from gold-labeled human Mregs could be detected in mouse lung, liver, and spleen for at least 7 d by solution-based inductively
coupled plasma mass spectrometry and LA-ICP-MS. These promising results indicate that LA-ICP-MS tissue imaging has great
potential as an analytical technique in immunology. The Journal of Immunology, 2014, 193: 000–000.
A
dministration of regulatory or suppressor cell populations
to nontolerant recipients as a means of establishing
tolerance is a well-known technique in experimental
immunology, but its clinical application is only now being seriously
investigated (1). In principle, a broad spectrum of immunological
conditions might be amenable to treatment with cell-based im-
munoregulatory therapies, including T cell–mediated autoimmune
diseases (2, 3), chronic inflammatory conditions (4), graft-versus-
host disease (5), and solid organ transplant rejection (6). In such
conditions, cell-based immunoregulatory therapies might reduce
or obviate the need for conventional immunosuppressive therapy,
sparing patients its attendant complications. Moreover, because
tolerance achieved through peripheral regulation (as opposed to
purely deletional mechanisms or immunological ignorance) is
dominant and self-sustaining, there exists the staggering possi-
bility that cell-based immunotherapy might offer curative treat-
ments for diseases that would otherwise require long-term general
immunosuppressive therapy (7).
Several immunoregulatory cell types are now reaching the point
of preclinical development that would allow them to be investigated
as immunosuppressive agents in early-phase clinical trials (8–11).
One particularly promising candidate cell type for use as an ad-
junct immunosuppressive agent in transplantation is the regulatory
macrophage (Mreg) (12). The Mreg reflects a unique state of
macrophage differentiation, distinguished from macrophages in
other activation states by its mode of derivation, robust phenotype,
and potent T cell suppressor function (13). Mregs potently sup-
press mitogen-stimulated T cell proliferation in vitro, which can
be attributed to IFN-g–induced IDO activity, as well as contact-
dependent deletion of activated T cells. In addition, Mregs drive
the development of activated induced regulatory T cells that, in
turn, suppress the proliferation of effector T cells and inhibit the
maturation of monocyte-derived dendritic cells in response to
TNF-a (14). Therefore, it is thought that when Mregs are ad-
ministered to an allogeneic recipient they can initiate a feed-
forward loop of immunological regulation, potentially leading to
the long-term acceptance of a foreign transplant (15).
To use any therapeutic agent safely and effectively, clinicians
must be able to predict its effectiveness and safety in individual
patients (16). An important determinant of the biological effect
and safety of any therapeutic cell product is its pharmacokinetics
*Centre for Analytical Science, Department of Chemistry, Loughborough University,
Loughborough, Leicestershire LE11 3TU, United Kingdom; †Electro Scientific In-
dustries, Huntingdon, Cambridgeshire PE29 6XS, United Kingdom; ‡Division of
Experimental Surgery, Department of Surgery, University Hospital Regensburg,
Regensburg 93053, Germany; xDepartment of Obstetrics and Gynaecology, Univer-
sity Hospital Regensburg, Regensburg 93053, Germany; {Institute for Immunology,
University of Regensburg, Regensburg 93053, Germany; and ‖Department of Trans-
fusion Medicine, University Hospital Regensburg, Regensburg 93053, Germany
Received for publication April 3, 2014. Accepted for publication June 22, 2014.
This work was supported by the European Union 7th Framework Programme through
The ONE Study initiative (Award 260687) and the Regensburger Centrum f€ur Inter-
ventionelle Immunologie.
Address correspondence and reprint requests to Dr. James A. Hutchinson, Depart-
ment of Surgery, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11,
93053 Regensburg, Germany. E-mail address: james.hutchinson@ukr.de
The online version of this article contains supplemental material.
Abbreviations used in this article: DPBS, Dulbecco’s PBS; LA-ICP-MS, laser
ablation–inductively coupled plasma mass spectrometry; Mreg, regulatory macro-
phage.
Copyright 2014 by The American Association of Immunologists, Inc. 0022-1767/14/$16.00
www.jimmunol.org/cgi/doi/10.4049/jimmunol.1400869
 Published July 23, 2014, doi:10.4049/jimmunol.1400869
 at U
niversity of Regensburg on A
ugust 5, 2014
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
(i.e., its distribution, survival, and fate in the recipient). Typically,
pharmacokinetic studies in humans are performed as part of the
early clinical pharmaceutical development process; however, in
the case of Mregs, and cell-based medicinal products in general,
adequate methods for reliably detecting infused cells in tissues
over days or weeks after transfer are not available (17). In a pre-
vious study, we used single-photon emission computed tomogra-
phy to track 111In oxine-labeled allogeneic human Mregs in one
patient: Mregs given by central venous infusion were first con-
centrated in the pulmonary vasculature but by 3 h postinfusion had
migrated to the liver, spleen, and hematopoietically active bone
marrow via the blood (13). Although this radiological tracing
study provided valuable information, it tells us very little about the
precise distribution of Mregs within tissues, and, owing to the
short half-life of 111In, the survival and fate of Mregs after 30 h
postinfusion could not be characterized.
Cell tracking in patients presents a number of substantial
obstacles (18). To identify cells after administration to a recipient,
it is necessary that they are specifically and durably labeled. A
variety of cell labeling reagents and corresponding detection
technologies exist, notably radioisotopic labeling (19), stable
isotope labeling (e.g., deuterium), nuclear magnetic resonance
labels (20), nanoparticles (21), and luminescent dyes (22); how-
ever, to some degree, each of these approaches is limited by de-
tection sensitivity, signal nonspecificity, and the impermanence or
toxicity of labels. Thus, there is an unfulfilled need for a cell la-
beling and cell detection technology capable of reliably quanti-
fying very low-frequency cells (perhaps as few as 1 in 107 cells) in
tissues with a very low false-positive detection rate. Most im-
portantly, none of the existing cell-tracking techniques are capable
of reliable single-cell detection at a suitable level of resolution to
identify single cells and their microanatomical context. Judged by
these performance requirements, existing technologies are not
suitably sensitive or specific, so alternative approaches must be
considered.
Laser ablation–inductively coupled plasma mass spectrometry
(LA-ICP-MS) is an analytical technique that is predominantly
used in earth and material sciences, but it is also beginning to be
applied to analysis of biological samples (23). In principle, LA-
ICP-MS entails vaporizing small parts of a sample using a focused
pulse of laser energy. The elemental composition of this vaporized
material is analyzed by mass spectrometry, which provides ex-
quisitely sensitive detection. By taking contiguous samples across
a specimen, a map of the distribution of elements within a com-
plex sample can be constructed. This strategy has been used to
visualize endogenous elements in biological tissues (24), and
elemental tagging prior to LA-ICP-MS enables specific tissue
features, such as amyloid deposits in brain tissue (25), to be
distinguished. Applications of this remarkable technique to the
problem of tracking rare cells would overcome many of the lim-
itations associated with other methodologies: A “microscope” that
used LA-ICP-MS to map tissue components labeled with rare
earth metals would be incredibly sensitive and specific, because
most rare earth metals are completely absent from tissues. Hence,
the objective of the work presented in this article was to develop
an LA-ICP-MS method for identifying labeled human Mregs in
tissues specimens.
Materials and Methods
Experiments in animals
Animal experiments were performed in accordance with permission Nr. 54-
2532.1-10/12 granted by the Regierung von Oberbayern. NSG (NOD.Cg-
Prkdc
scid
Il2rg
tm1Wjl/SzJ) mice were bred in-house. Animals were kept in
individually ventilated cages and fed a conventional diet.
Generation and gold labeling of human Mregs
Human Mregs were generated as previously described (26). Briefly, CD14+
monocytes were isolated from Ficoll-prepared PBMCs by positive selec-
tion using anti-CD14 MicroBeads (Miltenyi Biotec, Bergisch Gladbach,
Germany). Monocytes were plated in six-well Cell+ plates (Sarstedt,
N€umbrecht, Germany) at 106 cells/well in RPMI 1640 (Lonza, Cologne,
Germany) containing 10% heat-inactivated human AB serum (Lonza),
2 mM GlutaMAX (Invitrogen, Karlsruhe, Germany), 100 U/ml penicillin
(Lonza), 100 mg/ml streptomycin (Lonza), and recombinant human
M-CSF (R&D Systems, Wiesbaden-Nordenstadt, Germany) at 25 ng/ml
carried on 0.1% human albumin (CSL-Behring, Hattersheim-am-Main,
Germany). On day 6 of culture, cells were stimulated for 18 h with 25
ng/ml recombinant human IFN-g (Chemicon, Billerica, MA). To label
Mregs with 50-nm gold nanoparticles (Sigma, Munich, Germany), human
Mregs were harvested, washed twice in Dulbecco’s PBS (DPBS), and
resuspended at 106 cells/ml in prewarmed X-Vivo 10 (Lonza) containing
3.5 3 109 gold nanoparticles/ml. The cell suspension was incubated at
37˚C for 1 h in a closed 15-ml tube with end-over-end rotation. Thereafter,
the cells were washed three times in DPBS before further processing.
Flow cytometry
Cell surface staining was performed at 4˚C in DPBS/1% BSA/0.02% NaN3/
10% FcR-block (Miltenyi Biotec), as described elsewhere (13). Dead cells
were excluded with 7-aminoactinomycin D (BD Biosciences, Heidelberg,
Germany). Data were collected using a FACSCanto II cytometer (BD
Biosciences), and the proportion of live Mregs, gated by physical char-
acteristics, was analyzed using FlowJo v7.6.5 software. To assess the
T cell–suppressive capacity of Mregs, allogeneic PHA-stimulated CFSE-
labeled CD3+ T cells and Mregs were set in direct 1:1 coculture for 5 d.
Subsequently, T cell proliferation was quantified by flow cytometry, as
previously described (26).
Culture of gold-labeled Mregs in chamber slides
Mregs were resuspended in Mreg-generation medium (as above) before
replating into chamber slides (BD Falcon, Heidelberg, Germany) at a
density of 106 viable Mregs/ml. Cells replated in chamber slides were
allowed to adhere over 24 h. For counterstaining, adherent Mregs were
washed three times in ice-cold DPBS, air dried, and stained with Diff-Quik
Giemsa reagents (Medion Diagnostics, Munich, Germany).
Administration of gold-labeled human Mregs to NSG mice and
tissue preparation
Immediately prior to injection, the concentration of gold-labeled Mregs
was adjusted to 5 3 106 viable cells/ml in DPBS, without Ca2+ or Mg2+,
supplemented with 60 IU/ml heparin. Cell suspensions were injected
through a 27-gauge needle into the tail vein of recipient NSG mice over
30–180 s. For solution-based ICP-MS and LA-ICP-MS analyses, organs
were harvested at 24 h or 7 d postinfusion by postmortem dissection.
Tissues for analysis by LA-ICP-MS were fixed in paraformaldehyde and
embedded in paraffin wax, and 6-mm sections were cut. Sections were
mounted on SuperFrost glass microscope slides (Thermo Fisher Scientific,
Schwerte, Germany) and stored in a dry environment at 37˚C for several
days prior to further processing. Sections were dewaxed with Roti-Histol
(Carl Roth, Karlsruhe, Germany) and progressively rehydrated in increas-
ingly dilute ethanol. Following conventional immunohistochemical techni-
ques, tissues were blocked with 5% normal mouse serum in TBS for 1 h.
Tissues were stained overnight at 4˚C using primary metal-tagged MaxPar
Abs (Fluidigm Sciences, Sunnyvale, CA) diluted in TBS + 5% normal
mouse serum, according to the manufacturer’s recommendations. Specifi-
cally, tissues were stained with 154Sm-tagged anti-CD45 (clone HI30) or
174Yb-tagged anti–HLA-DR (clone L243). Sections were counterstained
with H&E before progressive dehydration in alcohol and air drying.
Solution-based ICP-MS
Analyses were performed on a sector-field ICP-MS instrument (Element
2XR; Thermo Scientific, Bremen, Germany). The instrument was fitted with
a cyclonic spray chamber, a conical glass concentric nebulizer (both from
Glass Expansion, West Melbourne, VIC, Australia), and a 0.25-mm inner
diameter probe (Elemental Scientific, Omaha, NE). Prior to analysis, the
samples were digested in small volumes of concentrated acid using the
procedure reported previously by our group (23). Following evaporation of
the acid, a 5% aqua regia solution was used to reconstitute the samples.
Gold is known to have a high affinity for the surfaces of the sample in-
troduction system (27). Therefore, to minimize memory effects, solutions
of 5% aqua regia and 10 mM cysteine were aspirated between samples.
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LA-ICP-MS
Analyses were performed on a laser ablation system (UP-213, Nd:YAG, l
213 nm; ElectroScientific Industries) coupled to a sector-field ICP-MS
instrument (Element 2XR; Thermo Scientific) in external trigger mode.
The laser ablation system was fitted with a low-volume, teardrop-shaped
ablation cell, which was described elsewhere (28). Helium was used as
the ablation gas, at a typical flow rate of 0.6 l/min, with an argon make-
up flow introduced, at a flow rate of 0.8 l/min, after the ablation cell.
Single-cell identification was demonstrated by ablating 55-mm-diameter
areas at locations corresponding to individual cells. Only single cells
were targeted; cells present in clusters or ,55 mm apart were discounted.
The presence of label was determined from the time-resolved 197Au
signal-intensity profile. Imaging of the cells and tissue sections was ac-
complished by performing adjacent line scans over sections of the slide,
while measuring 197Au, 154Sm, or 174Yb in time-resolved mode. Images were
constructed using Iolite version 2.15 (Melbourne Isotope Group, Melbourne,
VIC, Australia), a freeware data deconvolution package that runs on the
IGOR-Pro 6.22A platform (WaveMetrics, Lake Oswego, OR). The software
converts each raw data point into a color-coded pixel; thus, the color profile
of the resulting image depicts the distribution of the respective elements
across the sampled region.
Results
Labeling of human Mregs for detection by LA-ICP-MS
From an analytical chemistry perspective, most d-block and f-block
elements can be equally easily quantified by LA-ICP-MS. Metal
labels can be incorporated into living cells by various biological
processes, including phagocytosis, pinocytosis, receptor-mediated
endocytosis, or cell surface labeling. Retention of a metal label may
be passive or active, and it may or may not require reaction of the
metal with cellular constituents. The choice of metal label, its
chemical form, and the mechanisms by which it is taken up and
retained by living cells determine its properties as a tracer label.
From a biological perspective, the qualities that we expect of
a useful living cell label for in vivo tracking studies are durability,
biological inertness, and specificity; hence, absence of label from
normal tissues. Omniscan, a gadolinium-based nuclear magnetic
resonance contrast agent, was shown to be a suitable reagent for
labeling human regulatory T cells, which presumably acquired
label by fluid-phase pinocytosis (23).
In the current study, 50-nm gold particles were selected as a label
because Mregs are known to be highly phagocytic (15). Optimal
conditions for labeling were determined by incubating Mregs with
gold particles at a range of concentrations for various periods prior
to measuring cellular gold content by solution-based ICP-MS
(Table I). Label uptake was time and concentration dependent
and did not reach saturation within the range of tested conditions;
nevertheless, gold incorporation after 1 h of incubation with 3.5 3
109 particles/ml was .500-fold the lower limit of detection. To
ascertain whether gold labeling had any effect on Mreg viability,
cell surface phenotype, or in vitro function, gold-labeled and un-
labeled Mregs were analyzed by flow cytometry and suppression
assays (Fig. 1). After labeling, no differences in dead cell
frequency, marker phenotype, or suppressor activity were ob-
served. Accordingly, gold nanoparticles at concentrations of
3.5 3 109 particles/ml are suitable for labeling human Mregs with-
out obvious toxic effects.
Laser ablation of single Mregs
To assess the uptake of gold label by individual cells, gold-labeled
Mregs were washed extensively after labeling and replated in
chamber slides. The majority of replated Mregs readhered to the
vessel surface within 1 h and acquired typical Mreg morphology
(Fig. 2A). After 1 h, the adherent cells were washed extensively
and Giemsa stained prior to analysis by LA-ICP-MS. Single
Mregs were ablated with single shots of a 55-mm-diameter laser.
This beam size ensured complete ablation of an individual cell,
while reducing the chance of inadvertently ablating neighboring
cells. LA-ICP-MS of the labeled cells yielded an average signal
intensity of 1.9 3 105 counts/cell (77% relative SD). Each signal
was clearly distinguishable from the low background signal ∼0–
10 counts (Fig. 2B). No signals above background were observed
for the ablation of nonlabeled cells or from control areas of the
slide containing no cells (Fig. 2C). This demonstrated that labeled
cells can be rapidly and reliably distinguished from their non-
labeled counterparts, a point that was subsequently confirmed
during the analysis of mixed populations of labeled/nonlabeled
cells (Table II). To prove that gold nanoparticles are retained by
living Mregs, labeled cells were cultured for 36 h in chamber
slides before LA-ICP-MS analysis. Clear signals, with an average
signal intensity of 1.6 3 105 counts/cell (69% relative SD), were
obtained for this analysis (Fig. 2D). Therefore, it is concluded that
living, adherent Mregs can be labeled with 100% labeling effi-
ciency and retain gold nanoparticles for $36 h after labeling.
The above experiments sampled entire cells to demonstrate
100% cell labeling and detection capability. For tissue imaging, it is
clearly beneficial to decrease the diameter of the laser spot to less
than the size of the cell and, hence, increase the resolution of the
image. To demonstrate that the cells internalize sufficient label for
high-resolution imaging, 8-mm-wide line scans were performed
across a cluster of labeled cells (Fig. 3). The count rates remained
sufficient to enable detection of the cells, whereas the 8-mm spot
size was sufficient to discriminate between the signals from in-
dividual cells.
Gold-labeled Mregs can be dual labeled with 154Sm-tagged or
174Yb-tagged Abs
When gold-labeledMregs are administered to a recipient, release of
gold nanoparticles and subsequent reuptake by recipient phag-
ocytes could lead to misidentification of those recipient cells as
Mregs. One solution to this problem is to establish that cells bearing
the tracer label express the anticipated marker phenotype by im-
munohistochemical “postlabeling” using metal-conjugated Abs.
Table I. Optimizing conditions for labeling human Mregs with 50-nm gold particles
Gold Concentration
(particles/ml)
Incubation Time
10 s 1 h 2 h
0 Not detected Not detected Not detected
3.50 3 107 Not detected 1.79E+06 1.75E+06
1.75 3 108 Not detected 1.06E+07 9.52E+06
3.50 3 108 1.54E+06 3.09E+07 3.76E+07
1.75 3 109 1.05E+07 1.71E+08 3.64E+08
3.50 3 109 1.51E+07 3.39E+08 4.36E+08
Human Mregs were incubated with various concentrations of gold nanoparticles, and their gold uptake was determined
by ICP-MS. Data are the average number of gold atoms internalized/cell for each labeling condition.
The Journal of Immunology 3
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Therefore, we examined the technical feasibility of codetecting
Mregs labeled with gold and 174Yb-tagged anti–HLA-DR (Fig. 4A)
or 154Sm-tagged anti-CD45 (Fig. 4B) Abs. Mregs were labeled with
gold nanoparticles prior to overnight culture in chamber slides.
Unfixed, adherent Mregs were counterlabeled by incubation with
metal-conjugated Abs. After extensive washing, the dual-labeled
Mregs were analyzed by LA-ICP-MS. Coextensive signals were
obtained for gold labeling and the postlabels, proving that this
method could, in principle, be used to detect dual labeling of cells
in tissues.
FIGURE 1. Labeling human Mregs with 50-nm gold nanoparticles did not affect their viability, phenotype, or suppressor function. Human Mregs were
incubated for 1 h in the presence or absence of 3.5 3 109 gold nanoparticles/ml. Subsequently, the phenotype and viability of unlabeled and gold-labeled
Mregs were assessed by flow cytometry. Data are representative of n = 3 independent allogeneic pairs. No difference was observed in the viability of gold-
labeled Mregs compared with unlabeled Mregs. Likewise, no differences were observed between gold-labeled and unlabeled Mregs in the expression of
CD11b, HLA-DR, CD14, or CD16. Both gold-labeled and unlabeled Mregs expressed similar levels of IDO, which is indispensible for the T cell–sup-
pressive function of human Mregs. Accordingly, gold labeling of Mregs did not affect their capacity to suppress polyclonal proliferation of CFSE-labeled,
PHA-stimulated allogeneic CD4+ T cells in direct 1:1 cocultures.
FIGURE 2. One hundred percent labeling efficiency was achieved when Mregs were incubated with 3.5 3 109 gold nanoparticles/ml for 1 h. (A) After
labeling with gold nanoparticles, Mregs were able to readhere to a plastic tissue culture surface. Cells were visualized using a Giemsa counterstain. (B) Single
gold-labeled Mregs were ablated with single shots of a 55-mm-diameter laser, yielding an average signal intensity of 1.9 3 105 counts/cell (77% relative SD).
(C) No signals above background were observed when unlabeled Mregs were ablated. (D) Labeled Mregs retained gold for $36 h after labeling.
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Tracking of human Mregs in NSG mice
The eventual anatomical distribution of Mregs after i.v. infusion
reflects their passive and active migration and engraftment into
different tissues, as well as their death and elimination. To track the
survival and tissue distribution of Mregs in vivo, gold-labeled
human Mregs were injected into NSG mice. The presence of la-
bel in brain, heart, kidney, liver, spleen, small intestine, large in-
testine, skeletal muscle, and tail skin was assessed on days 1 and 7
postinjection by solution-based ICP-MS (Table III). At both time
points, gold label was principally detected in lung, liver, and
spleen (although above-background signal was also detected in
kidney, heart, brain, and intestine), which is consistent with pre-
vious results from flow cytometry experiments that showed tran-
sient engraftment of Mregs in these tissues (28).
To investigate whether LA-ICP-MS permits detection of in-
dividual gold-labeled cells in tissues, recipient tissues were
harvested at day 1 or 7 postinjection of gold-labeled Mregs. These
tissues were fixed with paraformaldehyde and embedded in
paraffin. Six-micron sections of lung, liver, and spleen were
conventionally counterstained with H&E prior to analysis by
LA-ICP-MS. Sampled areas were 320 3 245 mm in size, with
two sampled areas selected per tissue section. As predicted by
solution-based ICP-MS, label was detected in all three tissues at
1 and 7 d postinjection (Fig. 5). Within the relatively small areas
of tissue examined, no particular pattern of signal distribution
was perceived.
Discussion
Faced with the problem of detecting very rare cells in tissues, the
aim of this work was to demonstrate that LA-ICP-MS can be used
to identify metal-labeled cells in tissue samples with high sensi-
tivity and specificity. In principle, this objective has been realized;
Table II. Specificity of 197Au labeling of human Mregs
Ratio of Labeled/Nonlabeled
Cells
Culture Time after
Labeling (h)
No. of Cells
Ablated
No. of Labeled
Cells Detected
1:0 1 100 100
0:1 1 100 0
1:1 1 100 45
1:0 36 100 100
0:1 36 100 0
1:1 36 100 43
Various proportions of gold-labeled Mregs were plated in chamber slides and allowed to adhere for 1 or 36 h. The
relative numbers of labeled and unlabeled Mregs were assessed by LA-ICP-MS. Labeled and unlabeled Mregs were clearly
discriminable. There was no significant transfer of gold label from labeled to unlabeled Mregs over the 36-h incubation
period.
FIGURE 3. An 8-mm laser spot–size is sufficient to
allow detection of gold-labeled Mregs. Eight-micro-
meter– line scans were made across a group of gold-la-
beled, Giemsa-counterstained Mregs. Count rates were
adequate to detect labeled cells, whereas the spot size
was small enough to allow spatial resolution of adjacent
cells. The upper panel shows optical images and the
lower panel shows the distribution of gold label.
The Journal of Immunology 5
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in practice, the technology is not ready to be commonly used in
immunological research. Nevertheless, the results presented in this
article indicate the enormous future potential of LA-ICP-MS in
imaging biological specimens at a level of resolution suitable for
identifying individual cells. Although this study focused on the
narrow application of this approach to detecting gold-labeled
Mregs, clearly LA-ICP-MS tissue imaging could be useful for
a much broader range of applications. Therefore, we must ask
ourselves how the current system might be improved to better serve
the needs of biologists.
The resolution of images generated by LA-ICP-MS is dictated
primarily by laser parameters (e.g., laser spot diameter, line
spacing, repetition frequency, and scanning speed). Finer reso-
lution is necessarily better when imaging histological specimens.
In the current study, a beam width of 8 mm and scan speed of 8
mm/s were used for the analysis of tissue sections, which pro-
vided sufficient resolution to identify single cells. In principle,
the resolution of images could be increased to #1 mm. However,
the choice of laser parameters must take into account additional
factors, such as the instrument sensitivity and the required
analysis speed.
Presently, the speed of analyzing specimens is slow: to image an
area of 1 mm2 using an 8-mm spot diameter and 8-mm/s scan speed
takes ∼4.5 h. The speed of analysis is largely limited by the
washout time of the laser ablation chamber, which determines
the duration of the signal from each laser pulse. Commercially
available systems typically provide washout times in the order of
a few seconds; however, with custom modifications, many users
have reduced this time, in some cases to ,100 ms. With improved
instrumentation, washout times might be reduced to ∼10 ms,
which would drastically improve both the sensitivity and the speed
of analysis.
Using our current LA-ICP-MS system, it was possible to detect
two labels on cultured cells; however, for many applications it
FIGURE 4. Gold-labeled Mregs can be dual labeled with 174Yb-tagged or 154Sm-tagged Abs. Gold-labeled Mregs were cultured overnight in chamber
slides prior to postlabeling with either 174Yb-conjugated anti–HLA-DR (A) or 154Sm-conjugated anti-CD45 (B) mAbs. After extensive washing, the dual-
labeled Mregs were counterstained with Giemsa and subjected to LA-ICP-MS analysis.
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would be useful to measure many more parameters. In principle, this
could be achieved by combining the existing LA-ICP-MS with
conventional fluorescence microscopy or by developing the system
to detect multiple metal labels. The principal restriction on analyzing
a greater number of metal labels is the rate at which sector field mass
spectrometers detect each element, which they must do sequentially.
Therefore, the capability of the current system to detect multiple
metal labels could be improved by using a simultaneously detecting
mass spectrometer, such as a time-of-flight mass spectrometer.
In this study, we applied LA-ICP-MS to the real-world biological
problem of identifying rare cells in tissues. In doing so, we
demonstrated the potential usefulness and power of this method
in biological research. The technology presented in this article
allowed detection of gold-labeled cells in tissues with very high
specificity and sensitivity, as well as revealing their microana-
tomical relationship to recipient tissue structures. The specificity of
LA-ICP-MS tissue imaging reflects the large signal-to-background
ratio afforded by using rare earth metals or biologically inert
nanoparticles as labels. The sensitivity of LA-ICP-MS tissue im-
aging (i.e., the ability to reliably detect very rare cells) is a re-
flection of the incredible sensitivity of mass spectrometry as an
analytical technique. Unsurprisingly, there is now great interest in
exploiting mass spectrometry as a specific and sensitive detection
method in various biological applications, most notably in flow
cytometry (30). A commercially available device known as the
CyTOF is being adopted by many groups interested in clinical
immune monitoring, with astonishing results (31, 32). The coupling
of laser ablation with ICP-MS–based detection presented in this
article takes this technology to a new level by combining detection
of specific Ags with spatial resolution, allowing accurate, sensitive,
and specific mapping of Ag distribution within tissues.
Concurrent detection of signals fromMregs prelabeled with gold
and postlabeled with metal-tagged Abs would imply the presence
of intact human Mregs in mouse tissues. Dual labeling and LA-
ICP-MS detection of gold-labeled Mregs grown on chamber slides
with either 174Yb-tagged anti–HLA-DR or 154Sm-tagged anti-CD45
was successful. Unfortunately, when sections of spleen from mice
that had received gold-labeled Mregs were counterstained with the
174Yb-conjugated anti–HLA-DR Ab before being analyzed at low
resolution by LA-ICP-MS, very high and spatially diverse back-
ground signals for 174Yb were detected (Supplemental Fig. 1).
Therefore, no correlation in the distribution of 174Yb and 197Au
signals could be established. We are unable to explain this
nonspecific staining in mouse tissues. One possibility is that our
metal-tagged mAbs are unsuitable for use on tissue sections,
possibly owing to the destruction of Ags during tissue fixation.
Also, we cannot discount the possibility that MaxPar reagents
have a greater propensity for nonspecific binding to tissues than do
Abs with alternative labels. Because of the very high sensitivity of
LA-ICP-MS, postlabeling with rare earth metal–labeled Abs
might require development of more suitable metal-conjugated
Abs, possibly labeled using different chemistries, as well as bet-
ter histological techniques to block nonspecific binding of Abs.
Importantly, our inability to identify colabeled Mregs does not
detract from the potential usefulness of LA-ICP-MS in detecting
colabeled cells in tissues; rather, it speaks to the current limi-
tations of our metal-labeled Abs and histological techniques,
which are ultimately soluble issues.
Albeit a niche application of LA-ICP-MS tissue imaging,
characterizing the distribution, survival, and fate of therapeutic
cells in patients will be critical to their future development as
pharmaceutical agents (29, 33). LA-ICP-MS offers an unrivaled
combination of sensitivity, specificity, and spatial resolution,
which makes it an especially suitable method for cell tracking.
Moreover, using LA-ICP-MS as a detection method makes avail-
able a variety of nonradioisotopic tracers, which may be safer and
more convenient than currently available labels in the manufacture
and application of cell-based therapies. Another exciting possibility
of LA-ICP-MS cell tracking is that colabeling cells with two or
more metal-containing compounds that are metabolized, degraded,
or excreted by different mechanisms might make discrimination of
live and dead cells possible, because only live cells would carry
both labels. This article is proof-of-concept that gold-labeled Mreg
can be detected in tissues for at least 7 d after infusion. Serious
consideration is being given to the feasibility and clinical safety of
labeling Mreg with gold nanoparticles for infusion into patients;
indeed, clinical translation of cell tracking by LA-ICP-MS is a key
objective of The ONE Study initiative (www.onestudy.org).
We conclude that, although LA-ICP-MS tissue imaging is a
nascent technology, it has the potential to be a very powerful
analytical technique in biology. If the present limitations of res-
olution and number of labels can be overcome, then LA-ICP-MS–
based tissue imaging has a bright future.
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Table III. Presence of 197Au-labeled human Mregs in tissues of recipient mice on days 1 and 7 postinjection
by solution-based ICP-MS
Tissue
Day 1 Day 7
Au-Labeled Mregs Unlabeled Mregs Au-Labeled Mregs Unlabeled Mregs
Lung 251.40 6 13 0.15a 122.47 6 9 0.09a
Spleen 147.85 6 12 0.04a 181.25 6 11 0.07a
Liver 120.46 6 26 0.02a 132.15 6 29 0.02a
Kidney 8.23 6 12 0.23a 2.56 6 3 0.12a
Heart 3.27 6 56 0.23a 1.09 6 124 0.12a
Skeletal muscle 0.48a 0.12a 0.49 6 97 0.21a
Brain 1.46 6 22 0.04a 0.06a 0.07a
Tail skin 35.70 6 134 2.10a 0.47 6 24 nt
Large intestine 0.67a 0.06a 0.63 6 44 0.45a
Small intestine 1.90 6 58 0.43a 0.86 6 47 0.50a
Data are pg Au/mg tissue 6 % RSD; n = 3/group.
aBelow the limit of detection.
nt, not tested; RSD, relative SD.
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